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This thesis explores genotype-phenotype relations in lupus nephritis. Over the past 
decade, advances in genetic research have improved our understanding of the genes 
that contribute to lupus susceptibility. However a clear understanding of how these 
genetic factors interact with the immune system to produce disease in a given patient 
or group of patients with SLE is difficult to define at this time. Recent monogenic 
causes of SLE have provided valuable insights into lupus pathogenesis. 
A comprehensive clinical characterisation of 164 biopsy proven lupus nephritis 
patients was undertaken in the initial phase of this research. 27% of patients recruited 
were of juvenile onset, as defined by diagnosis of nephritis before 18 years of age. 
Non-European lupus nephritis patients had a younger age of onset and higher rate of 
progression to end-stage renal disease. Sixteen individuals had a first degree family 
history of lupus nephritis including five sibling pairs. Familial clustering of nephritis 
was associated with juvenile onset disease and a more severe clinical phenotype.  
The entire cohort was genotyped by ImmunoChip for known lupus susceptibility 
polymorphisms. Associations with lupus nephritis were found in polymorphisms in 
the HLA region, IRF5, ITGAM, STAT4, TNFAIP3, TNFSF4 and ETS1. Whole Exome 
Sequencing of familial lupus nephritis cases identified a large number of potential 
candidates for functional investigation. A promising short list of candidates was 
created using pedigree information, focusing on variants predicted to be damaging 
and by incorporating prior knowledge of the biologic pathways implicated in lupus. 
Candidates under consideration for functional testing include genes involved in 
activation of Ras pathways, genes involved in the antioxidant defence system, 
variants in ubiquitination pathways, mutations in serine/threonine protein kinases 
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The purpose of this chapter is to: 
1. Provide an overview of SLE, diagnosis, epidemiology, classification criteria, 
assessment of disease activity and damage, treatment and outcomes. 
2. Describe the role of genetics in our understanding of SLE from Genome 
Wide Association Studies and monogenic lupus. 
3. Discuss important factors in the pathogenesis of lupus nephritis including the 
roles of complement, apoptosis, autoantibodies and type I interferon 
pathways. 
4. Introduce the role of monocytes in lupus nephritis providing evidence from 
murine models and human studies. 












1.1      Introduction to Systemic Lupus Erythematosus 
 
1.1.1 Systemic Lupus Erythematosus - a clinically heterogeneous disease 
Systemic Lupus Erythematosus (SLE) is considered the prototypic autoimmune 
disease with aberrations throughout the immune system resulting in diverse clinical 
manifestations. SLE is a heterogeneous disease and no single clinical feature or 
laboratory test is diagnostic of the disease. 
 The American College of Rheumatology (ACR) classification of SLE requires that a 
patient have 4 of 11 criteria to be classified as having SLE (Hochberg et al., 1997). 
These cardinal features include malar rash, discoid rash, photosensitivity, mucosal 
ulcers, serositis, arthritis, renal abnormalities, neurological disorders, haematological 
and immunological abnormalities and a positive ANA (anti-nuclear) antibody. The 
Systemic Lupus International Collaborating Clinics (SLICC) classification criteria 
for SLE were recently introduced and place more emphasis on renal and 
immunologic parameters and less on dermatological features than the previous ACR 
criteria. In the SLICC classification, 4 criteria are required for diagnosis, including at 
least one clinical criterion and one immunologic criterion or the patient may be 
considered to have SLE if they have biopsy-proven lupus nephritis in the presence of 
ANA or anti-double-stranded DNA antibodies (Petri et al., 2012). 
1.1.2 Lupus nephritis; a severe manifestation of SLE 
Lupus nephritis and CNS (central nervous system) lupus are considered to be at the 
severe end of the spectrum of clinical manifestations of SLE. Approximately 50% of 
SLE patients develop nephritis during their disease course, generally in the earlier 
stages of disease. Lupus nephritis is divided histologically into 6 subclasses as per 
the ISN/RPS (International Society of Nephrology/Renal Pathology Society) 
25 
 
classification. These classes encompass mesangial disease (classes I and II), 
proliferative nephritis (classes III and IV), membranous nephritis (class V) and 
glomerulosclerosis (class VI) (Weening et al., 2004). An estimated 10-15% of lupus 
nephritis patients progress to end-stage renal disease (ESRD) and require supportive 
therapy such as dialysis or renal transplantation (Cervera et al., 2003; Mavragani et 
al., 2003; Adler et al., 2006). Recurrent flares of lupus nephritis activity are 
associated with poor long-term renal outcomes (Moroni et al., 1996; Mosca et al., 
2002). Renal damage is the overall most important predictor of mortality in SLE 
patients (Danila et al., 2009).  
Treatment of lupus nephritis is comprised of two phases; induction and maintenance. 
The aim of induction therapy is to achieve a meaningful renal response with 
reduction in proteinuria and preservation of renal function. The goal of maintenance 
therapy is consolidate the renal response and prevent flares of disease with eventual 
gradual drug titration. Immunosuppressive treatment should ideally be guided by 
renal biopsy as clinical, serological or laboratory tests cannot accurately predict 
underlying renal biopsy inflammation. 
 
1.1.3 SLE prevalence and severity vary with patient ancestry 
The prevalence of SLE ranges from 40 to 200 per 100,000 of population, varying 
considerably in different ancestral groups. SLE is more common in African, Asian 
and Hispanic populations than in those of European ancestry (Johnson et al., 1995; 
Feldman et al., 2013; Lim et al., 2014; Somers et al., 2014). 
In addition to being more prevalent, the clinical phenotype of SLE is usually more 
severe in non-Europeans. SLE patients of African ancestry have an increased 
frequency of lupus nephritis and more damage accrual than Caucasian patients 
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(Dooley et al., 1997; Alarcon et al., 1999; Hopkinson et al., 2000; Alarcon et al., 
2001). SLE patients of East Asian ancestry have younger onset disease with a higher 
frequency of renal and CNS involvement (Thumboo et al., 2001; Johnson et al., 
2006; Peschken et al., 2009). European ancestry has actually been found to be 
protective against development of nephritis in SLE (Richman et al., 2012). 
1.1.4 Female preponderance of SLE 
90% of adult onset SLE patients are female. In juvenile onset disease, the female 
predominance is less pronounced (Hiraki et al., 2008; Mina et al., 2010; Watson et 
al., 2012). Given the peak incidence of SLE in females in the child bearing years, 
decreased incidence after the menopause and the increased rate of flare during 
pregnancy and with use of oral contraceptives and HRT (hormone replacement 
therapy),  a role has been proposed for female sex hormones in SLE pathogenesis. It 
remains unclear how female hormones could influence SLE pathogenesis. Clinical 
trials of hormone therapies have been disappointing (Chang et al., 2002). The X 
chromosome could potentially contribute to lupus aetiopathogenesis independent of 
sex hormones. The prevalence of Klinefelter's syndrome (47, XXY) is 14-fold higher 
in males with SLE as compared to those without (Scofield et al., 2008). Genetic 
modification of the number of X chromosomes carried by mice, XX or XO in 
females and XY or XXY in males leads to an increased incidence of SLE in those 
carrying two X chromosomes (Smith-Bouvier et al., 2008). 
1.1.5 Morbidity and mortality in SLE 
A bimodal pattern of mortality is well recognised in SLE. In the early stages, deaths 
are caused by intractable lupus activity or infection. In later stages, atherosclerotic 
manifestations such as myocardial infarction and strokes are common causes of 
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death (Urowitz et al., 1976; Gladman et al., 2007). The mortality associated with 
SLE has lessened over recent decades due to earlier diagnosis, improved treatment 
with immunosuppressive agents and advances in dialysis and renal transplantation. 
Survival has improved from a 5-year survival of 50% in the 1950s to a 15-year 
survival of 80% in the 1990s (Merrell et al., 1955; Abu-Shakra et al., 1995). A 
retrospective review of lupus nephritis patients in the UK over a 30 year period 
(1975-2005) showed that 5-year mortality decreased by 60% between the first and 
second decades of the study but has remained unchanged over the third decade. This 
suggests that the benefits of currently available immunosuppressive therapies have 
been maximized and that if further advances in SLE outcomes are to be achieved, 
novel therapeutic targets must be developed (Croca et al., 2011). 
1.1.6 Measures of SLE disease activity 
A number of indices have been developed to measure SLE disease activity in clinical 
practice and for research purposes. The most commonly used indices are the British 
Isles Lupus Activity Assessment Group index (BILAG) and the Systemic Lupus 
Erythematosus Activity Index (SLEDAI). The BILAG-2004 index is a composite 
clinical disease activity score, developed for the assessment of SLE disease activity 
on the principle of the physician’s intention to treat (Yee et al., 2009). Neither of 
these instruments are ideal, therefore a disease activity index combining the BILAG 
score, the SLEDAI score and a PGA (physician’s global assessment) was formulated 
and is known as the SLE Responder Index (SRI) (Furie et al., 2009). Another 
important clinical parameter in SLE is quantification of cumulative organ damage 





1.1.7 Current and emerging therapeutic options in SLE  
Conventional immunosuppressive therapies including corticosteroids, 
cyclophosphamide, mycophenolate mofetil and azathioprine have significantly 
improved patient survival in SLE over recent decades. Their use, however, is 
associated with considerable toxicity while a substantial proportion of SLE patients 
remain refractory to treatment. Recent advances in the understanding of SLE 
immunopathogenesis have led to the development of more targeted agents. Some of 
the agents are in advanced stages of development or have entered the realm of 
clinical practice (such as rituximab and belimumab) while others are in far earlier 
phases of development.  
Treatment of lupus nephritis is comprised of two phases; induction and maintenance. 
The aim of induction therapy is to achieve a meaningful renal response with 
reduction in proteinuria and preservation of renal function. The goal of maintenance 
therapy is consolidate the renal response and prevent flares of disease with eventual 
gradual drug titration. Immunosuppressive treatment should ideally be guided by 
renal biopsy as clinical, serological or laboratory tests cannot accurately predict 
underlying renal biopsy inflammation.    
B cell depletion therapy has emerged as a viable therapeutic option in the 
management of SLE. The main B cell depleting drug used in current clinical practice 
is rituximab, a chimeric anti-CD20 monoclonal antibody. Rituximab is widely used 
in SLE but remains unlicensed.  Initial open label trials of rituximab in SLE showed 
encouraging results (Leandro et al., 2002; Looney et al., 2004; Leandro et al., 2005). 
Disappointing, randomised controlled trial in non-renal SLE (EXPLORER) and 
lupus nephritis (LUNAR) failed to meet their primary end-points (Merrill et al., 
2010; Rovin et al., 2010). More recently corticosteroid sparing regimens in lupus 
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nephritis have been introduced, with rituximab as induction therapy and a large 
randomised controlled trial is ongoing (Condon et al., 2013). 
Other B cell depleting therapies in development include epratuzumab, an anti-CD22 
monoclonal antibody and ocrelizumab, a fully humanized anti-CD20 monoclonal 
antibody.  The B cell survival factor BLys (B-Lymphocyte stimulator) has also been 
successfully targeted in clinical trials (BLISS-52 and BLISS-76 trials) (Furie et al., 
2011; Navarra et al., 2011). In 2011, the United States Food and Drug 
Administration (FDA) and the European Medicines Evaluation Agency (EMEA) 
licensed belimumab, a monoclonal antibody against BLys, as the first new drug in 
over 50 years for SLE. Belimumab is licensed for use in autoantibody-positive SLE 
patients excluding those with active lupus nephritis and central nervous system 
manifestations of SLE. Clinical trials in lupus nephritis are currently ongoing. 
Abatacept, a fusion protein consisting of CTLA-4 combined with the Fc portion of 
human IgG1 (CTLA-4-Ig) is in the advanced stages of clinical trials in SLE. This 
therapeutic agent blocks the co-stimulatory interactions between T and B 
lymphocytes can induce immunological tolerance. Therapies targeting cytokines in 
clinical trials of SLE include tocilizumab, a monoclonal antibody against 
Interleukin-6, and monoclonal antibodies against interferon-α, sifalimumab and 
rontalizumab. 
The future of SLE treatment looks increasingly promising with the advent of ever 
more targeted and focused therapies that have emanated from the results of basic 
science and genetic research. With this in mind, I will now outline the current 
knowledge of SLE pathogenesis discussing the contributory roles of autoantibodies, 
complement pathways, defects in apoptosis, toll-like receptors (TLRs) and type I 
interferon signalling. I will also discuss the role of monocytes in the pathogenesis of 
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lupus nephritis outlining the growing body of literature supporting their role in the 
development of the disease. 
 
1.2 SLE - a genetic disease  
Epidemiologic studies suggest a significant contribution of genetic factors in the 
aetiology of SLE. Disease concordance in SLE is higher in monozygotic twins (25-
50%) than in dizygotic twins (2%) and there is a high sibling risk ratio (λs) of 20-29 
(Block et al., 1975; Deapen et al., 1992; Alarcon-Segovia et al., 2005). 
Linkage analysis, candidate gene studies and genome wide-association studies 
(GWAS) have deepened our understanding of the genetics factors underlying SLE 
and have led to the identification of several candidate genes. Monogenic causes of 
SLE are rare but have provided very useful insights into disease pathogenesis as 
exemplified by mutations discovered in DNASE1, TREX1, PRCKD and complement 
pathways. It is hoped that the knowledge of lupus genetics will expand significantly 
with the increasing availability of next generation sequencing (NGS). 
1.2.1 Susceptibility genes identified in GWAS 
The CD/CV (Common Disease Common Variable) hypothesis predicts that common 
disease-causing alleles will be found in human populations that harbor a given 
disease and has provided the theoretical basis for the development of GWAS (Reich 
et al., 2001; Pritchard et al., 2002; Botstein et al., 2003). GWAS are essentially large 
case-control studies were all participants are genotyped for the majority of common 
known SNPs. For each SNP, the allele frequency is compared between cases and 
controls using Pearson's Chi-squared (χ2) test allowing odds ratios and p-values to 
be calculated. A Manhattan plot is frequently used to illustrate the GWAS results and 
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shows the negative logarithm of the p-value as a function of genomic location. SNPs 
with the highest significance will appear most prominently on the Manhattan plot. 
The p-value for a particular SNP in GWAS is corrected for multiple testing issues, 
known as Bonferroni correction. If the risk allele remains significantly more 
prevalent in those with the disease than in controls despite correction for multiple 
testing, it is said to have genome-wide significance. 
In 2008, the first GWAS were published from SLE patients of European ancestry 
and found polymorphisms associated with lupus in the HLA region, IRF5, STAT4, 
ITGAM, TNFAIP3 BLK, BANK1, IRF7, PXK and WDFY4 (Kozyrev et al, 2008) 
(Hom et al, 2008) (Harley et al, 2008) (Graham et al, 2008). A GWAS of SLE 
patients of Han ancestry published shortly afterwards also found associations with 
STAT4, BLK, IRF5, and TNFAIP3. In addition, this study identified new candidate 
genes with associations in IKZF1, TNFSF4, ETS1, UBE2L3, and RASGRP (Han et 
al, 2009).  
In 2009, a further GWAS of European patients with SLE discovered associations in 
TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 (Gateva et al., 2009). In 2010, a 
GWAS of Chinese Han and Thai patients showed associations with polymorphisms 
in ETS1 and WDFY4 (Yang et al, 2010). A study of anti-dsDNA positive SLE 
patients found associations in the HLA region, IRF5, BLK, ITGAM, STAT4, TNXB 
and TNPO3 (Chung et al., 2011). In that same year, a large replication study in a UK 
dataset identified a number of genes involved in type I interferon pathways with SLE 
associations including IKZF1, IRF8, IFIH1 and TYK2 (Cunninghame Graham et al, 
2011).  
In one of the few studies focusing on African American SLE patients; BLK, BANK1, 
TNFSF4 and CTLA4 were found to be associated (Sánchez et al, 2011). In a multi-
32 
 
ancestral cohort of European, African American, Asian, Hispanic, Gullah and 
Amerindian SLE patients associations were found in IRF5, TMEM39A and IKZF3-
ZPBP2 (Lessard et al., 2012). Okada et al published GWAS of Japanese SLE 
patients with associations in AFF1 and LEF1
 
(Okada et al, 2012). 
 
In 2012, a further GWAS of SLE patients of European ancestry again confirmed the 
HLA region, IRF5, STAT4, BLK and TNPO3 as lupus susceptibility genes (Lee et al., 
2012). A combined Chinese and Thai GWAS also confirmed association with the 
HLA region, STAT4, BLK, TNFSF4 and TNFAIP3 and described new associations in 
GPR19, TET3, CD80 and UHRF1BP1 (Yang et al, 2012). A combined GWAS of 
SLE and Sjögren’s syndrome patients found disease associations with variants in 
IRF5, STAT4, PXK, ITGAM, IRF8, TNFAIP3, BLK, TNPO3, JAZF1 and TNIP1 
(Martin et al., 2012). 
 
GWAS in SLE patients have identified several potentially interesting candidate 
genes in biologic pathways that make sense in the context of our current knowledge 
of lupus pathogenesis, such as genes involved in TLR and type I interferon 
signalling, NFκB signalling, apoptosis and B and T cell signalling. Some of these 
susceptibility genes have been extensively investigated while others have yet to be 
examined in detail. In this thesis, we describe genotype-phenotype correlations for 
polymorphisms in many of these candidate genes, both on an individual level 






1.2.2 Monogenic lupus 
Classical Complement Pathway Defects 
Mutations in classical complement pathway components were the first monogenic 
causes of SLE to be identified and revealed valuable information about lupus 
pathogenesis. Mutations causing homozygous deficiencies in C1q and C4 are 
strongly associated with the development of SLE and will be discussed in the 
‘Complement’ and ‘Apoptosis’ sections of this thesis.   
Nuclease Defects 
Impaired apoptosis and disposal of nuclear debris have been implicated in lupus 
pathogenesis and in keeping with this, nuclease defects have been identified as 
monogenic causes of SLE. A functional heterozygous missense mutation in DNASE1 
was previously identified in 2 unrelated Japanese SLE patients (Yasutomo et al., 
2001). An autosomal recessive null mutation in DNASE1L3 has been described in 
juvenile onset SLE patients from consanguineous families in Saudi Arabia (Al-
Mayouf et al., 2011). These patients had a high frequency of lupus nephritis and 
autoantibodies including ANA, anti-dsDNA and ANCA. Dnase-1 deficient mice 
develop features similar to human SLE with autoantibody production and 
glomerulonephritis (Napirei et al., 2000). 
Interferonopathies 
Consistent with the pivotal role of type I interferon in the pathogenesis of SLE, a 
number of rare but insightful causes of monogenic lupus have been identified with 
aberrations in type I interferon signalling pathways, these syndromes have been 
coined interferonopathies. The first of these to be identified were mutations in 
TREX1, a 3'-5' DNA exonuclease with known properties as a negative regulator of 
interferon stimulatory cytosolic DNA (Stetson et al., 2008).  TREX1 is part of the 
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SET protein complex in the endoplasmic reticulum that is involved in apoptosis, 
transcription and histone binding. Mutations in TREX1 cause Aicardi-Goutieres 
syndrome (AGS), a progressive encephalopathy with cerebral calcification and 
raised interferon-α in the CSF (Lebon et al., 1988; Crow et al., 2006). TREX1 
mutations cause familial chilblain lupus (Rice et al., 2007). 0.5% - 2% of SLE 
patients carry a mutation in TREX1 (Lee-Kirsch et al., 2007) (Namjou et al., 2011). 
Mutations in other genes have since been identified as the cause of AGS and 
interferonopathy including RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and 
ADAR (Rice et al., 2013). 
An association has been described between SLE and spondyloenchondroplasia 
(SPENCD) (Briggs et al., 2011; Lausch et al., 2011). SPENCD is caused by 
mutations in ACP5 (acid phosphatase 5, tartrate resistant) that encodes the protein 
tartrate resistant acid phosphatase (TRAP). Clinical features of autoimmunity seen in 
SPENCD include the classic hallmarks of SLE; malar rash, lupus nephritis and the 
presence of anti-dsDNA antibodies. Other autoimmune diseases such as Sjögren’s 
syndrome, antiphospholipid syndrome, vitiligo, hypothyroidism and inflammatory 
myositis have been seen in overlap with SPENCD. A type I interferon gene 
expression signature and increased serum levels of type I interferon are present in 
SPENCD patients (Briggs et al., 2011).   
Gain-of-function mutations in IFIH1, a cytosolic double-stranded RNA receptor 
gene have been shown to cause upregulation of type I interferon signalling with 
neurological and autoimmune features (Rice et al., 2014). IFIH1 has previously been 
identified as a lupus susceptibility gene in a large scale replication study of European 
patients (Cunninghame-Graham et al., 2011). 
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A recent report has described a further interferonopathy known as SAVI (STING-
associated vasculopathy with onset in infancy). Children with de novo mutations in 
TMEM173 which encodes STING (stimulator of interferon genes) have neonatal 
onset systemic inflammation with severe cutaneous vasculitis, a pronounced type 1 
interferon signature and elevated levels of interferon-induced cytokines (Liu et al., 
2014). STING plays an important role in cytosolic DNA sensing and induces type I 
interferon gene expression via TBK1 (TANK binding kinase 1) and IRF3 (interferon 
response factor 3). The disease mechanisms underlying SAVI are, therefore, of 
interest in the context of SLE pathogenesis given the overlap with DNA-induced 
type I interferon production. 
Defective apoptosis 
Belot et al studied 3 siblings with juvenile onset lupus nephritis from a 
consanguineous kindred of North European ancestry and, using Whole Exome 
Sequencing (WES), identified a homozygous missense mutation in PRKCD (protein 
kinase Cδ) (Belot et al., 2013). This mutation leads to reduced expression and 
activity of its encoded protein PKC-δ. PRKCD is involved in deletion of autoreactive 
B-cells and this mutation is associated with dysregulated apoptosis and a shift to an 
immature B-cell phenotype. A Ca2+ dependent pro-apoptotic Erk signalling pathway 
that mediates negative selection of B-cells has recently been described. This pathway 
requires PKC-δ, STIM-1 (stromal interaction molecule 1) and the guanine 
nucleotide-exchange factor, RasGRP, to function efficiently (Limnander et al., 
2011). This pathway is impaired in PKC-δ deficient mice that are known to develop 
B cell associated autoimmunity with expansion of immature B-cells, autoantibody 
production and glomerulonephritis (Miyamoto et al., 2002). Interestingly, 
polymorphisms in RASGRP3 have been associated with SLE in East Asian GWAS 
36 
 
(Han et al., 2009). Furthermore, RASopathies, such as Noonan syndrome and 
Noonan-related syndromes, have been proposed as novel monogenic conditions 
predisposing to the development of SLE due to a growing number of case reports of 







































C1q AR Nephritis 
CNS involvement 






C1r/C1s AR Nephritis 






C4 AR Multi-systemic involvement 





C2 AR Musculoskeletal & skin  
Mild or absent renal disease 
















DNase 1L3 AR Juvenile onset SLE 
Lupus nephritis 
 
TREX1 TREX1 AD/AR Intracerebral calcifications   
Psychomotor retardation 




SAMHD1 AD Psychomotor retardation 
Intracerebral calcifications    




TRAP AR Growth retardation 
Spondyloenchondrodysplasia 











1.3 Pathogenesis of SLE 
 
1.3.1 The role of autoantibodies in SLE 
Autoantibody formation is a defining feature of SLE. The detection of autoantibodies 
in the serum is a key factor in making the diagnosis while subsequent monitoring of 
autoantibody titres is used for assessing the ongoing level of disease activity and 
response to treatments. Development of autoantibodies precedes overt clinical 
manifestations of SLE by several years (Arbuckle et al., 2003).  
ANA are the most frequently positive autoantibodies detected in patients with SLE, 
but are not specific to the disease. ANA are seen in several other autoimmune 
conditions including rheumatoid arthritis, Sjögren's syndrome, scleroderma, 
polymyositis, dermatomyositis, primary biliary cirrhosis, autoimmune hepatitis, 
multiple sclerosis, thyroid disease, and antiphospholipid syndrome, as well as in 
non-autoimmune diseases such as certain infections and malignancies. Patients with 
SLE who are ANA negative tend to have positive anti-Ro and /or anti-La antibodies 
and less renal involvement (Maddison et al., 1981). 
Anti-dsDNA (double stranded DNA) antibodies are more specific and are present in 
approximately 70% of SLE patients and less than 0.5% of healthy individuals 
(Isenberg et al., 1985). Serum anti-dsDNA titres are routinely measured in clinical 
practice as they tend to correlate with disease activity in SLE. Higher levels usually 
indicate more active lupus (Swaak et al., 1979; Lloyd et al., 1981; der Borg et al., 
1990; Okamura et al., 1993). Some patients, however, have discordant anti-dsDNA 
titres and disease activity. Some are serologically active but clinically quiescent 
(SACQ), while others have clinical activity with serological quiescence (CASQ) 
(LeBlanc et al., 1994; Gladmann et al., 2003; Steiman et al., 2012). 
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A matter of much debate has surrounded whether autoantibodies are a cause or 
consequence of SLE. The majority of studies examining the potential pathogenicity 
of autoantibodies in SLE have focused on the role of anti-dsDNA antibodies in lupus 
nephritis.  
Antibody-nucleosome complexes are known to deposit in the glomerular basement 
membrane of the kidney and initiate complement activation leading to tissue damage 
(Kramers et al., 1994; van Bruggen et al., 1997; Berden et al., 1999). Studies in SLE 
patients and murine models of disease indicate that IgG antibodies that bind with 
high affinity to dsDNA are associated with more severe tissue damage than IgM or 
low affinity IgG antibodies (Okamura et al., 1993; Ehrenstein et al., 1995; Ravirajan 
et al., 1998).  It has also been proposed that anti-dsDNA antibodies may have direct 
pathogenic effects on the kidney via cross-reactivity with renal proteins 
(Mostoslavsky et al., 2001). 
Studies of renal biopsy specimens from lupus nephritis patients have detected several 
non-DNA antigens bound to IgG, including Ro, La, C1q and Sm (Mannik et al., 
2003). Antibodies to C1q, a critical component in the early classical complement 
pathway are present in approximately 30% of SLE patients (Gunnarsson et al., 1997; 
Trendelenburg et al., 1999). In SLE, classical complement pathway activation is 
triggered by the interaction between C1q and immune complexes. Anti-C1q 
antibodies have been shown to be a good predictive marker of lupus nephritis flare 
(Siegert et al., 1993; Coremans et al., 1995; Moroni et al., 2001; Chen et al., 2012; 
Yin et al., 2012). The role of complement pathways in SLE will be discussed in 
detail later on in this thesis. 
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Antibodies to extractable nuclear antigens (Ro, La, Sm, and RNP) are found in up to 
a third of SLE patients and several lines of evidence support their role in nephritis 
and a severe disease phenotype. Anti-Sm and anti-RNP antibodies are more 
commonly seen in African SLE patients than those of European ancestry (Arnett et 
al., 1988; Quintero-Del-Rio et al. 2001; Cooper et al., 2002). Anti-Ro antibodies 
have been identified as a predictor of progression to ESRD in patients with lupus 
nephritis (Korbet et al., 2007). Young, African SLE patients with anti-Sm 
autoantibodies have a higher risk of developing nephritis (Alba et al., 2003). These 
RNA containing immune complexes are of relevance in the activation of TLR7 and 
subsequent type I interferon production. RNA containing immune complexes and 
their role in TLR activation will be discussed in detail in the TLR section of the 
introduction (Vollmer et al., 2005; Savarese et al., 2006). 
1.3.2 Complement pathways in SLE 
The role of complement pathways in SLE is complex as complement may both 
prevent and exacerbate disease. Inherited deficiencies of the classical complement 
pathway increase susceptibility to SLE. Complement is implicated at the effector 
phase of SLE when complement is known to deposit in inflamed tissue. Early 
components of the classical pathway, particularly C1q have important functions in 
the clearance of apoptotic cells, removing a potent source of antigenic material 
(Botto et al., 1998). Complement also plays a role in T and B cell activation thereby 
maintaining immune tolerance (Kemper et al., 2003). 
There are three distinct pathways within the complement system, the classical 
complement pathway, the alternative complement pathway and the lectin pathway, 
linking innate and adaptive immunity. Antibody-antigen complexes initiate 
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activation of the classical complement pathway involving the proteins, C1q, C1s, 
C1r, C2, C4 and C3. All three complement pathways merge at C3 which is then 
converted to C3a and C3b. C3b then forms part of C5 convertase which cleaves C5 
into C5a and C5b. C5b, C6, C7, C8 and C9 together form the membrane attack 
complex (MAC) that binds to cell surfaces and initiates lysis.  
Complement activation and consumption is common in SLE patients and results in 
hypocomplementaemia. C3 and C4 serum levels are routinely used in clinical 
practice to monitor disease activity with low C3/C4 levels, or a temporal reduction in 
consecutive serum levels being suggestive of active disease.  Deposition of 
complement is evident at sites of inflammation in SLE, particularly in the kidney and 
skin. Deposition of complement and immunoglobulins at the dermal-epidermal 
junction, known as the ‘lupus-band’ test has been used as a diagnostic test in SLE. 
Mutations causing homozygous deficiencies of classical complement pathway 
components are strongly associated with the development of SLE. C1q deficiency 
whilst rare with <100 cases reported in the literature, is highly penetrant and the 
strongest known genetic risk factor for the development of SLE. Patients with C1q 
deficiency tend to be of juvenile onset and have a severe clinical phenotype. 
Other known mutations of the classical complement pathway include mutations in 
C2, C3 and C4. C2 deficiency results in a clinical phenotype of SLE, increased 
susceptibility to infection, anti-C1q antibodies and anticardiolipin antibodies 
(Jonsson et al., 2007). C4 has 2 isoforms, C4A and C4B. Complete C4 deficiency is 
rare. Low CNV (copy number variation) of C4A has been associated with SLE while 
increased CNV is protective (Yang et al., 2007). Homozygous C3 deficiency is rare 
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and those with C3 deficiency have a much lower rate of SLE development than those 
who are C1q or C4 deficient (Botto et al., 1993). 
Encouraging results from murine models of nephritis have led to the targeting of 
complement in the treatment of lupus nephritis with a monoclonal antibody against 
C5 (eculizumab) (Wang et al., 1996). Successful blockade of complement has been 
clinically efficacious in haemolytic uraemic syndrome and dense deposit disease 
(Vivarelli et al., 2012; Wong et al., 2013). An early phase trial of 24 SLE patients 
with low disease activity showed good safety and tolerability. The prohibitively high 
cost of the drug has limited the progression of further clinical trials, however 
(Barilla-Labarca et al., 2013). 
 
1.3.3 Apoptosis in SLE 
Apoptosis is a genetically controlled process whereby specific endonucleases cleave 
DNA and generate nucleosomes, resulting in death of the cell followed by disposal 
of its contents (Hengartner et al., 2000; Savill et al., 2000). Chromatin condensation, 
fragmentation of DNA, membrane blebbing and externalisation of phosphatidyl 
serine (PS) are cardinal features of apoptosis. If apoptotic cells are not disposed of 
properly, they become secondary necrotic cells, triggering the release of danger 
signals and ultimately resulting in loss of tolerance and development of 
autoimmunity. Nucleosomes produced during apoptosis are a major autoantigen 
source in SLE (Mohan et al., 1993; Amoura et al., 1997; Bruns et al., 2000). 
Nucleosomes can bind antibody forming immune complexes and then deposit in 
tissue (Berden et al., 1999; Licht et al., 2001). Lupus autoantigens are known to be 




Apoptosis is dysregulated in SLE in two ways, firstly there is an increased rate of 
apoptosis and secondly a decreased clearance of apoptotic bodies by phagocytic 
cells. Increased apoptosis has been demonstrated in lymphocytes, neutrophils and 
monocytes from patients with SLE (Emlen, et al., 1994; Courtney et al., 1999; 
Shoshan et al., 2001; Kaplan et al., 2002; Ren et al., 2003). This increased rate of 
apoptosis in phagocytic cells increases the production of apoptotic debris and 
impairs clearance of this material by the cells themselves. T lymphocytes from 
patients with SLE demonstrate increased expression of the apoptotic ligands 
TWEAK, TRAIL and FasL (Kaplan et al., 2002). Increased apoptosis has also been 
seen in circulating endothelial cells in patients with SLE (Rajogopalan et al., 2004). 
Decreased clearance of apoptotic material by phagocytic cells has been demonstrated 
in patients with SLE (Hermann et al., 1998).  In support of the role of complement in 
apoptosis, there is impaired uptake of apoptotic cells by macrophages in the presence 
of serum depleted of C1q and C3 (Mevorach et al., 1998; Taylor et al., 2000). 
Macrophages from SLE patients have defective ability to internalise apoptotic cells 
even in the presence of normal serum (Tas et al., 2006). Genetic mutations in SLE 
patients support the concept of reduced clearance of apoptotic debris in lupus 
pathogenesis, including mutations in C1Q and DNASE1. C1q deficient mice develop 
autoantibodies, glomerulonephritis and large quantities of glomerular apoptotic 
bodies (Botto et al., 1998). As discussed earlier in this thesis, patients with 
homozygous C1Q mutations have a high risk of developing SLE. Mutations in 
DNASE1 and DNASE1L3 have been identified as monogenic causes of SLE 
(Yasutomo et al., 2001; Al-Mayouf et al., 2011). Dnase-1 deficient mice develop 
features similar to human SLE with autoantibody production and glomerulonephritis 
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(Napirei et al., 2000). Furthermore C1q and DnaseI have been shown to cooperate in 
degrading chromatin (Gaipl et al., 2004).  
A recently described monogenic cause of SLE arising from a mutation in PRKCD 
(protein kinase Cδ) may primarily exert its effect through apoptosis. PRKCD is 
involved in the deletion of autoreactive B cells. Patients with this mutation had 
evidence of dysregulated apoptosis and a shift to an immature B-cell phenotype 
(Belot et al., 2013). 
1.3.4 Toll-like receptors in SLE 
Toll-like receptors (TLRs) are a family of innate immune pattern-recognition 
receptors (PRRs) that recognise ‘danger signals’ or pathogen-associated molecular 
patterns (PAMPs) including viral nucleic acids. Activation of TLRs sets in motion a 
complex system of downstream adaptor proteins and signalling pathways. When 
TLRs sense endogenous RNA and DNA in immune complexes, type I interferon is 
induced with resultant autoimmunity (Akira et al., 2001; Schnare et al., 2001).  
As opposed to other TLRs on the cell surface, TLR3, TLR7/8 and TLR9 are 
endosomal and thus have restricted access to foreign nucleic acids. TLR7 senses 
ssRNA and therefore can be activated by SLE immune complexes containing RNA 
(Leadbetter et al., 2002; Lau et al., 2005). The lupus autoantigen U1snRNP RNA has 
been identified as an endogenous ligand for TLR7 and 8 (Vollmer et al., 2005; 
Savarese et al., 2006). The BXSB-Yaa (Y-linked autoimmune acceleration) lupus-
prone mouse model is the consequence of a translocation from the telomeric end of 
the X chromosome onto the Y chromosome. This results in the duplication of a 
number of genes including the gene encoding TLR7, which is deemed to be the 
major functional contributor to this phenotype (Pisitkun et al., 2006; Subramanian et 
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al., 2006). These mice spontaneous develop SLE like features and males have 
disease onset at a younger age than females. TLR9 senses unmethylated CpG DNA 
and is activated by DNA containing immune complexes (Boule et al., 2004; Means 
et al., 2005). Plasmacytoid dendritic cells (pDCs) which have been identified as the 
primary source of type I interferon production in humans are known to constitutively 
express TLR7 and TLR9 (Ronnblom et al., 1983).  
Polymorphisms in TLR7 have been associated with SLE in an East Asian candidate 
gene study. Males were found to have a stronger association than females and an 
enhanced type I interferon gene expression signature (Shen et al., 2007). Subsequent 
studies found an association with other TLR7 variants and SLE but did not replicate 
the link with male disease (Deng et al., 2010; Kawasaki et al., 2011). Increased TLR7 
CNV is a risk factor for juvenile onset SLE (Garcia-Ortiz et al., 2010). TLR9 
polymorphisms have not been associated with SLE with genome wide significance, 
as yet. A number of studies have shown weak associations of TLR9 variants with 
SLE (Tao et al., 2007; Xu et al., 2009; dos Santos et al., 2012). TLR9 is upregulated 
in B lymphocytes of SLE patients (Papadimitraki et al., 2006). Other studies, 
however, have not shown an association between TLR9 polymorphisms and SLE 
(Ng et al., 2005). While studies of TLR9 in SLE appear contradictory, the overall 
consensus on the available evidence is that TLR9 contributes to the development of 
SLE rather than having a protective role.  
In addition to TLR7 and TLR9 polymorphisms, variants in genes involved in 
signalling downstream of TLRs have been associated with SLE. The most strongly 
associated and extensively investigated candidate is IRF5 (Harley et al, 2008; Hom 
et al, 2008; Han et al. 2009; Lee et al., 2012). Polymorphisms in IRF7 and IRF8 have 
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also been associated with SLE with genome wide significance (Harley et al., 2008; 
Cunninghame-Graham et al., 2011; Li et al., 2011). 
TLR7 and TLR9 represent interesting therapeutic target in SLE. A dual TLR7/TLR9 
inhibitor (IRS954) reduced autoantibody production, proteinuria and histologic 
severity of glomerulonephritis in (NZB NZW) F1 mice (Barratt et al., 2007). 
Definitive clinical trials in patients with SLE are pending.  
 
1.3.5 Type I interferon in SLE 
Type I interferon family members play a major role in innate immunity and host 
viral defense. The type I interferons present in humans are IFN-α, IFN-β, IFN-ε, 
IFN-κ and IFN-ω. Interferon-α is a homogeneous family of proteins encoded by 13 
different genes. During viral infection, viral nucleic acids bind endosomal TLRs 
(TLR3, TLR7, TLR8, TLR9), leading to the activation of intracellular signaling 
pathways. Type I interferon production ensues, that in turn activates the expression 
of interferon-inducible genes and, ultimately results in viral elimination.  
Several lines of evidence link type I interferon to the pathogenesis of lupus. It is well 
established that patients with SLE have high serum levels of interferon-α (Hooks et 
al., 1979; Ytterberg et al., 1982). It has also been noted that viral hepatitis and 
oncology patients receiving interferon-α therapy develop autoimmune side-effects. 
An estimated 20% of patients receiving interferon-α therapy develop a positive ANA 
detectable in their blood or other autoimmune features while 1% develop clinical 
SLE (Ronnblom et al., 1990; Ronnblom et al., 1991; Kalkner et al., 1998). Serum 
interferon-α levels have been shown to correlate with disease activity and severity in 
SLE (Bankhurst et al., 1987; Bengtsson et al., 2000).  
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Debris from apoptotic cells has been shown to induce interferon-α production in 
vitro (Vallin et al., 1999, Bave et al., 2000, 2001). Apoptotic and necrotic U937 cells 
(a myeloid leukaemia cell line) release material that, when combined with SLE 
immunoglobulin, induce interferon-α production (Lövgren et al., 2004). As 
discussed, above, SLE patients have increased levels of apoptosis and decreased 
clearance of apoptotic debris. This provides an endogenous source of chromatin that, 
leads to autoantibody production and immune complex formation. Serum from 
patients with SLE can induce monocytes to differentiate into DCs in an interferon-α 
dependent process (Blanco et al., 2001).  Both DNA and RNA-containing immune 
complexes can induce interferon-α production (Lövgren et al., 2004, 2006).  More 
recently, neutrophil extracellular traps (NETs) have been identified as major 
producers of type I interferon, triggering pDC activation via TLR9 (Garcia-Romo et 
al., 2011; Lande et al., 2011; Villaneuva et al., 2011). 
While not all SLE patients have raised serum interferon-α, the majority have an 
interferon gene expression signature in PBMCs particularly in the early stages of 
their disease (Baechler et al., 2003; Bennett et al., 2003). Gene expression 
microarray profiles demonstrate upregulation of interferon-inducible genes, 
particularly in patients with severe SLE manifestations such as lupus nephritis and 
CNS disease. Haematologic findings such as haemolytic anaemia, leucopenia, 
lymphopenia and thrombocytopenia are associated with a somewhat less pronounced 
interferon signature. Milder disease features such as serositis and photosensitivity do 
not significantly correlate with the interferon signature (Bennett et al., 2003). In 
paediatric-onset SLE, which is generally deemed to have a more severe clinical 
phenotype than adult disease, a pronounced interferon-α signature is seen and has 
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been shown to down-regulate after high dose intravenous corticosteroid therapy 
(Bennett et al., 2003). 
Additional evidence of the contribution of type I interferon to lupus pathogenesis is 
provided by the regularity with which variants in genes involved in interferon 
signalling pathways are identified in SLE GWAS including IRF5, IRF7, IRF8, 
STAT4, TYK2, and IFIH1. Furthermore, there is a strong link between monogenic 
causes of lupus and interferonopathies. Aicardi-Goutieres syndrome (AGS), the 
prototypic interferonopathy, characterised by raised CSF interferon-α levels, cerebral 
calcification and progressive encephalopathy is a prime example of this (Lebon et 
al., 1988). The first genetic mutation underlying AGS was identified in TREX-1, a 
DNA exonuclease that is also associated with SLE and has been discussed in detail 
in the ‘Monogenic Lupus’ section of this thesis (Lee-Kirsch et al., 2007). Since that 
discovery a number of other genes have been implicated in AGS and 
interferonopathies including RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and 
ADAR (Rice et al., 2013). More recently, gain-of-function mutations in IFIH1, a 
cytosolic double-stranded RNA receptor gene have been shown to cause a spectrum 
of disease phenotypes associated with upregulation of type I interferon signalling 
(Rice et al., 2014). IFIH1 has previously been identified as a lupus susceptibility 
gene in a large scale replication study of European patients (Cunninghame-Graham 
et al., 2011). 
A number of therapeutic strategies are under development to target interferon-α in 
clinical practice, including the use of monoclonal antibodies directed both against 
interferon-α itself and against the type I interferon-α receptor and immunization 
against interferon-α. Monoclonal antibodies targeting interferon-α, currently in 
clinical development include sifalimumab and rontalizumab.  
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Sifalimumab has been tested in a phase I clinical trial and was found to be safe and 
well tolerated with no increased rate of viral infections. Approximately 60% of the 
patients recruited had a positive interferon signature at study onset and a dose-
dependent reduction in the expression of interferon-inducible genes was evident in 
these individuals (Merrill et al., 2011). A phase II study, showed similar inhibition of 
the interferon signature but no differences in clinical response were seen between the 
sifalimumab and placebo groups (Merrill et al., 2011). The other monoclonal 
antibody in development against interferon-α, rontalizumab, has produced a similar 
reduction in the expression of interferon-inducible genes in clinical trials and there 
were some indications that patients treated with rontalizumab fared better than those 
who received placebo (McBride et al., 2012; Kalunian et al., 2012). 
 
1.3.6 The role of monocytes in the pathogenesis of lupus nephritis 
Over the past decade there has been an accumulation of evidence from studies 
involving patients with proliferative lupus nephritis and from experiments in lupus 
mouse models suggesting an important role of monocytes in renal damage. 
Monocytes are a heterogenous population of blood leucocytes that play important 
roles in the innate immune system. In mice, there are two phenotypically and 




. A subset of Gr1
-
 ‘resident’ monocytes 
patrol the endothelium of blood vessels, allowing rapid tissue invasion by these cells 
in the case of local tissue damage or infection (Auffray et al., 2007).
.
  
Selective recruitment of Gr1
-
 monocytes in lupus mouse models of nephritis  
Expansion and activation of Gr1
- 
patrolling monocytes has been demonstrated in 
several lupus mouse models of nephritis.  The onset of proliferative nephritis and 
proteinuria in NZB/NZW F1 mice is associated with the expression of chemokines 
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such as CCL2 (MCP-1), CCL3 (MIP-1α), and CCL5 (RANTES) that mediate 





monocytes are present in the kidneys and peripheral blood of 
NZB/NZW F1 mice during active renal disease.  Further histologic analysis confirms 
the disappearance of these cells early in remission. It remains to be determined 
whether these cells die in situ following immunosuppressive therapy or migrate out 
of the kidney (Schiffer et al., 2008).   
MRL/lpr mice spontaneously develop autoantibodies, circulating immune complexes 
and progressive nephritis resembling human proliferative glomerulonephritis.  By 20 
weeks these mice develop progressive renal damage, including hypercellular 
glomeruli, crescent formation, glomerulosclerosis, and prominent interstitial 
mononuclear cell infiltrates (Inoue et al., 2005).  
A unique cellular feature in the BXSB -Yaa lupus mouse model, is the striking 
expansion of monocytes. By 8 months of age, monocytes account for 50% of 
peripheral blood mononuclear cells in BXSB -Yaa mice (Santiago-Raber et al., 
2009). This monocytosis is characterized by selective expansion of the Gr1
- 
subset 
(Amano et al., 2005). 
CD16
+
 monocytes in lupus nephritis patients, clinical significance and hallmark of 
disease activity 
There are three subsets of monocytes in humans distinguished from each other based 













). Interestingly, the human subset orthologous to murine patrolling 
Gr1
- 
monocytes is characterized by expression of CD16
+ 
(FcgRIII). Mean glomerular 
CD16
+ 
monocytes counts are higher in class IV proliferative nephritis than in other 
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nephritis classes and positively correlate with blood urea nitrogen levels, anti-DNA 
antibody titres, and proteinuria. Glomerular CD16
+ 
monocyte counts negatively 
correlate with serum albumin levels, complement levels and estimated glomerular 
filtration rate (Yoshimoto et al., 2007).  Glomerular CD16
+ 
monocyte counts 
correlate with histopathological activity index but not with chronicity index 
(Yoshimoto et al., 2007).  
Glomerular monocytes have been reported to be more prevalent on immunostaining 
of class IV-G nephritis renal biopsies than in class IV-S (Hill et al., 2005). The 
presence of glomerular monocytes on repeat renal biopsy six months after induction 
of immunosuppressive therapy is negatively associated with renal survival, with 
survival rates of 35.5% at 10-years in those with persistence of monocytes on biopsy 
versus 75.8% survival for those without (Hill et al., 2001). 
CD16
+ 
monocytes are present in the urine of patients with proliferative forms of 
nephritis including rapidly progressive crescentic glomerulonephritis, 
membranoproliferative glomerulonephritis and lupus nephritis unlike patients with 
non-proliferative renal disease such hereditary nephropathy and renal calculi. 
Increased urinary CD16+ monocytes are observed during acute exacerbations of 
urinary abnormalities and their disappearance closely precedes improvements in 
urinary abnormalities in patients with proliferative glomerulonephritis and therefore 






The role of Fc gamma receptors and myeloid cells in lupus nephritis 
Extracellular nucleic acids do not normally trigger cell activation in part because 
receptors for nucleic acids such as TLRs 3, 7, 8 and 9 are located in endosomes. 
However, when part of an immune complex, nucleic acids can be internalised into 
endosomes by Fc receptor bearing cells, and potently trigger TLR mediated 
activation of immune cells, which result in the production of type I interferon 
(Lövgren et al., 2004) . This is due to the fact that myeloid cells can internalise 
immune complexes via Fcγ receptors. NZB/NZW F1 lupus prone mice bearing a 
deletion of the common Fcγ chain do not develop proteinuria or histological 
evidence of lupus nephritis despite producing anti-DNA antibodies, circulating 
immune complexes and IgG and C3 deposits in glomeruli (Clynes et al., 1998). 
Therefore, antibody deposition alone is insufficient for the development of lupus 
nephritis; activation of FcR-bearing myeloid cells such as monocytes/ macrophages 
via immune complexes is required for pathogenicity to develop (Bergtold et al., 
2006). Indeed, Gr1
- 
monocyte expansion in BXSB Yaa mice is characterized by high 
expression of activating FcγRIV and low expression of inhibitory FcRγIIB 
(Santiago-Raber et al., 2009). 
The role of monocytes and TLR pathway activation in lupus nephritis 
Immunostaining of renal sections in MRL-lpr lupus-prone mice shows TLR7 
expression in infiltrating macrophages and repeated injection of the TLR7 ligand 
imiquimod aggravates glomerular disease in these mice with evidence of increased 
glomerular immune complex deposition and expression of CCL2 (Pawar et al., 
2006). Inhibition of TLR-7 signaling, results in reduced serum levels of 
autoantibodies including anti-Sm, improved activity and chronicity indices and 
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significantly decreases renal glomerular and interstitial macrophage infiltrates in 
MRL/ lpr mice (Pawar et al., 2007). 
TLR7-dependent nucleic acid ‘danger’ signals trigger intravascular retention of 
patrolling monocytes by the endothelium. Following this, monocytes recruit 
neutrophils in a TLR7-dependent manner to mediate focal necrosis of endothelial 
cells, with monocytes then removing the ensuing cellular debris (Carlin et al., 2013). 
 
Fractalkine antagonists ameliorate glomerular damage in lupus mouse models 
 Fractalkine (CX3CL1) and its receptor, CXRCR1, are known to mediate cell 
migration and adhesion (Imai et al., 1997) (Fong et al., 1998). Fractalkine is 
expressed on endothelial cells and is a membrane-bound chemokine that attracts 
cells expressing its receptor, CX3CR1, including CD16
+
 monocytes (Ancuta et al., 
2003). Renal histologic sections from lupus nephritis patients demonstrate 
fractalkine expression in the mesangial area and along the capillary wall in 
proliferative nephritis classes III and IV. There is a strong correlation between 
glomerular fractalkine expression, CD16
+ 
monocyte count and histopathological 
activity index (Yoshimoto et al., 2007). 
MRL/lpr mice show a progressive increase in renal fractalkine expression from 12 to 
20 weeks predominantly in glomerular endothelial cells and to a lesser degree in 
mesangial cells (Inoue et al., 2005). Antagonism of fractalkine by subcutaneously 
injecting MRL/lpr mice with an N-terminal truncated fractalkine analog transfected 
into a non-metastatic fibroblast cell line delays onset and slows progression of 
nephritis. Inhibition of fractalkine resulted in significantly lower levels of interstitial 
mononuclear cell infiltration, glomerular hypercellularity, crescent formation and 
glomerulosclerosis as compared to control MRL/lpr mice. There was a 75% 
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reduction in intra-glomerular macrophages in fractalkine antagonist treated mice 
compared to control, although no significant difference in intra-glomerular T cells 
was seen (Inoue et al., 2005). Proteinuria was significantly reduced in mice who 
received the fractalkine antagonist. Other features of autoimmunity such as 
pneumonitis, lymphadenopathy and splenomegaly did not improve with fractalkine 
inhibition in the MRL/lpr model. Circulating immune complexes and anti-DNA 
antibody levels were not reduced by fractalkine antagonism (Inoue et al., 2005).  
Further studies have demonstrated elevated fractalkine expression and CD16
+ 
monocyte accumulation within proliferative glomerular lesions in SCID mice, which 
lack T and B cells. Antagonism of fractalkine in this model protected against the 
development of glomerular endocapillary proliferative lesions and significantly 
reduced glomerular CD16
+ 
monocyte counts (Nakatani et al., 2010). It appears that, 
by stimulating CD16
+ 
monocyte accumulation, fractalkine contributes to the 
development of endocapillary proliferative glomerular lesions and thus represents a 
potentially important therapeutic target in ameliorating glomerular injury in lupus 
nephritis. 
These data strongly suggest that monocytes play an important role in the 
pathogenesis of lupus nephritis. Monocytes may represent a potential biomarker of 
disease activity with the extent of their presence being a predictor of poor renal 
outcome. Monocytes and the pathways governing their recruitment to the kidney and 
activation may represent legitimate therapeutic targets in the treatment of 





1.4 Thesis overview 
1.4.1 Thesis outline 
Chapter 1 has provided an introduction to SLE. Important concepts in pathogenesis 
have been discussed including the role of autoantibodies, TLRs, dysregulated 
apoptosis, complement pathways and type I interferon. The genetics of SLE has been 
introduced with an overview of lupus susceptibility genes identified in GWAS and 
monogenic causes of SLE that provide enlightening insights into lupus pathogenesis.  
Chapter 2 is a comprehensive clinical characterisation of the 164 lupus nephritis 
patients who were recruited for this study with the aim of identifying patients with a 
severe clinical phenotype who might represent good candidates for whole exome 
sequencing (WES). As an extension of this, Chapter 3 focuses on histopathological 
findings in our lupus nephritis cohort specifically ISN/RPS class of nephritis and 
CD68 glomerular immunostaining. 
Chapter 4 provides an in-depth description of genotype-phenotype relations of 
polymorphisms in lupus susceptibility genes identified in GWAS with clinical 
parameters in lupus nephritis patients. This is an attempt to try to make sense of 
GWAS findings in everyday clinical practice. In Chapter 5, the cumulative effect of 
these polymorphisms is analysed by compiling a polygenic risk score.   
Chapter 6 introduces WES and discusses sequencing results of 8 families with 
clustering of lupus nephritis in first degree relatives. Adopting this approach has 
culminated in a shortlist of novel candidate genes under consideration for future 
functional testing.  
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Chapter 7 summarizes the main findings of this research and discusses our data in 
the context of what is already known in the literature. Limitations of this research are 
discussed as well as an overview of recommendations and future directions. 
1.4.2 Thesis aims 
This thesis aims to explore genotype-phenotype relations in lupus nephritis. The first 
aim is to constitute and characterize a cohort of lupus nephritis patients; clinically, 
including renal outcomes and familial history, genetically, including  susceptibility 
polymorphisms identified in GWAS and potential novel causative genes by exome 
sequencing of selected patients, serologically including autoantibody profile and 
 histologically as per the ISN/RPS classification in conjunction with investigation of 
monocyte/ macrophage enrichment on renal biopsy. 
 
The second aim is to integrate these clinical, genetic, serological and histologic 
 findings in different clinical forms of lupus nephritis with a view to testing if 
 polymorphisms in lupus susceptibility genes correlate with clinical data, 
 histopathology findings or autoantibody profile. 
 
Our final aim, adopting a Mendelian approach by exome sequencing familial lupus  
nephritis is to identify novel causative genetic mutations with a view to future  









Clinical characterisation of lupus nephritis cohort 
 
The purpose of this chapter is to: 
1. Provide an overall clinical and demographic description of the cohort of 
lupus nephritis patients recruited for this study.  
2. Identify patients with a severe clinical phenotype of lupus nephritis.  
3. Determine if gender, ancestry, juvenile onset disease or family history of SLE 
















2.1 Ethical Approval and Recruitment Centres                                                                
Ethical approval for this research was given in March 2010 by the Outer South East 
London Research Ethics Committee (REC reference number 10/H0805/3) for the 
project entitled ‘CD14-CD16+ peripheral blood monocytes as both a reliable 
biomarker and a potential therapeutic target in lupus nephritis.’ This ethical approval 
was extended to facilitate patient recruitment from University College London 
Hospitals under the auspices of UCL/UCLH/RF Joint Biomedical Research Unit. 
When this initial ethical approval expired a second application was submitted 
entitled ‘Investigation of immune regulation and cellular response in autoimmune 
and inflammatory rheumatic diseases’ and a favourable opinion was given in 
September 2011 by the London City Road and Hampstead Research Ethics 
Committee (REC reference number 11/LO/1433). For both sets of ethical approval, 
the study sponsor was Guy’s and St Thomas’ NHS Foundation Trust Research and 
Development Department.  
Patients were recruited from the Louise Coote Lupus Unit at St Thomas’ Hospital 
(Professor David D’Cruz) (Dr Yousuf Karim), the Nephrology Department, Guy’s 
Hospital (Dr Mike Robson) and the Rheumatology Department at UCLH (Professor 
David Isenberg).  In addition, a family with clustering of lupus nephritis was recruited 
from the Rheumatology Department at Lahore, Pakistan (Dr Saira Khan and Dr Dr 






2.2 Study Participants 
164 biopsy-proven lupus nephritis patients were recruited from the designated 
clinical centres from July 2010 to January 2012. Serum, whole blood for DNA 
extraction and PBMCs (peripheral blood mononuclear cells) were stored for each 
patient recruited.  Paraffin-embedded renal biopsy slides were obtained where 
possible. In families with clustering of lupus nephritis, unaffected family members 
were invited to participate. 11 unaffected family members were recruited in total.  
Inclusion criteria included patients with a definite diagnosis of SLE according to the 
American College of Rheumatology (ACR) revised classification criteria (Hochberg 
et al., 1997), patients with biopsy-proven lupus nephritis, and patients capable to 
giving written informed consent prior to enrolment in the study. Individuals who 
were pregnant or breast-feeding and those unable to give written informed consent 
were excluded from the study. 
2.3 Clinical Variables 
Clinical variables explored in this study included gender, age at diagnosis of 
nephritis, family history of SLE, and ancestral background. Autoantibody positivity 
was ascertained including ANA, anti-dsDNA, anti-Ro, anti-Sm and anti-RNP. Long-
term renal outcomes in lupus nephritis patients were assessed using the National 
Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) 
scoring system (Collins et al., 2002). Information regarding a concurrent diagnosis 
of Antiphospholipid syndrome (APS) and/or the presence of anti-cardiolipin 
antibodies (aCL) and lupus anticoagulant (LA) was also gathered. Those with APS 
met the Sapporo classification criteria (Lockshin et al., 2000). 
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2.4 Statistical Analysis 
Continuous variables were described as mean with standard deviation (SD). 
Categorical variables were compared using Pearson's Chi-squared (χ2) test, except in 
instances where counts were <5, when a Fisher’s exact test was used. The 
D’Agostino-Pearson omnibus normality test was used to ascertain if data was 
parametrically or non-parametrically distributed. Student’s t-test or Wilcoxon rank 
sum tests were used to compare continuous variables that were normally or non-
normally distributed, respectively. Correlation between two quantitative variables 
was assessed using Pearson’s correlation coefficient, r, giving a   between +1 and −1, 
where 1 is a total positive correlation, 0 is no correlation, and −1 is a total negative 
correlation. A value of p<0.05 was considered to be significant. Analysis was carried 
out using GraphPad Prism 6 software. 
2.5 Materials and Methods 
2.5.1 Autoantibody testing 
Autoantibody profiles were performed in all patients at either Guy’s and St Thomas 
NHS Foundation Trust or University College London Hospital including ANA (anti-
nuclear antibodies), anti-double stranded DNA, anti-Ro (SS-A), anti-RNP 
(ribonucleoproteins) and anti-Sm (Smith antigen) antibodies using a standardized 
counterimmunoelectrophoresis (CIE). Availability of autoantibody results were as 
follows; ANA 99% (n=162), anti-dsDNA 98% (n=160), anti-Ro 93% (n=152) and 
92% (n=151) for anti-RNP and anti-Sm. Screening for LA was performed using the 
dRVVT (dilute Russell’s viper venom time) assay in accordance with standard 
methods (Miyakis et al., 2006). Confirmatory tests used a combination of mixing 
studies and correction with phospholipid. IgG and IgM aCL antibodies were 
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measured using a standardized ELISA (Harris et al., 1986). The normal reference 
range is 0-7 U/ml and levels above 20 U/ml (3 SD above the mean of the normal 
range) were considered moderate to high titres. Anti-C1q and anti-beta-2-
glycoprotein-1 (anti-β2-GP1) antibodies were available for a minority of patients 
only and hence were not included.  
2.5.2   NKF KDOQI scoring of chronic kidney disease 
The degree of chronic kidney disease was assessed as per the NKF KDOQI scoring 
system as follows; Stage 1, kidney damage with normal or elevated glomerular 
filtration rate (GFR), Stage 2, kidney damage with mild reduction in GFR (60-89 
mL/min); Stage 3, moderate reduction in GFR (30-59 mL/min); Stage 4, severe 
reduction in GFR (15-29 mL/min); Stage 5, kidney failure (GFR<15 or dialysis). 
Kidney damage was defined as ‘pathologic abnormalities or markers of damage, 
including abnormalities in blood or urine tests or imaging studies’ as per NKF 
KDOQI (Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, 
classification and stratification. 2002). Patients with KDOQI stages 4 and 5 were 
classified as having advanced renal impairment in our lupus nephritis cohort. 
2.6 Results 
2.6.1 Overall description of lupus nephritis cohort 
The study cohort was comprised of 85% (n=139) females and 15% (n=25) males. 
The mean current age of the cohort at study enrolment was 38.3 years ± 11.4 years. 
The overall mean age at diagnosis of nephritis was 25.8 ± 11.2 years. The mean 
disease duration in the group is 11.8 ± 7.5 years. 27% (n=44) of the study group 
were of juvenile onset as defined by diagnosis of nephritis before 18 years of age. 
62 
 
19% (n=31) were diagnosed with lupus nephritis before the age of 16 years and 2% 
(n=4) under the age of 10 years. 
2.6.2  A clinical comparison of lupus nephritis in patients of different ancestral 
backgrounds 
41% (n=68) of the cohort were of European origin, predominantly from the United 
Kingdom. 33% (n=54) were of African ancestry, the majority being of Afro-
Caribbean descent and others from Nigeria, Ghana, Sierra Leone and Uganda. 13% 
(n=21) were of South Asian extraction, all from India and Pakistan. 9% (n=14) were 
East Asian, from China, Vietnam and Singapore. 4% (n=7) were classified as 
outliers from the 4 main ancestral groups, 2 of these were from the Middle East and 
5 reported parental admixture. Of these 3 had an African parent and a European 
parent, 1 had an African parent and an East Asian parent and 1 had a European 
parent and an East Asian parent.  Population stratification will be discussed in more 
detail in the section pertaining to ImmunoChip analysis. 
Females accounted for 87% (n=47) of the African patients, 85% (n=58) of 
Europeans, 71% (n=15) of South Asians and 86% (n=12) of those of East Asian 
extraction. Juvenile onset disease was seen in equal measure in African and 
European patients at 24% each. The youngest onset patients were of East Asian 
ancestry with 50% diagnosed before age 18 years (Figure 2.1). Confirmed first 
degree family history of lupus nephritis was seen in 20% (n=11) of African patients 
and 14% of South and East Asian patients (n=3, n=2 respectively). None of the 
European patients had a first degree relative with lupus nephritis. East Asian patients 
were most likely to progress to ESRD at 14% (n=2), followed by African patients at 
11% (n=6), South Asian patients at 10% (n=2) and European patients at 6% (n=4). 
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The distribution of ISN/RPS classes in different ancestral background in lupus 
nephritis is available in Appendix 1. 
 



























































Mean age at diagnosis in lupus nephritis patients of European ancestry was 27.1 
±11.9 years, Africans 26.8 ±10.7 years, South Asians 23.9 ±12.0 years and East 
Asians 20.9 ±9.1 years. East Asian patients were significantly younger at diagnosis 
of nephritis than European patients (p=0.042), otherwise there were no statistical 






































































































































































































































ANA positivity was 98%, 94%, 95% and 93% for European, African, South Asian 
and East Asian respectively. Anti-dsDNA was highest in South Asian individuals at 
81%. European and East Asian patients both had 69% anti-dsDNA positivity and 
67% in Africans. Anti-Ro antibodies were most frequent in African and South Asian 
nephritis patients at 46% positivity. 28% of Europeans and 36% of East Asian were 
anti-Ro positive. Anti-RNP antibodies were seen in 61% of African and 64% of East 
Asians patients. European and South Asian individuals had less frequent anti-RNP 
antibodies at 18% and 25% respectively. Similarly anti-Sm antibodies were highest 
in African and East Asian patients at 39% and 45% positivity. South Asians and 
Europeans were less likely to have anti-Sm antibodies at 8% and 5% respectively. 
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2.6.3   Familial lupus nephritis 
During clinical assessment 13% (n=22) of patients randomly recruited self-reported 
a family history of SLE. 4 of these relatives with biopsy proven lupus nephritis were 
subsequently recruited to the study resulting in a total of 26 patients with a family 
history of SLE in our cohort. A first-degree family history was defined as having 
parents, siblings or children affected with SLE. A second-degree family history was 
defined as having affected grandparents, grandchildren, aunts, uncles, nephews, 
nieces or half-siblings. A third-degree family history was defined as having affected 
first-cousins, great-grandparents or great grandchildren. 10% (n=16) self-reported a 
first degree family history which included sibling pairs and parent-child 
combinations. 3% (n=5) reported a second degree family history and 3% (n=5) a 
third degree family history. All self-reported first degree family relatives were 
confirmed with the exception of one. Relatives with biopsy proven lupus nephritis 
were also recruited to the study where possible. In addition, unaffected family 
























SLE 19 F African No Brother with confirmed nephritis 
Sister with non-renal SLE 
 
SLE 24 F African Yes Brother with confirmed nephritis 
 
SLE 40 F African Yes Father with confirmed discoid 
lupus/membranous nephritis 
 
SLE 55 F African No Mother with confirmed nephritis 
 
SLE 56 F African No Sister with confirmed nephritis 
 
SLE 95 F African No Sister with confirmed nephritis  
 
SLE 112 F African No Sister with confirmed nephritis  
 
SLE 127 M African No Sister with confirmed SLE 
 
SLE 128 M South 
Asian 
Yes Mother with confirmed nephritis 
 
SLE 131 M South 
Asian 
Yes Brother with confirmed nephritis,  
SLE 132 M South 
Asian 
Yes Brother with confirmed nephritis,  
 
SLE 139 M African Yes Sister with confirmed nephritis 
 
SLE 143 M East Asian Yes Brother with confirmed nephritis 
 
SLE 146 M East Asian Yes Brother with confirmed nephritis 
 
SLE 153 F African No Sister with confirmed nephritis 
 







All five patients who reported a second degree family history of SLE were female. 
Two were European, one was African, one was East Asian and one was of other 
ancestry. Two of these patients had juvenile-onset disease. Three of these patients 
reported non-renal SLE in aunts but the clinical details have not been confirmed. A 
further patient reported SLE in an uncle and another stated her grandmother had 
SLE, the clinical details of these relatives have not been confirmed by our study 
group. Four of the five patients who reported a third degree family history of SLE 
were female.  Four patients were African and one was European. All reported 
cousins with SLE but the clinical details have not been confirmed. 
In second and third degree relatives with reported SLE, no cases of lupus nephritis 
were confirmed neither was any further individual recruited to the study on the basis 
of self-reported information. We then carried out a clinical comparison of 
demographic and phenotypic data of lupus nephritis patients with a confirmed first 
degree family history and sporadic cases of lupus nephritis. Individuals with a self-
reported second or third degree family history were excluded from this analysis.  
2.6.4   Clinical comparison of familial and sporadic onset nephritis 
56% (n=9) of those with a confirmed first degree family history of lupus nephritis 
were female as compared to 88% (n=121) of sporadic cases (**p=0.0042). Familial 
cases were younger (Figure 2.3) with 50% (n=8) of juvenile onset as opposed to 22% 
(n=30) in the sporadic onset group (*p=0.027). 31% (n=5) and 16% (n=22) of 
patients were diagnosed before age 16 years in the familial and sporadic groups 
respectively (p=0.160). 13% (n=2) of the familial nephritis patients were diagnosed 




69% (n=11) of familial cases were African while this ancestry accounted for 28% 
(n=38) of sporadic patients (**p=0.0015). No European patients were classified as 
having a first degree relative with lupus nephritis. 19% (n=3) of familial and 13% 
(n=18) of sporadic cases were of South Asian origin (p=0.460). 13% (n=2) of 
familial and 8% (n=11) of sporadic onset patients were of East Asian ethnicity 
(p=0.627). 
25% (n=4) of familial nephritis cases had progressed to advanced renal disease while 
7% (n=9) has done so in the sporadic onset patient cohort (*p=0.032). The duration 
of clinical follow-up was longer in the familial group than the sporadic group, 15.1 ± 
6.8 years and 11.3 ± 7.3 years respectively (p=0.054). The distribution of ISN/RPS 
classes in familial and sporadic lupus nephritis is available in Appendix 2. 
Figure 2.3: Age of diagnosis of nephritis in familial and sporadic cases 





























Mean age of diagnosis of lupus nephritis in familial cases was 20.4 ± 10.6 years and 




Figure 2.4: Autoantibody profile in familial and sporadic lupus nephritis 
























































































ANA positivity was 94% in familial lupus nephritis and 97% in sporadic onset 
disease (p=1.0). Anti-dsDNA antibodies were present in 67% of familial and 71% of 
sporadic cases (p=0.77). Anti-Ro were positive in 40% of familial and 36% of 
sporadic nephritis patients (p=0.76). Anti-RNP antibodies were seen in 43% and 
36% of familial and sporadic respectively (p=0.61). Anti-Sm antibody positivity was 








2.6.5   A clinical comparison of juvenile and adult onset lupus nephritis 
27% (n=44) of the study cohort were of juvenile onset as defined by diagnosis of 
nephritis before 18 years of age, while 73% (n=120) were of adult onset. 19% (n=31) 
were diagnosed with lupus nephritis before the age of 16 years and 2% (n=4) were 
diagnosed under the age of 10 years. 68% (n=30) of juvenile onset lupus nephritis 
patients were female as compared to 91% (n=109) of adult onset patients 
(***p=0.0009).  
Juvenile onset patients were more likely to progress to ESRD at 16% (n=7) in 
comparison with 7% (n=8) of adult onset disease but this did not reach statistical 
significance (p=0.069). Duration of clinical follow-up was longer in the juvenile 
onset patients than the adult onset group, 14.2 ± 0.94 years and 10.8 ± 0.75 years 
respectively (*p=0.015)).  57% (n=4) of juvenile patients who developed ESRD 
were female and 43% (n=3) were male. 57% (n=4) were of African ancestry, 29% 
(n=2) were of South Asian descent and 14% (n=1) were European.  
18% (n=8) of juvenile onset patients had a confirmed first degree family history of 
lupus nephritis while only 7% (n=8) of adult onset patients did so (*p=0.038). 
Juvenile patients with a first degree family history were more likely to develop 
advanced renal impairment than sporadic onset juveniles (*p=0.014). 
30% (n=13) of juvenile onset patients and 34% (n=41) of adult patients were of 
African origin (p=0.577). 36% (n=16) of juvenile and 43% (n=52) of adult onset 
disease were European (p=0.422). South Asian ancestry was seen in 14% (n=6) of 
juvenile onset and 13% (n=15) of adult onset (p=0.847). 18% (n=8) of juvenile onset 
were of East Asian extraction as compared to 5% (n=6) of adult onset (**p=0.007).  
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Figure 2.5   Autoantibody profile in juvenile and adult onset lupus nephritis 
























































































The frequency of ANA was similar in both groups at 95% and 97% positivity in 
juvenile and adult onset respectively (p=0.51). Anti-dsDNA was present in 70% of 
both groups (p=0.81). Anti-Ro antibody was positive in 31% of juvenile onset cases 
and 38% of adult onset patients (p=0.43). Anti-RNP antibody was more frequently 
found in adult onset nephritis at 40% positivity as compared to 29% of juvenile onset 
individuals (p=0.19). Anti-Sm antibody was similar in both groups at 19% in 
juvenile and 20% in adult onset disease (p=0.89). 
The distribution of ISN/RPS classes in juvenile and adult onset lupus nephritis is 




2.6.6 A clinical comparison of male and female nephritis 
Male patients were diagnosed with lupus nephritis at a significantly younger age than 
their female counterparts (Figure 2.6). 56% (n=14) of males were diagnosed before 
the age of 18 as opposed to 21% (n=29) of females (***p=0.0008). 44% (n=11) of 
males were diagnosed below age 16 years as compared to 14% (n=20) of females 
(**p=0.0014). 12% (n=3) of males had very early onset nephritis, younger than 10 
years while only 1 female presented in this age group (*p=0.011). 
The mean age of female nephritis patients at study enrolment was 38.8 ± 10.9 years, 
while the mean current age for male patients was lower at 35.5 ± 14.8 years 
(*p=0.028). There was no significant difference in progression to end-stage renal 
failure between the genders with 9% (n=12) of females and 12% (n=3) of males 
reaching KDOQI stages 4 and 5 (p=0.591). The duration of follow-up between the 
two groups was similar, 11.5 ± 7.7 years in females and 13.2 ± 6.2 years in males 
(p=0.138).  
28% (n=7) of male patients and 34% (n=47) of female patients were African 
(p=0.569). 36% (n=10) of males and 42% (n=58) of females were of European 
ancestry (p=0.872). 24% (n=6) of male nephritis patients and 11% (n=15) of females 
were of South Asian extraction (p=0.069). 8% (n=2) of males and 9% (n=12) 
females were of East Asian origin (p=0.917).  
Confirmed first degree family history of lupus nephritis was significantly more 
common in male patients at 28% (n=7) when compared to females at 6% (n=9) 
(***p=0.0008). The distribution of ISN/RPS classes in male and female lupus 




Figure 2.6    Age at diagnosis of lupus nephritis in female and male patients 
 































Mean age at diagnosis in male lupus nephritis was 21.3 ± 14.8 years while mean age 


































































































Figure 2.8    Autoantibody profile in female and male lupus nephritis 
 

























































































Anti-RNP antibody was more prevalent in female lupus nephritis patients at 41% as 
opposed to 17% in male patients (*p=0.037). Otherwise there were no significant 
differences in autoantibody positivity between the genders. ANA positivity was seen 
in 96% of females and 97% of males (p=0.572). Anti-dsDNA was positive in 71% of 
females and males (p=0.981). Anti-Ro tested positive in 38% of females and 29% of 






2.6.7   Bimodal distribution of disease onset in male lupus nephritis patients  
A bimodal distribution of nephritis onset was noted in male patients. 84% (n=21) 
developed nephritis in the 2nd and 3rd decades while 16% (n=4) developed later-onset 
disease in the 5th and 6th decades. Mean age of diagnosis for the younger males was 
16.5 ± 7.2 years and 54.2 ± 7.4 years in the older onset age group. 33% (n=7) of the 
younger males had a family history of SLE while none of the older males did. 14% 
(n=3) of the younger males have progressed to end-stage renal failure while none of 
the older group have done so despite similar length of follow-up between the two 
groups (13.5 ± 6.4 years and 11.2 ± 3.7 years respectively, p=0.436). 75% (n=3) of 
the older onset group were of European ancestry and 25% (n=1) was of South Asian 
origin. In the younger onset nephritis group 33% (n=7) were African, 33% (n=7) 
were European, 24% (n=5) were South Asian and 10% (n=2) were East Asian. There 
were no significant differences in autoantibody positivity between the two groups. 
2.6.8   Antiphospholipid syndrome in lupus nephritis 
16% (n=27) of lupus nephritis patients recruited to this study had a concurrent 
diagnosis of APS. 25% (n=41) had positive aCL and 29% (n=47) had a positive LA. 
89% (n=24) of lupus nephritis patients with APS were female as compared to 84% 
(n=115) of those without APS (p=0.77). 4% (n=1) of those with APS and lupus 
nephritis had a first degree family history of lupus nephritis as opposed to 11% 
(n=15) of non-APS patients (p=0.48). Progression to advanced renal impairment did 
not significantly differ between APS and non-APS with 8% (n=2) and 9% (n=13) 
respectively (p=1.0). 48% (n=13) of APS patients and 42% (n=55) of non-APS were 
European (p=0.58). 22% (n=6) of APS and 37% of non-APS (n=48) were African 
(p=0.14). 19% (n=5) of APS and 12% (n=16) of non-APS were South Asian 
(p=0.39). 7% (n=2) of APS and (n=12) 10% of non-APS were East Asian. 
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Figure 2.9    Age of diagnosis of lupus nephritis in patients with and without APS 































Mean age at diagnosis in lupus nephritis with APS was 30.1 ± 12.0 years while mean 

















2.6.9   Progression to advanced renal impairment in lupus nephritis 
To date 9% (n=15) of the study cohort have progressed to ESRD and 40% (n=6) of 
these have undergone renal transplantation. 80% (n=12) of those who progressed to 
ESRD were female and 20% (n=3) were male.  47% (n=7) were of African ancestry, 
27% (n=4) were European, 13% (n=2) were of South Asian ethnicity and 13% (n=2) 
were of East Asian origin. 27% (n=4) had a confirmed first degree family history of 
lupus nephritis. 47% (n=7) were originally diagnosed with nephritis younger than 18 
years of age. 33% (n=5) were diagnosed before age 16 years and 7% (n=1) before 
the age of 10 years. Of the nine renal biopsy samples available from these patients 
for our study all had proliferative nephritis, 56% (n=5) had class IV-G nephritis, 
33% (n=3) had class IV-S nephritis, and 11% (n=1) had class III nephritis.  
100% (n=15) were ANA positive, 75% (n=11) were anti-dsDNA positive, 27% 
(n=4) were anti-Ro positive, 33% (n=5) were anti-RNP positive and 27% (n=4) were 
anti-Sm positive. 13% (n=2) had a concurrent diagnosis of APS. 20% (n=3) had a 











2.7 Chapter Overview and Discussion 
 
 
2.7.1   Lupus nephritis in different ancestral backgrounds 
 
SLE is known to be more common and clinically more severe in non-European 
populations. Large multi-ancestral studies such as LUMINA (LUpus in MInorities: 
NAture versus Nurture) have helped characterize the role of ancestry in clinical 
phenotype and outcomes in SLE (Alarcon et al., 2004; Fernandez et al., 2007). 
SLE patients of African ancestry have an increased frequency of lupus nephritis as 
compared to Caucasians (Alarcon et al., 1999; Hopkinson et al., 2000; Seligman et 
al., 2002). In fact European ancestry has been found to be protective against 
development of nephritis in SLE (Richman et al., 2012). African SLE patients 
experience more damage accrual and higher progression to ESRD than those of 
European ancestry (Dooley et al., 1997; Alarcon et al., 2001; Bastian et al., 2002; 
Korbet et al., 2007).  
East Asian patients have been shown to have younger onset disease with a higher 
frequency of renal and CNS involvement (Thumboo et al., 2001; Johnson et al., 
2006; Peschken et al., 2009; Golder et al., 2013). Some authors have shown 
increased renal and overall damage accrual in East Asian patients (Thumboo et al., 
2001; Johnson et al., 2006). However a large multi-ancestral study in Canada 
comparing East Asian with Caucasian and African SLE patients did not find 
ethnicity to be predictive of damage accrual (Peschken et al., 2009). 
In the United Kingdom the estimated prevalence of lupus nephritis in females is 
reported to be 110.3 per 100,000 in Chinese patients, 99.2 per 100,000 in Afro-
Caribbean, 21.4 per 100,000 in Indo-Asian and 5.6 per 100,000 in Caucasian patients 
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(Patel et al., 2006). Our cohort of patients was of a multi-ancestral background with 
41% of European origin, 33% of African ancestry, 13% of South Asian extraction, 
and 9% from East Asia. Patients of European ancestry had the latest onset of disease 
at 27.1 ±11.9 years. East Asian patients had the earliest onset disease at 20.9 ±9.1 
years, followed by South Asians at 23.9 ±12.0 years and Africans at 26.8 ±10.7 
years. In keeping with the literature Caucasian patients were the least likely to 
progress to ESRD at 6%, while non-European patients in our cohort had a similar 
frequency of advanced renal impairment of 12% approximately. It was difficult 
however to draw conclusions from the South and East Asian subgroups due to the 
limited number of patients.  
In our cohort, ANA positivity was similar in European, African and South Asian 
patients and somewhat lower in East Asian patients at 93%. It is well established that 
anti-Sm and anti-RNP are more commonly seen in African SLE patients than those 
of European ancestry (Arnett et al., 1988; Quintero-Del-Rio et al. 2001; Cooper et 
al., 2002). In our patient population, anti-RNP antibodies were seen in 61% of 
African and 18% of Europeans. Similarly, anti-Sm antibodies were more frequent in 
African nephritis patients at 39% as compared to 5% of Europeans. 
East Asian SLE patients have been reported to have higher anti-dsDNA, anti-Ro, 
anti-RNP and anti-Sm than Caucasian patients (Golder et al., 2013). Findings were 
similar in our cohort. Less has been published regarding autoantibody profile data in 
South Asian patients. ANA and anti-dsDNA prevalence has been reported to be 
similar in Indian SLE patients to other ethnicities (Malaviya et al., 1997). The 
authors also reported anti-Sm antibody positivity to be more common than in 
European patients but less prevalent than in Africans. Anti-Sm was least frequent in 
South Asian patients in our cohort at only 5%. 
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2.7.2   Familial versus sporadic onset lupus nephritis 
 
An increased frequency of autoimmune disease in relatives of SLE patients is well 
documented in the literature. A study of 69 juvenile onset SLE patients of multiple 
ancestries revealed that 42% had a first, second or third degree family history of 
autoimmune diseases such as SLE, thyroid disease, psoriatic arthritis, rheumatoid 
arthritis, spondyloarthropathy, vitiligo, multiple sclerosis or type I diabetes mellitus. 
The most frequent autoimmune diseases seen in their relatives were SLE at 21% and 
thyroid disease at 15%.  However having a family history of general autoimmune 
disease did not correlate with more severe SLE in their cohort (Walters et al., 2012). 
Previous work by Pluchinotta et al divided juvenile onset SLE into 3 subgroups; 
infantile (<age 2), pre pubertal and post pubertal. Family history of autoimmune 
disease was seen in 46% of infantile cases, 25% of prepubertal and 29% of post 
pubertal patients (Pluchinotta et al., 2007). In a study of juvenile SLE in the UK, 
15% of juvenile cases had a family history of SLE and 38% had a family history of 
autoimmune disease in general (Watson et al., 2012). 
 
A retrospective study, by Apenteng et al, investigated whether children with lupus 
nephritis and a family history of autoimmune disease had worse renal outcomes 
when compared with those who did not have a family history. They found that male, 
African patients with a family history of autoimmunity were more likely to double 
their serum creatinine and reach ESRD (Apenteng et al., 2006). Familial clustering 
of ESRD has been demonstrated in African patients with lupus nephritis (Freedman 
et al., 1997). Multiplex SLE families in Saudi Arabia have been shown to have 




Other reports, however, do not support a more severe clinical phenotype in familial 
SLE cases. Multi-ancestral studies in the United States have not shown any 
difference in damage accrual or survival between familial and sporadic cases of SLE 
(Sestak et al., 2008; Burgos et al., 2010). A study of Chinese lupus nephritis patients 
found that clinicopathological features did not differ between familial and sporadic 
cases other than that class V nephritis was less common in familial disease (Wang et 
al., 2009). A large French study of 125 Caucasian multiplex SLE families did not 
show any differences in gender ratio, age of onset, clinical or immunologic features 
when compared to sporadic onset SLE controls (Michel et al., 2001). 
 
69% of familial cases in our patient population were African, 19% were South Asian 
and 13% were East Asian. No European patients in our study had a first degree 
relative with lupus nephritis. In our cohort, familial cases were younger with 50% of 
juvenile onset as opposed to 22% in the sporadic onset group. Mean age of diagnosis 
in familial cases was 20.4 ± 10.6 years and 26.7 ± 11.2 years in sporadic cases. Data 
on frequency of family history of other autoimmune diseases was not collected in 
our patient group. Juvenile onset patients with a first degree family history of lupus 
nephritis in our study population were significantly more likely to develop advanced 
renal impairment than sporadic onset juvenile cases (25% versus 7%). Two of these 
were of African descent and two were of South Asian ancestry. Autoantibody profile 
was not significantly different between familial and sporadic cases nor was the 
distribution of proliferative and membranous nephritis between the two groups.  
Overall, we found familial lupus nephritis cases to have a more severe clinical 
phenotype in our cohort. This may have been influenced by our strict definition of 
familial disease that only included first degree relatives with confirmed clinical 
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details and biopsy proven lupus nephritis rather than self-reported histories. Many of 
the studies in the literature have used a broader definition and reported on family 
history of autoimmune disease in general in first, second and third degree relatives. 
Another relevant demographic feature of our families with clustering of nephritis is 
that they were all of non-European ancestry, the majority being African who are 
known to have an increased frequency of nephritis and more severe disease. 
 
2.7.3 Juvenile versus adult onset lupus nephritis 
 
An estimated 20% of SLE is diagnosed in childhood or adolescence and is generally 
defined in the literature as disease onset before 16 years of age (Jimenez et al., 2003; 
Mina et al., 2010). Juvenile onset SLE typically manifests between the ages of 12 
and 14 years and remains extremely rare under the age 5 years (Kamphuis et al., 
2010; Watson et al., 2012).  27% of the patients in our cohort were diagnosed with 
nephritis before 18 years of age, 19% before the age of 16 years and 2% under the 
age of 10 years. The youngest patient in our cohort was diagnosed at 2 years of age. 
Female preponderance in SLE is well established in adult populations with a female: 
male ratio of 10:1.  In juvenile onset SLE this female preponderance is less 
pronounced with a female: male ratio of approximately 5-6:1 (Lo et al., 1999; Hiraki 
et al., 2008; Mina et al., 2010; Watson et al., 2012). In our cohort 68% of juvenile 
onset lupus nephritis patients were female as compared to 91% of adult onset 
patients.  
Patients with juvenile onset SLE tend to present with a more aggressive disease 
course and a higher frequency of internal organ involvement such as nephritis and 
CNS disease than their adult onset counterparts. In addition, juvenile onset SLE 
patients are subject to more damage accrual over time leading to increased morbidity 
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and mortality in the long-term (Gutierrez Suarez et al., 2006; Brunner et al., 2008; 
Tucker et al., 2008). Lupus nephritis is more often a presenting feature of SLE in 
juvenile onset patients when compared to adult onset disease (Brunner et al., 2008; 
Tucker et al., 2008). In addition, lupus nephritis is clinically more aggressive in 
juvenile cases with significantly higher adjusted mean SLEDAI renal scores than in 
the adults with lupus nephritis (Font et al., 1998; Brunner et al., 2008; Sato et al., 
2012). In our cohort juvenile onset patients were more likely to progress to ESRD 
than those with adult onset disease (16% versus 7%). It should be noted, however, 
that the duration of clinical follow-up was longer in juvenile onset than in the adult 
onset disease in our study (14.2 ± 0.94 years versus 10.8 ± 0.75 years).  
Levy et al explored the influence of ethnicity on childhood onset SLE in a multi-
ancestral cohort of patients clustered into mild, moderate and severe disease. They 
demonstrated that 20% of European patients were in the severe cluster as compared 
to 51% of Asian and 41% of African patients (Levy et al., 2013).  In contrast, 
Miettunen et al found that neither gender nor non-European ancestry was associated 
with a worse clinical outcome in juvenile onset SLE patients (Miettunen et al., 
2004). In our cohort, 57% of juvenile onset patients who progressed to ESRD were 
of African ancestry, 29% were of South Asian descent and 14% were European.  
Al-Mayouf et al reported that male juvenile onset lupus nephritis had a higher 
progression to renal failure requiring dialysis or renal transplantation than female 
patients (Al-Mayouf et al., 2008). This was not the case in our patient cohort with 




A significant difference in frequency of ISN/RPS classes between juvenile and adult 
nephritis was not detected in our cohort. Previous studies have suggested a similar 
distribution of histologic classes in juvenile and adult onset lupus nephritis (Brunner 
et al., 2008). Marks et al showed the following distribution of ISN/RPS classes in 
juvenile lupus nephritis cases: 2%, 13%, 15%, 51% and 20% for classes I-V, 
respectively, which is similar to the findings in our group of juvenile patients (Marks 
et al., 2007).  
The vast majority of SLE patients have positive ANA. This was true for both adult 
and juvenile onset patients in our cohort. Previous studies in the literature have 
shown that anti-dsDNA antibodies are more common and at higher titre in juvenile 
than adult onset SLE (Font et al., 1998; Hiraki et al., 2008; Hoffman et al., 2009). 
Our cohort had equal prevalence of anti-dsDNA with 70% positivity in both age 
groups. Anti-dsDNA antibody titres were not measured as part of our study. Anti-Ro, 
anti-RNP and anti-Sm antibodies are thought to be equally prevalent in juvenile and 
adult onset lupus (Hoffman et al., 2009). While anti-Ro and anti-RNP were more 
frequent in juvenile than adult onset disease in our cohort with 31% versus 38% and, 
40% versus 29%, respectively, these findings not did reach statistical significance. 
Anti-Sm antibody was similar in both age groups in our cohort with 19% positivity 
in juvenile and 20% in adult onset disease. 
2.7.4 The role of gender in lupus nephritis 
 
While SLE is more common in females than males, males who develop SLE have a 
higher prevalence of lupus nephritis in both juvenile and adult onset disease 
(Kaufman et al., 1989; Molina et al., 1996; Carbone et al., 2002; Voulgari et al., 
2002; Soto et al., 2004; Garcia et al., 2005). Some authors have observed an 
increased rate of progression to ESRD in male lupus nephritis (Specker et al., 1994; 
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Carbone et al., 2002) while others have not demonstrated a difference in disease 
severity (Miller et al., 1983; Renau et al., 2012). A multiethnic US cohort has shown 
that male SLE patients have a poorer long-term prognosis than females in terms of 
damage accrual due to accelerated damage particularly early on in their disease 
course (Andrade et al., 2007) 
 
A comparison of SLE clinical data in a UK cohort over a 30-year period found a 
similar age of onset (29.3 years) in male and female patients (Renau et al., 2012). 
Male patients in their study had a different proportion of ancestral backgrounds than 
our cohort with 66% of European ancestry, 13% African and 18% South Asian. Our 
study cohort was more representative of non-European ancestries with male patients 
comprised of 36% Europeans, 28% Africans and 24% South Asians. In our patient 
population males were diagnosed with lupus nephritis at a significantly younger age 
(21.3 ± 14.8 years) than their female counterparts (26.6 ± 10.2 years). 44% of males 
in our study were diagnosed below age 16 years as compared to 14% of females. We 
noted a bimodal distribution of nephritis diagnosis in males.  A similar distribution of 
disease onset in males was seen in the Renau study. 31% of males and 36% of 
females developed lupus nephritis in their study with 4.4% of males and 6.6% of 
females progressing to ESRD. In a similar fashion, we did not demonstrate a 
significant difference in progression to advanced renal impairment between genders 
in our study with 9% of females and 12% of males reaching KDOQI stages 4 and 5.  
Autoantibody profile has been reported to be similar in males and females by some 
authors (de Carvalho et al., 2009; Renau et al., 2012) while others have documented 
more frequent anti-dsDNA and anti-Sm antibodies in male patients (Molina et al., 
1996; Soto et al., 2004). In our cohort, anti-RNP antibody was significantly more 
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prevalent in female lupus nephritis at 41% as opposed to 17% in males. While anti-
Ro and anti-Sm antibodies were more common in females than males (38% versus 
29%) and (22% versus 9%) respectively, these did not reach statistical significance. 
There were similar frequencies of ANA and anti-dsDNA positivity in both genders in 
our study population. 
2.7.5   Bimodal distribution of lupus nephritis 
A bimodal distribution of nephritis onset was noted in male patients within our study 
group with 84% developing nephritis in the 2nd and 3rd decades and 16% later on in 
the 5th and 6th decades. A review of 47 patients with SLE onset after the age of 50 
years from a tertiary referral centre combined with analysis of a further 714 cases 
from the literature found lower disease severity and a less pronounced female: male 
ratio (4:1) in older onset patients. The authors also demonstrated that deaths occurred 
more frequently in late-onset patients, with a 10-year survival rate of 71% as 
compared to 95% in early-onset disease, although the ultimate causes of death were 
usually unrelated to SLE (Boddaert et al., 2004). 14% of the younger males in our 
cohort have progressed to ESRD while none of the older group of males have done 
so despite similar length of follow-up in the two groups (13.5 ± 6.4 years and 11.2 ± 
3.7 years respectively). Two females were diagnosed with lupus nephritis over the 
age of 50 years in our cohort and both have well maintained renal function. The 
majority of older-onset patients in our study were of European ancestry. 
 
2.7.6   APS in lupus nephritis 
 
Anti-cardiolipin antibodies and lupus anticoagulant were positive in 25% and 29% of 
the cohort respectively, figures that are comparable to the literature (McNeil et al., 
1992). 16% of lupus nephritis patients in our study had a concurrent diagnosis of 
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APS. Previous studies have described the association between Antiphospholipid 
Syndrome Nephropathy (APSN), and hypertension, higher serum creatinine and 
more severe interstitial fibrosis on biopsy. Classic findings of APSN include acute 
thrombotic microangiopathy, arterial fibrous intimal hyperplasia and focal cortical 
atrophy (Nochy et al., 1999). Studies of European lupus nephritis patients have failed 
to demonstrate more rapid progression to end-stage renal failure in those with co-
existent APSN (Daugas et al., 2002; Tektonidou et al., 2004). A study of Thai SLE 
patients found an association between APSN and poor renal outcome (Cheunsuchon 
et al., 2007). Patients in our cohort with APS in addition to lupus nephritis did not 
have an increased rate of developing advanced renal impairment as compared to non-
APS nephritis patients. Specific histologic findings of APSN were not examined in 




The patient population in our study was of a multi-ancestral background. As 
expected, non-European lupus nephritis patients had a younger age of onset and 
higher rate of progression to ESRD. Familial clustering of nephritis was associated 
with juvenile onset disease and a more severe clinical phenotype. Several probands 
within these families have required renal replacement therapy. While male nephritis 
patients in our cohort were younger and frequently had a family history, overall they 
did not have an increased progression to ESRD. This outcome may have been 
affected by the bimodal distribution of disease onset in males and the small number 
of older-onset males with relatively benign disease. The next step in our genotype: 
phenotype analysis of lupus nephritis will be to assess if lupus susceptibility 






Histopathological findings in lupus nephritis cohort 
 
The purpose of this chapter is to: 
1. Discuss renal histology findings including ISN/RPS class of nephritis and 
CD68 glomerular immunostaining  















As outlined earlier in this thesis, there is growing evidence from studies involving 
patients with proliferative lupus nephritis and from experiments in lupus mouse 
models as to the importance of monocytes in renal damage. In this chapter, we will 
evaluate glomerular CD68 immunostaining as a general monocytes/macrophage 
marker and correlate this with age at diagnosis of nephritis, gender, ancestry and 
other clinical parameters of clinical activity including proteinuria. We will also 
classify the patients enrolled in our study as per the ISN/RPS classification of lupus 
nephritis, introduced in 2004 to replace the previous WHO classification (Weening et 
al., 2004). 
3.2 Study Participants 
Paraffin-embedded renal biopsy tissue was available from 77% (n=126) of lupus 
nephritis patients recruited to this study. Biopsies were traced back to the time of the 
patients’ original diagnosis of lupus nephritis (n=107) or when this was not possible 
biopsies taken at the onset of a new nephritis flare before induction 
immunosuppression was commenced were obtained (n=19).  During analysis of 
immunostaining, slides with < 7 glomeruli present were excluded. 
3.3 Clinical Variables 
Histologic variables included NIH (National Institutes of Health) activity index (AI), 
chronicity index (CI) and ISN/RPS class of lupus nephritis. CD68 immunostaining 
in the glomerular tuft was examined as a general monocyte/macrophage marker. 
Urinary protein-creatinine ratio (uPCR) at the time of renal biopsy was examined 




3.4 Statistical Analysis 
Descriptive statistics (mean, SD) were calculated to compare between groups. 
Categorical variables were compared using Pearson's Chi-squared (χ2) test, except in 
instances where counts were <5, when a Fisher’s exact test was used. The 
D’Agostino-Pearson omnibus normality test was used to ascertain if data was 
parametrically or non-parametrically distributed. Student’s t-test or Wilcoxon rank 
sum tests were used to compare continuous variables that were normally or non-
normally distributed, respectively. Correlation between two quantitative variables, 
for example, CD68 count and urinary protein-creatinine ratio was assessed using 
Pearson’s correlation coefficient, r. A value of p<0.05 was considered to be 
significant. 
3.5 Materials and Methods 
3.5.1 Histological techniques with renal biopsy tissue 
Paraffin-embedded renal biopsy slides from transplant rejection patients were 
available and used to optimise immunostaining protocols prior to trial 
immunostaining of lupus nephritis renal biopsies. Unfortunately co-staining of lupus 
nephritis slides with CD68 and CD16 did not consistently provide satisfactory 
images for accurate quantification of cell counts in the glomerulus by confocal 
imaging. Given the limited amount of renal tissue that was available, it was decided 
to proceed to light microscopy for quantification of CD68 in the glomerulus.  
3.5.2 Confocal Microscopy 
Renal biopsy slides were de-paraffinised using a xylene de-waxing protocol. Slides 
were then rehydrated with decreasing percentages of ethanol (100%, 70% 50%). 
Antigen retrieval was performed using trisodium citrate (2.94g in 1L deionized 
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water, pH 6.0) where the slides were brought to boiling point in a microwave. Goat 
IgG at a 1/60 dilution was used as a blocking antibody and incubated for 30 minutes 
at room temperature. Primary mouse monoclonal antibodies CD68 (IgG1) at 1/100 
dilution or CD31 (IgG1) at 1/50 dilution and CD16 (IgG2a) at 1/50 dilution were 
incubated for 1 hour at room temperature. Purified mouse IgG1 and IgG2a were used 
as isotype controls. DyLight 488 goat anti-mouse IgG1 and DyLight 549 goat anti-
mouse IgG2a were used as secondary antibodies. Slides were mounted with Prolong-
Gold Anti-fade with DAPI at a 1/300 dilution. Coverslips were placed on the slides 
and allowed to dry thoroughly overnight prior to confocal imaging.  
A Leica SP5 microscope was used to obtain images. The 10x dry, the 20x dry and 
40x oil objectives were used, with 0.4, 0.5 and 1.25 numerical apertures.  Images 
were acquired with a resolution of 1024 x 1024 or 512 x 512 pixels and a scan speed 
of 200 or 400Hz.  All confocal images were acquired and analysed using Leica LAS-
AF software. 
 
3.5.3 CD68 immunostaining 
Slides were deparaffinised with xylene as described previously and a Tris buffer 
antigen retrieval protocol was followed. Mouse anti-human CD68 (Dako, KP-1) was 
used. Sections were then counterstained with haematoxylin. Once mounted and 
dried, the slides were scanned and the number of CD68 positive cells in the 
glomerular tuft was quantified using a virtual microscope, Pannoramic Viewer 
(3DHISTECH). The surface area of the tuft was used to correct for glomerular size 
using the Pannoramic Viewer software. This analysis was carried out by Dr Suzanne 




3.5.4 ISN/RPS classification 
ISN/RPS classification subdivides lupus nephritis into 6 classes (Weening et al., 
2004): 
Class I: Minimal mesangial disease 
Class II: Mesangial proliferative lupus nephritis 
Class III: Focal lupus nephritis (<50% of glomeruli involved) 
Class IV is when >50% of glomeruli are involved and is subdivided into 2: 
Class IV-G: diffuse global lupus nephritis, when ≥50% of the involved glomeruli 
have global lesions. 
Class IV-S: diffuse segmental lupus nephritis, when ≥50% of the involved glomeruli 
have segmental lesions. 
Class V: Membranous lupus nephritis 
Class VI: Advanced sclerotic lupus nephritis 
 
3.5.5 Activity and chronicity indices 
All lupus nephritis biopsies were independently reviewed for ISN/RPS class by two 
of three renal histopathology collaborators, Professor Terry Cook, Dr Ingeborg 
Bajema and Dr Suzanne Wilhelmus. Lupus nephritis biopsies with discordant 
classification were additionally reviewed at a joint meeting of the involved 
collaborators and a consensus class was reached for each patient.  
The NIH AI and CI are composite histologic scores of the active and chronic 
findings on renal biopsy in lupus nephritis (Austin et al., 1983). The AI reflects 
activity and potentially reversible changes and is scored from 0-24. The AI 
parameters of glomerular activity include cellular proliferation, fibrinoid necrosis 
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(karyorrhexis), cellular crescents, wire loop lesions (hyaline thrombi) and leucocyte 
infiltration. The AI parameter of tubulointerstitial activity is mononuclear cell 
infiltration. All AI parameters score 3 points each with the exception of fibrinoid 
necrosis and cellular crescents which score 6 points each. The CI reflects chronic 
irreversible changes and is scored from 0-12. There are 4 parameters each scoring 3 
points each. The CI parameters of glomerular chronicity include glomerular sclerosis 
and fibrous crescents. The CI parameters of tubulointerstitial chronicity are tubular 















3.6.1 ISN/RPS classification in lupus nephritis 
Renal biopsy slides with <7 glomeruli were excluded from the analysis, leaving 117 
biopsies for CD68 analysis and 114 biopsies for ISN/RPS classification. 85% (n=97) 
of biopsies were concordantly classified by both renal histopathologists. Discordant 
ISN/RPS classification occurred in 15% (n=17) of cases. Of these 42% (n=8) were 
due to class IV-G/class IV-S discordance, 32% (n=6) were class IV-S/class III 
discordance and 16% (n=3) were due to class IV-G/class III discordance. Following 
review of these 17 cases at a consensus meeting, a final decision was made on 
ISN/RPS class for these individuals. 
2% (n=2) of the study group were classified as ISN/RPS class I, minimal mesangial 
disease. 4% (n=5) were classified as class II, mesangial proliferative lupus nephritis. 
27% (n=31) were class III, focal proliferative lupus nephritis. 25% (n=28) were 
classified as class IV-G, diffuse global lupus nephritis. 28% (n=32) were class IV-S, 
diffuse segmental lupus nephritis. 14% (n=16) had ‘pure’ class V. In addition, 7% 
had proliferative nephritis overlapping with class V, of these 2 had class IV-G, 3 had 
class IV-S and 3 has class III. There were no biopsies showing class VI, advanced 









3.6.2 CD68 immunostaining results 
 




Class IV-G had significantly higher glomerular CD68 than classes I, II, III and V 
(*p=0.05, *p=0.027, *p=0.017, ****p<0.0001 respectively. Class IV-S had 
significantly higher CD68 enrichment than classes I, II, III and V (*p=0.034, 
**p=0.007, ***p=0.0004, ****p<0.0001 respectively. There was no significant 
difference in the number of CD68 positive cells between classes IV-S and IV-G. 
Given the low CD68 staining in classes I, II and V, these classes were then excluded 
from further histopathological correlation with clinical parameters. 
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Figure 3.2: Representative images of CD68 staining in ISN/RPS classes 
            
Class I                                                      Class II 
            
Class III                                                   Class IV-S 
            
Class IV-G                                               Class V 
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Figure 3.3: CD68 positivity in proliferative lupus nephritis comparing juvenile and 
adult onset nephritis  













































































































































The mean CD68 count in adult onset nephritis was 8.8 ± 6.3 and 11.1 ± 8.5 in 
juvenile onset disease (p=0.37). Classes I, II and V were excluded from the analysis. 
Red indicates lupus nephritis patients with diagnosis before age 10 years. Glomerular 
CD68 count correlated with age at diagnosis of nephritis (r=-0.314, **p=0.0096).   
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Figure 3.4:  CD68 cell positivity in proliferative lupus nephritis comparing 
familial and sporadic disease  
 

































































The mean glomerular CD68 count in familial nephritis was 13.3 ± 8.0 and in 














Figure 3.5: CD68 cell positivity in proliferative lupus nephritis comparing male 
and female disease. 
 
 

































































The mean glomerular CD68 count in males was 10.9 ± 8.3 and 9.1 ± 6.7 in females 
(p=0.49). Classes I, II and V were excluded from the analysis. When analysed 



























































































































The mean glomerular  CD68 count in European, African, South Asian and East Asian 
patients were 8.2 ± 5.9, 8.3 ± 6.1, 13.4 ± 9.1 and 11.6 ± 8.8 respectively. Classes I, II 
and V were excluded from the analysis. South Asian CD68 enrichment was 
significantly higher than African (*p=0.038) otherwise there were no statistically 











Figure 3.7: CD68 cell positivity in proliferative lupus nephritis in APS  
 

































































The average number of CD68 positive cells per glomerular tuft (corrected per 
surface area) in nephritis patients with and without APS. Mean glomerular CD68 
count in APS was 8.8 ± 4.6 and 7.9 ± 7.5 in non-APS patients (p=0.15). Classes I, II 











Figure 3.8: Correlation of urinary protein-creatinine ratio with activity & 
chronicity indices 






U r i n a r y  p r o t e i n  c r e a t i n i n e  r a t i o


















U r i n a r y  p r o t e i n  c r e a t i n i n e  r a t i o















NIH AI correlated positively with uPCR: r= 0.311 (*p=0.031). NIH CI did not 
correlate with uPCR: r= 0.046 (p=0.757).      
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Figure 3.9:  Correlation of CD68 with age at diagnosis/proteinuria/activity 
index/chronicity index 









































































U r i n a r y  p r o t e i n  c r e a t i n i n e  r a t i o


























































































































































































Glomerular CD68 count correlated with age at diagnosis of nephritis (r=-0.314, 
**p=0.0096).  There was no correlation between CD68 and uPCR (r= - 0.079, 
p=0.583). There was a positive correlation between CD68 count and AI (r= 0.525, 
****p<0.0001). A negative correlation was seen between CD68 count and CI  










Figure 3.10:   Proteinuria, activity & chronicity indices in proliferative lupus 
nephritis  
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Mean uPCR was 191.8 ± 181.2 in class III, 409.0 ± 324.1 in class IV-G and 414.1 ± 
252.2 in class IV-S nephritis. Class III patients had significantly lower uPCR than 
class IV-G and class IV-S, (*p=0.01) (**p=0.004) respectively. There was no 
difference in uPCR between class IV-G and class IV-S (p=0.66).  
Mean AI was 5.8 ± class III, 10.0 ± 3.5 in class IV-G and 11.1 ± 3.2 in class IV-S. 
Class III had significantly lower AI than classes IV-G and IV-S (**p=0.0016) 
(****p< 0.0001) respectively. AI was similar in classes IV-G and IV-S nephritis 
(p=0.32).  Mean CI was 2.2 ± 1.2 in class III, 4.0 ± 2.0 in class IV-G and 2.7 ± 1.2 in 
class IV-S. CI in class IV-G was significantly higher than in classes III and IV-S 
(**p=0.0034) (*p=0.02) respectively. There was no difference in CI between classes 
III and IV-S (p=0.19). 
 
3.7  Chapter Overview and Discussion 
 
3.7.1 Discussion of ISN/RPS classification 
The role of the mononuclear phagocytic system in lupus nephritis has been reviewed 
in the introduction of this thesis. In our study cohort, we used CD68 as a general 
monocyte/macrophage marker and were interested in correlating CD68 
immunostaining with clinical parameters in lupus nephritis. We have focused on 
CD68 staining in the glomerular tuft, however, while not examined in depth here, the 
importance of tissue resident macrophages and dendritic cells in the pathogenesis of 
lupus nephritis should not be minimized. In addition, tubulointerstitial disease is a 
well-recognized feature of lupus nephritis however CD68 immunostaining in this 
area was not quantified in our study. 
107 
 
We found that classes I, II and V nephritis had minimal glomerular CD68 infiltration 
and, therefore, excluded these classes from our clinical analysis. We chose, instead, 
to focus primarily on the proliferative classes III, IV-G and IV-S. Class III nephritis 
had significantly less CD68 enrichment than classes IV-G and IV-S. We did not find 
a significant difference in glomerular CD68 cell count between class IV-G and IV-S. 
This is contrary to previous work by Hill et al who showed that class IV-G nephritis 
had more glomerular monocytes/macrophages than class IV-S nephritis (Hill et al., 
2005). Their study included 15 class IV-S and 31 class IV-G patients as compared to 
the 28 class IV-G and 32 class IV-S patients in our cohort.  There were some 
potentially relevant demographic differences between the two study populations 
given the known higher severity of nephritis in juvenile and non-Caucasian patients. 
The Hill study population was comprised of 63% Caucasian, 17% North African, 8% 
Asian and 11% African patients. Our cohort, in contrast, had fewer Caucasian 
patients and more African and Asian individuals. South and East Asian patients in 
our study were among those with the highest CD68 scores. The age of patients who 
had a renal biopsy in their study population was older, with an average age of 35 
years, as compared to the average age of 25 years of patients who were biopsied in 
our study. While age at diagnosis did not correlate strongly with CD68 count in our 
cohort, patients with juvenile onset disease <10 years had higher than average CD68 
scores. 
A number of studies have reported that AI is higher in global than segmental class 
IV nephritis ( (Najafi et al., 2001; Yokoyama et al., 2004; Hill et al., 2005). We 
found similar AI scores in classes IV-S and IV-G. CI has also been reported to be 
higher in global than segmental nephritis (Mittal et al., 2004; Yokoyama et al., 2004; 
Hill et al., 2005). Our study findings were consistent with that of these authors.  
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Hill et al describe higher levels of proteinuria in class IV-G nephritis than class IV-S. 
Our study found similar urinary protein-creatinine ratios in both classes. Anti-
dsDNA titres at time of biopsy were higher in class IV-G cases than class IV-S cases 
in the Hill and Najafi studies. We found anti-dsDNA to be more prevalent in class 
IV-S than IV-G nephritis cases (84% versus 75%), however data on antibody titres 
were not consistently available due to changes in laboratory methodology over the 
study period in our cohort making comparison of antibody titres difficult. We did not 
find any differences in CD68 cell count in patients who were autoantibody positive 
or negative for ANA, anti-dsDNA, anti-Ro, anti-RNP and anti-Sm. The distribution 
of autoantibody prevalence and ISN/RPS class is available in Appendix 5. 
Although a number of retrospective studies have shown significant clinical and 
morphological differences between class IV-G and class IV-S nephritis, there is a 
lack of consensus as to which class has a worse clinical outcome. A recently 
published meta-analysis did not show a significant difference in renal outcome 
between class IV-G and IV-S using doubling of serum creatinine and development of 
end-stage renal failure as clinical endpoints (Haring et al., 2012). Of the nine renal 
biopsy samples available from patients who progressed to ESRD in our study, 56% 
had class IV-G, 33% had class IV-S, and 11% had class III nephritis. It is difficult to 
draw definitive conclusions on progression to ESRD from our data given the 
multitude of confounding factors that may have affected renal outcomes including 
the retrospective nature of the study, differences in duration of disease follow-up, 
differences in immunosuppressive agents used, variable degrees of hypertension, and 




3.7.2 Discussion of CD68 immunostaining results 
Glomerular CD68 count correlated with age at diagnosis of nephritis (r=-0.314, 
**p=0.0096) and a subgroup of patient with disease onset before age 10 years had 
particularly high CD68 counts. Unsurprisingly, we found a strong positive 
correlation between CD68 and AI (r= 0.525, ****p<0.0001) and a negative 
correlation between CI and CD68 (r= -0.3128, *p=0.021) in our patients. The mean 
glomerular CD68 count was higher in familial nephritis (13.3 ± 8.0) than in sporadic 
cases (8.9 ± 6.8) but this did not reach statistical significance (p=0.07). No difference 
was seen in CD68 between genders, even when older onset males with relatively 
benign disease were removed from the analysis. The mean glomerular CD68 count 
was highest in South Asian patients, followed by East Asian individuals. European 
and African patients had similar CD68 counts.  
 
A number of variables need to be mentioned that may have influenced CD68 count, 
including the time duration between subclinical nephritis onset and biopsy, the 
duration between diagnosis of SLE and diagnosis of nephritis at biopsy and 
immunosuppression at time of biopsy. Further immunostaining of our patients’ renal 
biopsies is ongoing with CD16 in an attempt to further decipher the functional 
heterogeneity of the mononuclear phagocytic system and its role in lupus nephritis.  
Other markers are also being considered for immunostaining including CX3CR1. 
Analysis of CD68 immunostaining in the context of lupus susceptibility 










Genotype-phenotype relations of lupus susceptibility genes 
in lupus nephritis patients 
 
The purpose of this chapter is to: 
1. Establish if known lupus susceptibility polymorphisms are associated with 
lupus nephritis in patients of different ancestral backgrounds within our 
cohort. 
2. Determine if susceptibility polymorphisms are associated with clinical 
parameters including family history of nephritis, age of disease onset, 













4.1 An introduction to genotyping by ImmunoChip 
 
ImmunoChip is an Illumina Custom Genotyping array containing approximately 
2000,000 polymorphisms, designed to perform replication studies of GWAS in 
autoimmune and inflammatory diseases and fine-mapping of known GWAS hits. 
Development of the chip was initiated by the Wellcome Trust Case-Control 
Consortium and designed following contributions from research groups with an 
interest in diseases such as SLE, rheumatoid arthritis, ankylosing spondylitis, 
psoriasis, Crohn’s disease, ulcerative colitis, coeliac disease, autoimmune thyroid 
disease, type I diabetes, primary biliary cirrhosis, primary sclerosing cholangitis,  
and multiple sclerosis. For each of these disorders, approximately 3,000 SNPs were 
chosen from available GWAS data. In addition, ancestry informative markers 
(AIMs) are included on ImmunoChip to facilitate identification of outliers from 
ancestral groups and to avoid bias caused by population stratification. 
The use of ImmunoChip has enabled us to genotype many of the known lupus 
susceptibility polymorphisms identified by GWAS (Table 4.1) and to study them in 
detail, both on an individual basis and as an aggregate in a Genetic Risk Score 
(GRS). Firstly, we can test if individual SNPs are associated with lupus nephritis 
within our cohort using healthy control genotype data from the 1,000 Genomes 
Project. Secondly, and perhaps more relevant to clinical practice we can also test 
how these polymorphisms correlate with clinical findings within our cohort such as 






Table 4.1 Lupus susceptibility genes of interest genotyped by ImmunoChip 
Gene Chromosome 
 



















rs2476601 A 1.35 












































































































8q12.1 rs7829816 C 1.30 





4.2.1 Genotyping by ImmunoChip 
Genomic DNA was extracted from thawed frozen whole blood using the GenElute™ 
Blood Genomic DNA Kit (Sigma Aldrich) as per the manufacturer’s instructions. 
Genotyping was performed using the Illumina ImmunoChip with the assistance of 
Dr Urmas Roostalu in the Genomics Facility, 7th Floor, Guy’s Tower, Guy’s Hospital. 
Analysis and genotype calling was performed using Illumina GenomeStudio 
software. Of 196,524 polymorphisms available on ImmunoChip, 184,962 passed 
quality control and were suitable for analysis. 
4.2.2 Study Participants 
164 patients with biopsy-proven lupus nephritis were genotyped by ImmunoChip. 4 
patients’ genotyping results did not meet quality control standards leaving 160 
patients results suitable for analysis. Population stratification is a major 
consideration when analysing association studies as genetic allelic frequencies differ 
significantly between different ancestral groups and may be a confounding factor 
leading to false positive results. To deal with this issue of population stratification, 
Multidimensional Scaling (MDS) was carried out using PLINK (Purcell et al., 2007).  
Complete linkage clustering on the basis of autosomal genome-wide SNP data was 
performed based on IBS (identity-by-state) distance between individuals. This 
subdivided the study group into clusters, in our study these clusters were named; 
clusters 1, 2 and 3. Multidimensional Scaling (MDS) analysis was then performed on 
the matrix of genome-wide IBS distances. Plotting each cluster’s values against 
another resulted in a scatter plot on which each point was an individual. When all 3 
clusters were ultimately plotted against one another, it enabled us to identify outliers 
from the main ancestral groups. 
114 
 
Figure 4.1: Identifying population outliers by Multidimensional Scaling 
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Cluster 1: African (n=54) 
Cluster 1 (denoted in blue) were patients of African ancestry (Afro-Caribbean, 
Nigeria, Ghana, Sierra Leone, and Uganda). 
Cluster 2: European (n=62) 
Cluster 2 (denoted in green) were patients of Northern European ancestry (United 
Kingdom and Ireland). 
Cluster 3: East Asian (n=14) 
Cluster 3 (denoted in purple) were patients of East Asian ancestry (China, Vietnam, 
and Singapore). 
 
Population Outliers from the main 3 clusters 
Black denotes patients who were classified as outliers from the main ancestral 
groups. Red denotes patients who reported being of South Asian ancestry (India and 
Pakistan) (n=21). Yellow denotes patients from the following countries: Spain, 
Portugal, Chile, Columbia and Brazil (n=6). Two of these patients were from 
countries in the Middle East and are denoted by the 2 points nearest to the European 
cluster. Five patients reported parental admixture. Of these; 3 had an African parent 
and a European parent, 1 had an African parent and an East Asian parent and 1 had a 
European parent and an East Asian parent. 
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On the basis of this MDS, genotyping results from the 3 distinct ancestral clusters 
(African, European and East Asian) were compared with 1,000 genomes data from 
the same ancestry for frequency of risk alleles of lupus susceptibility 
polymorphisms. Patients with Hispanic ancestry were excluded from the European 
group due to their position outside the main genetic cluster. When exploring the 
association of clinical parameters with a particular polymorphisms risk allele, all 
patients were included regardless of ancestry or being a population outlier. 
 
4.2.3 Statistical Analysis  
The difference in allelic distribution between lupus nephritis patients and 1,000 
genomes control data was examined by Pearson X
2 
test and odds ratios (OR) with 
95% confidence intervals (CIs) were calculated as an estimation of relative risk for 
lupus nephritis. Continuous variables were described as mean with standard 
deviation (SD). Categorical variables were compared using Pearson's Chi-squared 
(χ2) test, except in instances where counts were <5, when a Fisher’s exact test was 
used. The D’Agostino-Pearson omnibus normality test was used to ascertain if data 
was parametrically or non-parametrically distributed. Student’s t-test or Wilcoxon 
rank sum tests were used to compare continuous variables that were normally or 
non-normally distributed, respectively. Correlation between two quantitative 
variables was assessed using Pearson’s correlation coefficient, r. A value of p<0.05 








4.2.4 FCGR2A H/R131 polymorphism genotyping by allele-specific restriction 
enzyme digestion (ASRED) 
Genomic DNA was extracted from thawed whole blood using the GenElute™ Blood 
Genomic DNA Kit (Sigma Aldrich) as per the manufacturer’s instructions. 
Following initial PCR amplification, allele-specific restriction enzyme digestion was 
performed and products analysed by electrophoresis on a 3% (w/v) agarose gel 
(Jiang et al., 1996). 
 
Figure 4.2: Restriction digestion patterns 
 Uncut     R/R131 
(GG) 
    H/R131 
(AG) 
    H/H131 
(AA) 
366bp -    
343bp   - - 
322bp  - -  
 
 






4.3     Results 
4.3.1 HLA region (rs3135394) and (rs9271366) genotyping results 
 















GG 0.3% (n=1) 4.9% (n=3)    
AG 15.3% (n=58) 37.7% (n=23) ****< 0.0001 0.276  0.168 to 0.451 








   
GG 0% 0%    
AG 1% (n=2) 2% (n=1) 0.439 0.420 0.0377 to 4.68 
AA 99% (n=244) 98% (n=51)    






   
GG 0% 0%    
AG 0% 0% - - - 
AA 100% (n=197) 100% (n=13)    
 
The difference in HLA-DRB1 (rs3135394) allelic distribution between lupus 
nephritis patients and healthy subjects was examined by Pearson X
2 
test and odds 
ratios (OR) with 95% confidence intervals (CIs) were calculated as an estimation of 
relative risk for lupus nephritis. A value of p<0.05 was considered to be significant. 
Control data as per 1,000 Genomes Project. 
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Table 4.3: Univariate analysis exploring clinical parameters associated with the 




Odds ratio 95% Confidence Interval 
Gender (female) 
 
2.6 0.575 to 11.8 
 
First degree family history 
 
0.12 0.00721 to 2.13 
 
Juvenile onset (<18 years) 
 




































0.34 0.111 to 1.05 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=28) 
Variable absent (n=132) 
 
 
28.0 ± 13.5 





Duration of follow-up (years) 
Variable present (n=28) 
Variable absent (n=132) 
 
 
12.9 ± 7.5 




Glomerular CD68 count 
Variable present (n=16) 
Variable absent (n=76) 
 
 
7.8 ± 5.2 





































































































































































Average number of CD68 positive cells per glomerular tuft. There was no significant 
difference in CD68 positivity between GG, AG and AA genotypes nor was there a 



















GG 3% (n=13) 3% (n=2)    
AG 19% (n=73) 31% (n=21) *0.029 0.583 0.835 to 1.00 




African      
lupus nephritis 
(n=52) 
   
GG 3% (n=8) 3.8% (n=2)    
AG 27% (n=67) 44.2% (n=23) *0.030 0.579 0.352 to 0.952 
AA 70% (n=171) 51.9% (n=27)    






   
GG 2% (n=3) 0%    
AG 24% (n=48) 46.2% (n=6) 0.186 0.529 0.203 to 1.38 
AA 74% (n=146) 53.8% (n=7)    
 
 
The difference in HLA-DRB1 (rs9271366) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 





Table 4.5: Univariate analysis exploring clinical parameters associated with the 





Odds ratio 95% Confidence Interval 
Gender (female) 
 
0.64 0.267 to 1.53 
 
First degree family history 
 
2.70 0.928 to 7.84 
 
Juvenile onset (<18 years) 
 




































1.48 0.741 to 2.97 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=65) 
Variable absent (n=95) 
 
 
24.9 ± 11.2 




Duration of follow-up (years) 
Variable present (n=65) 
Variable absent (n=95) 
 
 
11.2 ± 6.0 
12.1 ± 8.2 
 
0.905 
Glomerular CD68 count 
Variable present (n=40) 
Variable absent (n=52) 
 
 
10.1 ± 6.8 





























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). CD68 positivity was significantly higher in GG than AG genotypes (*p=0.028). 
There no difference between those who were G allele positive or negative. Classes I, 








The HLA region is consistently the most strongly associated region for genetic risk 
in SLE in GWAS and large replication studies. The HLA has proven challenging to 
study. It is the most gene-dense area of the genome and strong linkage disequilibrium 
(LD) spans the region making it difficult to ascertain if an identified variant is 
functional or in LD with functional polymorphisms nearby. The HLA is subdivided 
into 3 classes: I, II and III. SLE associations have been independently seen in Class 
II and Class III (Harley et al., 2008; Hom et al., 2008; Gateva et al., 2009). Multiple 
autoimmune and inflammatory diseases have been associated with polymorphisms in 
the HLA region including rheumatoid arthritis, type I diabetes, coeliac disease and 
Sjögren’s syndrome. 
We examined two of the most associated SNPs with SLE in the HLA region in our 
cohort and have shown an association between the rs3135394 risk allele and lupus 
nephritis in European patients and the rs9271366 risk allele and nephritis in 
European and African patients. Neither variant was associated with an increased rate 
of progression to ESRD. 
Patients with the rs3135394 risk variant were more likely to have adult-onset 
sporadic disease. ANA and anti-Ro were more frequently seen in patients carrying 
the minor allele (OD 1.47, 95% CI 0.173 to 12.5 and OD 1.3, 95% CI .055 to 3.08 
respectively). 
Patients with the rs9271366 risk allele tended to be of younger onset. Familial 
nephritis was more frequently seen in those carrying the risk variant (OD 2.70, 95% 
CI 0.93 to 7.84). Anti-dsDNA and anti-Sm were more prevalent in those carrying the 
risk allele (OD 1.27, 95% CI 0.63 to 2.58 and OD 1.46, 95% CI 0.65 to 3.31 
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respectively). Antiphospholipid syndrome was more common in patients with the 
minor allele (OD 2.05, 95% CI 0.89 to 4.73). Anti-cardiolipin antibody and lupus 
anticoagulant were also more frequent in those with this risk variant. 
Patients homozygous for the rs9271366 risk allele had a mean higher CD68 
glomerular count than other genotypes. When CD68 was analysed comparing those 
who were positive or negative for the risk allele, however, no difference was seen.   
Lupus nephritis patients with the rs3135394 risk variant were more likely to have 




















4.3.3    IRF5/IRF7/IRF8 genotyping results 
 
IRF5 (rs4728142) and (rs2070197) genotyping results 
 
















AA 20.6% (n=78) 21.3% (n=13)    
AG 49.1% (n=186) 50.8% (n=31) 0.741 0.938  0.639 to 1.38 
GG 30.3% (n=115) 27.9% (n=17)    




African         
lupus nephritis 
(n=52) 
   
AA 4.5% (n=11) 11.5% (n=6)    
AG 37.4% (n=92) 40.4% (n=21) 0.066 0.649  0.408 to 1.03  
GG 58.1% (n=143) 48.1% (n=25)    
 East Asian 
controls  
(n=197) 
East Asian    
lupus nephritis 
(n=13)  
   
AA 0.5% (n=1) 0%    
AG 19.3% (n=38) 30.8% (n=4) 0.399 0.621 0.204 to 1.89 
GG 80.2% (n=158) 69.2% (n=9)    
 
 
The difference in IRF5 (rs4728142) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 




Table 4.7: Univariate analysis exploring clinical parameters associated with the 
IRF5 (rs4728142) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
1.46 0.606 to 3.49 
 
First degree family history 
 
0.24** 0.0795 to 0.735 
 
Juvenile onset (<18 years) 
 




































0.86 0.364 to 2.05 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=99) 
Variable absent (n=61) 
 
 
25.8 ± 10.5 




Duration of follow-up (years) 
Variable present (n=99) 
Variable absent (n=61) 
 
 
12.1 ± 7.3 
11.1 ± 7.4 
 
0.367 
Glomerular CD68 count 
Variable present (n=58) 
Variable absent (n=34) 
 
 
9.8 ± 7.1  




























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AG and GG 
genotypes nor was there a difference between those who were A allele positive or 
negative. Classes I, II and V excluded.  
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GG 1.1% (n=4) 6.6% (n=4)    
AG 17.9% (n=68) 21.3% (n=13) *0.019 0.536 0.317 to 0.907 




African    
lupus nephritis 
(n=52) 
   
GG 0% 0%    
AG 1.6% (n=4) 5.8% (n=3) 0.075 0.276 0.0608 to 1.25 
AA 98.4% (n=242) 94.2% (n=49)    






   
GG 0% 0%    
AG 0.5% (n=1) 0% - - - 
AA 99.5% (n=196) 100% (n=13)    
 
 
The difference in IRF5 (rs2070197) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 






Table 4.9: Univariate analysis exploring clinical parameters associated with the 
IRF5 (rs2070197) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
0.86 0.292 to 2.51 
 
First degree family history 
 
0.26 0.0335 to 2.09 
 
Juvenile onset (<18 years) 
 




































1.64 0.698 to 3.83 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=30) 
Variable absent (n=130) 
 
 
29.3 ± 11.4 
24.9 ± 10.9 
 
*0.037 
Duration of follow-up (years) 
Variable present (n=30) 
Variable absent (n=130) 
 
 
11.9 ± 6.8 
11.7 ± 7.5 
 
0.669 
Glomerular CD68 count 
Variable present (n=18) 
Variable absent (n=74) 
 
 
8.6 ± 6.6 




























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between GG, AG and 
AA genotypes nor was there a difference between those who were G allele positive 
or negative. Classes I, II and V excluded.  
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IRF7 (rs4963128) genotyping results 
Table 4.10:  Association of IRF7 (rs4963128) polymorphism with lupus nephritis 














AA 9% (n=34) 13.1% (n=8) 
 
   




0.954 0.638 to 1.43 
 
GG 42.2% (n=160) 44.3% (n=27) 
 
   





 lupus nephritis 
(n=52) 
 
   
AA 22% (n=54) 
 
11.5% (n=6)    
AG 52% (n=128) 
 




0.920 to 2.18 
 
GG 26% (n=64) 
 
32.7% (n=17)    
 East Asian 
 controls  
(n=197) 
 




   
AA 1% (n=2) 
 
0%    
AG 8.1% (n=16) 
 




0.172 to 10.4 
 
GG 90.9% (n=179) 
 
92.3% (n=12)    
 
 
The difference in IRF7 (rs4963128) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 





Table 4.11: Univariate analysis exploring clinical parameters associated with the 
IRF7 (rs4963128) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
1.01 0.423 to 2.41 
 
First degree family history 
 
1.29 0.436 to 3.81 
 
Juvenile onset (<18 years) 
 




































1.03 0.516 to 2.05 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=87) 
Variable absent (n=73) 
 
 
26.5 ± 11.3 
24.6 ± 10.7 
 
0.238 
Duration of follow-up (years) 
Variable present (n=87) 
Variable absent (n=73) 
 
 
12.2 ± 7.9 
11.1 ± 6.7 
 
0.481 
Glomerular CD68 count 
Variable present (n=52) 
Variable absent (n=40) 
 
 
9.5 ± 6.8 




























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AG and GG 
genotypes nor was there a difference between those who were A allele positive or 
negative. Classes I, II and V excluded. 
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IRF8 (rs2280381) genotyping results 
 
Table 4.12:  Association of IRF8 (rs2280381) polymorphism with lupus nephritis 














GG 13.5% (n=51) 6.6% (n=4) 
 
   




1.12  0.751 to 1.68 
 
AA 39.3% (n=149) 37.7% (n=23) 
 
   





 lupus nephritis 
(n=52) 
 
   
GG 17.5% (n=43) 21.2% (n=11) 
 
   




0.869  0.568 to 1.33 
 
AA 32.1% (n=79) 28.8% (n=15) 
 
   
 East Asian 
 controls  
(n=197) 
 




   
GG 1.5% (n=3) 0% 
 
   




1.01 0.937 to 1.08 
AA 76.1% (n=150) 76.9% (n=10) 
 
   
 
The difference in IRF8 (rs2280381) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 




Table 4.13: Univariate analysis exploring clinical parameters associated with the 
IRF8 (rs2280381) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
0.78 0.320 to 1.91 
 
First degree family history 
 
0.83 0.286 to 2.41 
 
Juvenile onset (<18 years) 
 




































0.67 0.333 to 1.33 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=92) 
Variable absent (n=68) 
 
 
26.1 ± 12.1 
25.2 ± 10.1 
 
0.922 
Duration of follow-up (years) 
Variable present (n=92) 
Variable absent (n=68) 
 
 
10.6 ± 7.2 
12.9 ± 7.4 
 
*0.043 
Glomerular CD68 count 
Variable present (n=53) 
Variable absent (n=39) 
 
 
9.1 ± 6.1 





















































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AG and GG 
genotypes nor was there a difference between those who were A allele positive or 




4.3.4 Discussion of IRF5/IRF7/IRF8 genotyping results in lupus nephritis 
 
One of the major defining features of SLE is increased type I interferon production 
with associated enhanced expression of interferon-inducible genes in PBMCs 
(Baechler et al., 2003; Bennett et al., 2003). It is not surprising, therefore, that a 
number of lupus susceptibility genes identified in GWAS and large scale replication 
studies are involved in interferon signalling pathways. These genes include IRF5, 
IRF7, IRF8, STAT4, TYK2, and IFIH1.  
IRF5, IRF7 and IRF8 are members of the interferon regulatory factor family (IRF) 
and play essential roles in the repertoire of cellular responses to interferons. Of these, 
IRF5 has been the most extensively studied in the context of SLE to date. Variants in 
IRF5 have been associated with SLE in multiple ancestral groups. Genome wide 
association with IRF5 polymorphisms has been repeatedly seen in European and Han 
Chinese lupus patients (Harley et al, 2008; Hom et al, 2008; Han et al. 2009; (Lee et 
al., 2012). An association of IFR5 polymorphisms has also been seen in Japanese, 
Mexican and African American SLE patients (Reddy et al., 2007; Kelly et al., 2008; 
Ito et al., 2009; Kawasaki et al., 2009; Lessard et al., 2012). IRF5 SNPs have been 
associated with several other autoimmune and inflammatory diseases including 
Sjögren’s syndrome, rheumatoid arthritis, multiple sclerosis and inflammatory bowel 
disease, (Dideberg et al., 2007; Miceli-Richard et al., 2007; Sigurdsson et al., 2007; 
Kristjansdottir et al., 2008). 
Further evidence of the role of type I interferon in lupus pathogenesis is provided by 
the observation that STAT4 and IRF5 polymorphisms have been reported to act 
additively to increase lupus susceptibility (Abelson et al., 2009). Higher serum 
interferon-α activity has been demonstrated in SLE patients with the IRF5 risk 
haplotype. Furthermore, the effect of the IRF5 risk haplotype is more pronounced in 
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patients who are anti-dsDNA antibody or RNA-binding protein (anti-Ro, anti-Sm, 
anti-RNP) antibody positive (Niewold et al., 2008).  
We examined two IRF5 SNPs in lupus nephritis, rs4728142 and rs2070197, in our 
cohort. The IRF5 rs4728142 risk allele was not associated with lupus nephritis in 
patients of any ancestry. The IRF5 rs2070197 risk allele was associated with lupus 
nephritis in European patients in our study. There was a trend towards this variant 
being associated with lupus nephritis in African patients but this did not reach 
statistical significance. 
Patients with lupus nephritis carrying the rs4728142 risk allele were more likely to 
progress to ESRD (OD 2.67, 95% CI 0.721 to 9.87). Both IRF5 variants were more 
prevalent in sporadic onset disease than familial nephritis. Patients with the IRF5 
rs2070197 risk allele were significantly older at diagnosis of nephritis than those 
who did not carry the variant. Antiphospholipid syndrome was more prevalent in 
patients who carried the risk allele for either SNP. 
Polymorphisms in IRF7 have been associated with SLE in European and Han 
Chinese patients (Harley et al., 2008; Li et al., 2011). Subphenotype analysis in 
Chinese lupus patients has shown associations with lupus nephritis, arthritis and the 
production of anti-Ro and anti-Sm autoantibodies (Li et al., 2011). 
In a study of European, Hispanic and African American SLE patients, the IRF7 
rs702966 risk allele was associated with the presence of anti-dsDNA antibodies. 
European American and Hispanic American patients who were homozygous for the 
rs702966 risk allele and anti-dsDNA antibody positive had higher serum levels of 
interferon-α. In African American patients, the IRF7 rs4963128 SNP was associated 
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with anti-Sm antibodies and higher serum levels of interferon-α (Salloum et al., 
2010).   
We examined the IRF7 rs4963128 polymorphism in our cohort but did not find any 
association with nephritis in any of the ancestral groups. Those carrying the risk 
allele had a higher prevalence of ANA and anti-dsDNA antibodies (OD 1.58, 95% CI 
0.343 to 7.33) and (OD 1.60, 95% CI 0.798 to 3.10) respectively. Anti-Ro antibodies 
were more frequently positive in those who carried the risk variant (OD 1.29, 95% 
CI 0.656 to 2.54) as were anti-RNP and anti-Sm antibodies (OD 1.89, 95% CI 0.950 
to 3.58 and OD 1.66, 95% CI 0.71 to 3.87, respectively). 
Polymorphisms in IRF8 were initially found to be associated with SLE in patients of 
European ancestry (Cunninghame-Graham et al., 2011). In a later study, an IRF8 
variant was found to have genome wide significance of association in a study of 
European, African American, Asian, Hispanic, Gullah, and Amerindian SLE patients 
(Lessard et al., 2012). Associations with IRF8 polymorphisms have also been 
reported in multiple sclerosis patients (De Jager et al., 2009; Chrabot et al., 2013). 
We did not see an association between the IRF8 rs2280381 risk allele and lupus 
nephritis in our cohort of patients. There was no significant association of this SNP 
with autoantibody profile, disease onset or progression to ESRD. 
No associations were seen regarding CD68 glomerular count in the different 






4.3.5 ITGAM (rs1143679) (rs9888739) and (rs4548893) genotyping 
results. 



















   








0.309 to 0.786 




   








   




   






0.539 0.310 to 0.934 




   








   
AA 0% 
 
0%    
AG 0.5% (n=1) 
 
0% - - - 




   
 
The difference in ITGAM (rs1143679) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 




Table 4.15: Univariate analysis exploring clinical parameters associated with the 
ITGAM (rs1143679) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
1.94 0.681 to 5.54 
 
First degree family history 
 
0.51 0.136 to 1.88 
 
Juvenile onset (<18 years) 
 




































0.57 0.262 to 1.25 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=51) 
Variable absent (n=109) 
 
 
28.7 ± 12.6 
24.1 ± 10.1 
 
*0.045 
Duration of follow-up (years) 
Variable present (n=51) 
Variable absent (n=109) 
 
 
12.0 ± 7.0 
11.5 ± 7.5 
 
0.493 
Glomerular CD68 count  
Variable present (n=31) 
Variable absent (n=61) 
 
 
8.7 ± 6.5 




























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AG and GG 
genotypes nor was there a difference between those who were A allele positive or 
negative. Classes I, II and V excluded.  
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0.323 to 0.785 
 













   




   








0.660 to 1.59 




   








   
AA 0% 
 
7.7% (n=1)     
AG 0.5% (n=1) 
 




0.00267 to 0.349 




   
 
 
The difference in ITGAM (rs9888739) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 






Table 4.17: Univariate analysis exploring clinical parameters associated with the 




Odds ratio 95% Confidence Interval 
Gender (female) 
 
0.92 0.387 to 2.21 
 
First degree family history 
 
1.04 0.357 to 3.01 
 
Juvenile onset (<18 years) 
 




































0.96 0.483 to 1.91 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=84) 
Variable absent (n=76) 
 
 
27.6 ± 11.9 
23.5 ± 9.8 
 
*0.02 
Duration of follow-up (years) 
Variable present (n=84) 
Variable absent (n=76) 
 
 
11.1 ± 6.8 
12.3 ± 7.8 
 
0.390 
Glomerular CD68 count 
Variable present (n=) 
Variable absent (n=) 
 
 
7.9 ± 6.3 



























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). CD68 positivity was significantly lower in AA than GG genotypes (*p=0.038) 
and in those who were A allele positive than negative (*p=0.015). Classes I, II and V 


























   






0.615  0.404 to 0.936 
 














   




   






0.641  0.393 to 1.04 




   








   
AA 0% 
 
0%    




- - - 




   
 
 
The difference in ITGAM (rs4548893) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 




Table 4.19: Univariate analysis exploring clinical parameters associated with the 
ITGAM (rs4548893) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
0.72 0.302 to 1.72 
 
First degree family history 
 
0.45 0.136 to 1.47 
 
Juvenile onset (<18 years) 
 




































1.70 0.849 to 3.40 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=69) 
Variable absent (n=91) 
 
 
26.7 ± 12.1 
24.8 ± 10.4 
 
0.299 
Duration of follow-up (years) 
Variable present (n=69) 
Variable absent (n=91) 
 
 
12.0 ± 6.7 
11.5 ± 7.8 
 
0.366 
Glomerular CD68 count 
Variable present (n=44) 




8.1 ± 6.7 



























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area).  CD68 positivity was significantly lower in AA than GG genotypes (*p=0.018). 





4.3.6 Discussion of ITGAM genotyping results in lupus nephritis 
 
ITGAM encodes the integrin αM protein, also known as CD11b which dimerizes with 
integrin β2 to form the cell surface receptor CR3 (complement receptor 3) also 
known as Mac-1. ITGAM is expressed on monocytes, macrophages, neutrophils and 
dendritic cells and plays important roles in leucocyte migration, adhesion and 
phagocytosis. Polymorphisms in ITGAM have been associated with SLE in European 
patients in several GWAS (Graham et al., 2008; Harley et al., 2008; Hom et al., 
2008; Nath et al., 2008; Chung et al., 2011). Highest associations are consistently 
seen with the rs1143679 variant where an arginine/histidine amino acid substitution 
occurs at position 77 (R77H). The rs1143679 minor allele has been reported to 
impair phagocytosis and adhesion (MacPherson et al., 2011; Rhodes et al., 2012). 
Heterozygous 77R/H macrophages, monocytes and neutrophils have impaired 
phagocytosis with a reduced capacity to uptake complement coated targets as 
compared to 77R/R cells (Fossati-Jimack et al., 2013). ITGAM polymorphisms have 
also been associated with SLE in East Asian GWAS (Han et al., 2009; Yang et al., 
2010; Fan et al., 2011). In some East Asian populations, however, only the non-risk 
allele of rs1143679 is present. The ITGAM rs1143679 risk allele has been associated 
specifically with lupus nephritis and also with discoid skin features (Yang et al., 
2009; Kim-Howard et al., 2010). 
 
We examined 3 ITGAM polymorphisms, rs1143679, rs9888739 and rs4548893, in 
our study. The rs1143679 risk allele was associated with lupus nephritis in European 
and African patients. No East Asian patient carried the risk allele. ANA positivity 
was more prevalent in those carrying the rs1143679 risk variant (OD 5.2, 95% CI 
0.282 to 96.2). 
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The ITGAM rs9888739 polymorphism was associated with lupus nephritis in 
European and East Asian patients. Those carrying the risk allele had higher 
frequency of ANA and anti-cardiolipin positivity (OD 4.5, 05% CI 0.491 to 41.2 and 
OD 1.74, 95% CI 0.823 to 3.69, respectively). Anti-Ro antibodies were more 
frequently positive in those with the risk variant (OD 1.74, 95% CI 0.887 to 3.43), as 
were anti-RNP and anti-Sm antibodies (OD 1.79, 95% CI 0.907 to 3.52 and OD 
1.75, 95% CI 0.762 to 4.03, respectively). 
The ITGAM rs4548893 risk variant was associated with lupus nephritis in European 
patients and there was a trend for an association in African patients. ANA and anti-
dsDNA antibodies were more likely to be positive in those carrying the risk allele 
(OD 8.58, 95% CI 0.466 to 158 and OD 1.25, 95% CI 0.620 to 2.52, respectively). 
Anti-Ro and anti-RNP antibodies were more frequently positive in lupus nephritis 
patients with the rs4548893 minor allele (OD 1.15, 95% CI 0.589 to 2.26 and OD 
1.27, 95% CI 0.650 to 2.50, respectively). Antiphospholipid syndrome was more 
common in individuals with the risk variant (OD 1.86, 95% CI 0.808 to 4.30) as 
were anti-cardiolipin antibody and lupus anticoagulant. 
Lupus nephritis patients carrying the ITGAM rs1143679 or rs9888739 risk variants 
were significantly older at disease diagnosis than those without the risk alleles. There 
was no increased frequency of familial nephritis or progression to ESRD associated 
with any of the ITGAM risk alleles. Glomerular CD68 count was lower in those 
homozygous for the risk allele for all 3 polymorphisms. Three female nephritis 
patients of European ancestry were homozygous for all 3 ITGAM polymorphisms 




4.3.7 STAT4 (rs7574865) and (rs3821236) genotyping results 
















AA 5.5% (n=21) 
 
13.1% (n=8)    
AG 34.8% (n=132) 
 




1.36 to 3.04 
GG 59.6% (n=226) 
 









   
AA 3.7% (n=9) 
 
11.5% (n=6)    
AG 19.9% (n=49) 
 




1.27 to 3.53 
GG 76.4% (n=188) 
 
61.5% (n=32)    








   
AA 8.1% (n=16) 
 
7.7% (n=1)    
AG 54.5% (n=102) 
 




0.365 to 2.04 
GG 40.1% (n=79) 
 
46.2% (n=6)    
 
 
The difference in STAT4 (rs7574865)  allelic  distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 




Table 4.21: Univariate analysis exploring clinical parameters associated with the 
STAT4 (rs7574865) risk allele. 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
0.75 0.315 to 1.80 
 
First degree family history 
 
0.51 0.165 to 1.56 
 
Juvenile onset (<18 years) 
 




































0.84 0.421 to 1.68 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=77) 
Variable absent (n=83) 
 
 
23.8 ± 10.7 
27.3 ± 11.3 
 
*0.041 
Duration of follow-up (years) 
Variable present (n=77) 
Variable absent (n=83) 
 
 
12.3 ± 7.1 
11.2 ± 7.6 
 
0.189 
Glomerular CD68 count 
Variable present (n=45) 
Variable absent (n=47) 
 
 
9.9 ± 7.2 




























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AC and CC 



















AA 2.6% (n=10) 6.6% (n=4) 
 
   






0.303 to 0.697 
GG 64.9% (n=246) 39.3% (n=24) 
 









   
AA 9.3% (n=23) 21.2% (n=11) 
 
   






0.427 to 1.02 
GG 47.6% (n=117) 40.4% (n=21) 
 
   








   
AA 17.8% (n=35) 16.7% (n=3) 
 
   




0.815 0.367 to 1.81 
GG 35.5% (n=70) 33.3% (n=4) 
 
   
 
 
The difference in STAT4 (rs3821236) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 






Table 4.23: Univariate analysis exploring clinical parameters associated with the 




Odds ratio 95% Confidence Interval 
Gender (female) 
 
1.14 0.476 to 2.72 
 
First degree family history 
 
0.85 0.294 to 2.48 
 
Juvenile onset (<18 years) 
 












1.17 0.584 to 2.34 
Anti-Ro 
 




















0.55 0.272 to 1.09 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=91) 
Variable absent (n=69) 
 
 
24.6 ± 10.6 
27.9 ± 11.8 
 
0.197 
Duration of follow-up (years) 
Variable present (n=91) 
Variable absent (n=69) 
 
 
11.9 ± 6.9 
11.3 ± 7.9 
 
0.336 
Glomerular CD68 count 
Variable present (n=52) 
Variable absent (n=40) 
 
 
9.1 ± 6.7 



























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AG and GG 




4.3.8 Discussion of STAT4 genotyping results in lupus nephritis 
 
STAT4 (signal transducer and activator of transcription 4) is a member of the STAT 
family of transcription factors.  In addition to its role in type I interferon signaling, 
STAT4 is involved in Th1 and Th17 differentiation and Il-17 and interferon-γ 
production (Nguyen et al., 2002; Watford et al., 2004; Mathur et al., 2007). SLE 
patients with the STAT4 rs7574865 risk variant have increased expression of type I 
interferon regulated genes (Kariuki et al., 2009). 
STAT4 polymorphisms have been associated with SLE in European, East Asian and 
African patients (Chung et al., 2009; Han et al., 2009; Namjou et al., 2009). STAT4 
variants have also been associated with rheumatoid arthritis and antiphospholipid 
syndrome (Remmers et al., 2007; Horita et al., 2009; Yin et al., 2009). STAT4 risk 
variants have been associated with a more severe clinical phenotype of SLE. Taylor 
et al reported that the rs7574825 risk allele was associated with anti-dsDNA 
antibodies, lupus nephritis and younger disease onset. Patients with ESRD had an 
even higher association with the risk variant in their study (Taylor et al., 2008). A 
further study showed an association between the STAT4 rs7582694 polymorphism 
and severe renal insufficiency (GRF<30mL/min) in proliferative lupus nephritis 
(Bolin et al., 2013). 
We examined two STAT4 polymorphisms previously associated with SLE, 
rs7574865 and rs3821236, in our cohort. The STAT4 rs7574865 risk allele was 
associated with lupus nephritis in European and African patients in our study. 
Carriers of the risk variant did not have an increased progression to ESRD but they 
did have significantly younger onset of nephritis than those without the risk allele. 
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Anti-dsDNA antibodies were more prevalent in patients with the risk variant (OD 
1.30, 95% CI 0.650 to 2.60).  
The STAT4 rs3821236 risk allele was associated with lupus nephritis in European 
patients in our study. A trend was seen in African nephritis patients but this did not 
reach statistical significance. Juvenile onset nephritis was more frequent in the risk 
allele carrying patients (OD 1.60, 95% CI 0.775 to 3.30). Patients with the risk 
variant were more likely to progress to ESRD (OD 1.58, 95% CI 0.514 to 4.86). 
Anti-dsDNA and anti-Sm antibodies were more prevalent in lupus nephritis patients 


















4.3.9  IKZF1 (rs4917014) genotyping results  
Table 4.24: Association of IKZF1 (rs4917014) polymorphism with lupus nephritis 


















   






2.08  1.32 to 3.28 
 










 lupus nephritis 
(n=52) 
 
   




   






0.971  0.360 to 2.62 




   





 lupus nephritis 
(n=13)  
 
   




   






2.42 0.893 to 6.56 
 




   
 
 
The difference in IKZF1 (rs4917014) allelic  distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 





Table 4.25: Univariate analysis exploring clinical parameters associated with the 
IKZF1 (rs4917014) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
0.58 0.239 to 1.42 
 
First degree family history 
 
0.52 0.140 to 1.94 
 
Juvenile onset (<18 years) 
 




































1.13 0.539 to 2.36 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=50) 
Variable absent (n=110) 
 
 
23.2 ± 11.3 
26.7 ± 11.0 
 
*0.048 
Duration of follow-up (years) 
Variable present (n=50) 
Variable absent (n=110) 
 
 
11.5 ± 6.5 
11.8 ± 7.7 
 
0.926 
Glomerular CD68 count 
Variable present (n=28) 
Variable absent (n=64) 
 
 
13.5 ± 8.2 




























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). CD68 positivity significantly higher in AC than AA genotype (***p=0.0002), 
otherwise there was no difference between genotypes. CD68 was significantly higher in C 





4.3.10 Discussion of IKZF1 genotyping results in lupus nephritis 
Ikaros proteins are zinc finger DNA-binding transcription factors that are essential 
regulators of lymphocyte differentiation (Klug et al., 1998; Harker et al., 2002). 
IKZF1 (Ikaros family zinc-finger1) plays a role in regulation of STAT4 transcription 
(Yap et al., 2005). Polymorphisms in IKZF1 have been associated with SLE in 
European and Han Chinese patients (Han et al, 2009; He et al., 2010; Cunninghame-
Graham et al., 2011). A subphenotype analysis in East Asian SLE patients found 
associations between the IKZF1 rs4917014 risk variant with malar rash and renal 
nephritis (He et al., 2010) 
The IKZF1 rs4917014 risk allele was not associated with lupus nephritis in our 
cohort. The risk allele was more prevalent in the 1,000 Genomes Project European 
control population than in our European patients in fact. Patients with the risk allele 
were significantly younger at disease onset than those without the variant, however.  
Renal biopsy tissue was only available for one patient who was homozygous for the 
risk allele. CD68 glomerular immunostaining was significantly higher in those who 












4.3.11 IFIH1 (rs1990760) genotyping results  



















   
AG 50.6% (n=192) 
 
37.7% (n=23) 0.229 
 
0.781  0.522 to 1.17 
 










 lupus nephritis 
(n=52) 
 
   




   








0.648 to 2.84 
 




   





 lupus nephritis 
(n=13)  
 
   




   
AG 32% (n=63) 
 
46.2% (n=6) 0.613 
 
0.784  0.304 to 2.02 
 




   
 
 
The difference in IFIH1 (rs1990760) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 





Table 4.27: Univariate analysis exploring clinical parameters associated with the 
IFIH1 (rs1990760) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
0.51 0.197 to 1.30 
 
First degree family history 
 
0.46 0.155 to 1.35 
 
Juvenile onset (<18 years) 
 




































0.93 0.466 to 1.87 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=92) 
Variable absent (n=68) 
 
 
25.1 ± 11.3 
26.3 ± 10.9 
 
0.441 
Duration of follow-up (years) 
Variable present (n=92) 
Variable absent (n=68) 
 
 
12.9 ± 7.8 
10.0 ± 6.4 
 
*0.025 
Glomerular CD68 count 
Variable present (n=56) 
Variable absent (n=36) 
 
 
9.5 ± 7.1 



























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AG and GG 




4.3.12 Discussion of IFIH1 genotyping results in lupus nephritis 
 
IFIH1 (interferon induced with helicase C domain 1) also known as MDA5 is a 
cytosolic sensor of double-stranded RNA that promotes type I interferon production. 
Heterozygous gain-of-function mutations in IFIH1 have recently been described in 
which patients have an upregulated type I interferon response, neurological deficits 
and ‘lupus-like’ features (Rice et al., 2014). IFIH1 now joins the list of genes 
causing so-called interferonopathies including; TREX1, SAMDH, ADAR1, 
RNASEH2A, RNASEH2B and RNASEH2C (Crow et al., 2006; Rice et al., 2013). 
The IFIH1 rs1990760 polymorphism was associated with SLE in a large scale 
replication study of European SLE patients (Cunninghame Graham et al., 2011). 
Variants in IFIH1 have also been associated with other autoimmune diseases 
including type I diabetes and Graves’ disease (Smyth et al., 2006; Sutherland et al., 
2007). Robinson et al reported that the IFIH1 rs1990760 risk allele was associated 
with the presence of anti-dsDNA antibodies in African and European SLE patients 
and that those who carried the risk allele and were anti-dsDNA antibody positive had 
increased sensitivity to type I interferon signalling (Robinson et al., 2011). 
In our study, European lupus nephritis patients were more likely to be homozygous 
for the risk allele than 1,000 Genomes Project ancestral matched control individuals 
but the overall allelic frequency of the risk variant was not significantly higher. 
Patients carrying the IFIH1 risk variant did not have a higher frequency of familial 
nephritis, juvenile onset disease or progression to ESRD. Anti-dsDNA antibodies 
were not significantly more prevalent in those with the risk allele. RNA containing 
autoantibodies, anti-Sm and anti-RNP, in particular, were significantly less prevalent 
in patients carrying the risk allele. 
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4.3.13 Genes involved in NFκB signalling (IRAK1 and TNFAIP3) 
IRAK1 (rs2269368) genotyping results  














AA 2% (n=4) 3.3% (n=2)    
AG 29% (n=58) 24.6% (n=15) 0.949 0.983 0.573 to 1.68 




African      
lupus nephritis 
(n=52) 
   
AA 25.2% (n=33) 36.5% (n=19)    
AG 54.2% (n=71) 44.2% (n=23) 0.163 0.732  0.471 to 1.14 
GG 20.6% (n=27) 19.2% (n=10)    






   
AA 40% (n=41) 46.2% (n=6)    
AG 50% (n=52) 46.2% (n=6) 0.713 0.850  0.357 to 2.02 
GG 10% (n=10) 7.7% (n=1)    
 
 
The difference in IRAK1 (rs2269368) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 
as per 1,000 Genomes Project. 
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Table 4.29: Univariate analysis of clinical parameters associated with the IRAK1 
(rs2269368) risk allele. 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
1.25 0.520 to 2.98 
 
First degree family history 
 
3.11 0.841 to 11.5 
 
Juvenile onset (<18 years) 
 




































0.83 0.415 to 1.68 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=94) 
Variable absent (n=66) 
 
 
24.4 ± 10.1 
27.4 ± 12.4 
 
0.190 
Duration of follow-up (years) 
Variable present (n=94) 
Variable absent (n=66) 
 
 
11.1 ± 7.2 
12.6 ± 7.5 
 
0.193 
Glomerular CD68 count 
Variable present (n=56) 
Variable absent (n=36) 
 
 
10.3 ± 7.3  








Figure 4.16: CD68 immunostaining in IRAK1 (rs2269368) polymorphism in 


















































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AG and GG 




TNFAIP3 (rs6920220) and (rs5029939) genotyping results  
 
Table 4.30: Association of TNFAIP3 (rs6920220) polymorphism with lupus 
nephritis 


















   




**0.0014 0.499 0.324 to 0.769 




   





lupus nephritis  
(n=52) 
 
   




   








0.380 to 1.23 




   




East Asian  
lupus nephritis  
(n=13)  
 
   
AA 0% 
 
0%    




- - - 




   
 
 
The difference in TNFAIP3 (rs6920220) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test  and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 




Table 4.31: Univariate analysis exploring clinical parameters associated with the 
TNFAIP3 (rs6920220) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
1.06 0.421 to 2.65 
 
First degree family history 
 
1.31 0.440 to 3.88 
 
Juvenile onset (<18 years) 
 




































0.80 0.380 to 1.67 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=55) 
Variable absent (n=105) 
 
 
27.3 ± 11.6 
24.7 ± 10.8 
 
0.210 
Duration of follow-up (years) 
Variable present (n=55) 
Variable absent (n=105) 
 
 
11.1 ± 7.5 
12.1 ± 7.3 
 
0.325 
Glomerular CD68 count 
Variable present (n=30) 
Variable absent (n=62) 
 
 
10.1 ± 6.4 



























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AG and GG 
genotypes nor was there a difference between those who were A allele positive or 























0%    
AG 4% (n=15) 
 
11.5% (n=7) *0.014 
 
0.332 0.132 to 0.831 
GG 96% (n=364) 
 









   
AA 13.8% (n=34) 21.2% (n=11)  
 
  
AG 47.6% (n=117) 
 




0.556 to 1.32 
 
GG 38.6% (n=95) 
 
38.5% (n=20)    








   
AA 0% 
 
0%    
AG 9.1% (n=18) 
 




0.126 to 2.62 
GG 90.9% (n=179) 84.6% (n=11) 
 
   
 
 
The difference in TNFAIP3 (rs5029939) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test  and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 





Table 4.33: Univariate analysis exploring clinical parameters associated with the 
TNFAIP3 (rs5029939) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
2.71 0.879 to 8.38 
 
First degree family history 
 
2.08 0.708 to 6.08 
 
Juvenile onset (<18 years) 
 




































0.81 0.380 to 1.72 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=50) 
Variable absent (n=110) 
 
 
24.1 ± 9.6 
26.3 ± 11.8 
 
0.382 
Duration of follow-up (years) 
Variable present (n=50) 
Variable absent (n=110) 
 
 
10.4 ± 7.0 
12.2 ± 7.4 
 
0.146 
Glomerular CD68 count 
Variable present (n=26) 
Variable absent (n=66) 
 
 
8.9 ± 8.0 






Otherwise none statistically significant 
175 
 
Figure 4.18: CD68 immunostaining in TNFAIP3 (rs5029939) in proliferative 


















































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between CC, CG and GG 




4.3.14 Discussion of genes involved in NFκB signalling (IRAK1 and TNFAIP3 
genotyping results in lupus nephritis 
 
IRAK1 (interleukin-1 receptor associated kinase 1) is a serine/threonine protein 
kinase that is involved in TLR and IL-1 receptor signalling pathways. Irak1 deficient 
mice have decreased IgG and IgM autoantibodies to dsDNA and histone, reduced 
renal inflammation and lymphopenia (Jacob et al., 2009). Given that it is located on 
the X chromosome, it has been suggested that IRAK1 polymorphisms may explain, 
at least in part, the predominance of female patients developing SLE.  
Candidate gene studies in SLE have identified IRAK1 as a lupus susceptibility gene 
in both childhood-onset and adult-onset disease in multiple ancestral groups (Jacob 
et al., 2007, 2009; Sanchez et al., 2011; Kaufman et al., 2013; Zhai et al., 2013).  
We did not find an association of the IRAK1 rs2269368 risk allele with lupus 
nephritis in our cohort. Carriers of the risk variant did seem to represent a more 
severe clinical phenotype, however, as they were more likely to have juvenile-onset 
disease and progress to ESRD (OD 1.66, 95% CI 0.795 to 3.46 and OD 2.05, 95% 
CI 0.624 to 6.76, respectively).  Familial nephritis was seen at a higher frequency in 
patients with the risk allele (OD 3.11, 95% CI 0.841 to 11.5). Anti-Ro, anti-Sm and 
anti-RNP antibodies were more prevalent in those who carried the risk variant. 
TNFAIP3 (tumour necrosis factor, alpha-induced protein 3) also known as A20, 
encodes an ubiquitin-editing enzyme that acts a negative regulator of NF-κB 
signaling and mediates TNFR, IL1R and TLR pathways (Heyninck et al., 1999; 
Boone et al., 2004; Wertz et al., 2004). A20 deficient mice have dysregulated TNF-
induced apoptosis and multi-organ inflammation (Lee et al., 2000). 
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TNFAIP3 polymorphisms have been associated with SLE in European and Han 
Chinese GWAS (Graham et al., 2008; Han et al., 2009; Adrianto et al., 2011; Yang et 
al., 2012; (Martin et al., 2013). Variants in TNFAIP3 have also been associated with 
other autoimmune and inflammatory disease such as rheumatoid arthritis, multiple 
sclerosis and type I diabetes (Plenge et al., 2007; Thomson et al., 2007; De Jager et 
al., 2009; Fung et al., 2009). 
We examined two TNFAIP3 polymorphisms, in our study, rs6920220 and rs5029939, 
both of which were found to be associated with lupus nephritis in European patients. 
No associations were seen with African or East Asian patients. Individuals with the 
TNFAIP3 rs6920220 risk allele were more likely to progress to ESRD (OD 1.31, 
95% CI 0.44 to 3.88). Anti-Ro antibody positivity was higher in those who carried 
the risk variant (OD 1.47, 95% CI 0.734 to 2.95). 
The TNFAIP3 rs5029939 risk allele was more frequently present in familial nephritis 
than sporadic disease (OD 2.08, 95% CI 0.708 to 6.08).  RNA-containing 
autoantibodies, particularly anti-RNP and anti-Sm, were more prevalent in those 
carrying the risk allele (OD 3.47, 95% CI 1.68 to 7.17; p=0.0006 and OD5.02, 95% 








4.3.15 Genotyping results of genes involved in B-cell receptor 
signalling (BANK1/BLK/LYN) 
BLK (rs2736340) genotyping results 
















AA 6.9% (n=26) 13.1% (n=8) 
 
   






0.415 to 0.939 
GG 57.5% (n=218) 44.3% (n=27) 
 









   
AA 2.9% (n=7) 3.8% (n=2) 
 
   






0.388 to 1.19 
GG 76.4% (n=188) 67.3% (n=35) 
 
   








   
AA 53.8% (n=106) 75% (n=11) 
 
   






0.0554 to 1.03 
GG 5.6% (n=11) 0% 
 
   
 
 
The difference in BLK (rs2736340) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 
as per 1,000 Genomes Project. 
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Table 4.35: Univariate analysis exploring clinical parameters associated with the 
BLK (rs2736340) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
0.48 0.186 to 1.22 
 
First degree family history 
 
0.65 0.225 to 1.90 
 
Juvenile onset (<18 years) 
 




































1.68 0.824 to 3.43 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=90) 
Variable absent (n=70) 
 
 
25.9 ± 12.1 
25.2 ± 10.0 
 
0.952 
Duration of follow-up (years) 
Variable present (n=90) 
Variable absent (n=70) 
 
 
12.2 ± 7.6 
11.1 ± 6.9 
 
0.458 
Glomerular CD68 count 
Variable present (n=50) 
Variable absent (n=42) 
 
 
10.2 ± 7.3 



























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AG and GG 




BANK1 (rs10516487) genotyping results 
Table 4.36: Association of BANK1 (rs10516487) polymorphism with lupus 
nephritis 














GG 6.9% (n=26) 
 
8.2% (n=5)    
AG 43.5% (n=165) 
 
36.1% (n=22) 0.585 
 
1.13  0.732 to 1.74 
 
AA 49.6% (n=188) 
 
55.7% (n=34)    





 lupus nephritis 
(n=52) 
 
   
GG 4.9% (n=12) 
 
0%    
AG 37% (n=91) 
 
28.8% (n=15) *0.045 
 
1.81 1.01 to 3.25 
 
AA 58.1% (n=143) 
 
71.2% (n=37)    
 East Asian 
 controls  
(n=197) 
 




   
GG 1.5% (n=3) 
 
0%    
AG 29.9% (n=59) 
 
7.7% (n=1) 0.086 
 
4.94  0.657 to 37.1 
 
AA 68.5% (n=135) 
 
92.3% (n=12)    
 
The difference in BANK1 (rs10516487) allele distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test  and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 




Table 4.37:  Univariate analysis exploring clinical parameters associated with the 
BANK1 (rs10516487) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
0.72 0.291 to 1.78 
 
First degree family history 
 
0.06** 0.00357 to 1.04 
 
Juvenile onset (<18 years) 
 




































1.08 0.517 to 2.26 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=50) 
Variable absent (n=110) 
 
 
25.7 ± 11.1 
25.5 ± 11.2 
 
0.937 
Duration of follow-up (years) 
Variable present (n=50) 
Variable absent (n=110) 
 
 
11.7 ± 7.2  
11.7 ± 7.4 
 
0.909 
Glomerular CD68 count 
Variable present (n=28) 
Variable absent (n=64) 
 
 
9.2 ± 6.7 



























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between GG, AG and AA 




LYN (rs7829816) genotyping results 
Table 4.38: Association of LYN (rs7829816) polymorphism with lupus nephritis 


















   






0.866  0.530 to 1.42 










 lupus nephritis 
(n=52) 
 
   
GG 24% (n=59) 
 
26.9% (n=14)    




0.205 0.760  0.497 to 1.16 




   




 lupus nephritis 
(n=13) 
 
   
GG 0% 0% 
 
   




- - - 




   
 
 
The difference in LYN (rs7829816) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 





Table 4.39: Univariate analysis exploring clinical parameters associated with the 
LYN (rs7829816) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
0.69 0.288 to 1.64 
 
First degree family history 
 
2.53 0.824 to 7.78 
 
Juvenile onset (<18 years) 
 




































1.41 0.706 to 2.81 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=74) 
Variable absent (n=86) 
 
 
26.4 ± 11.3 
25.0 ± 11.0 
 
0.429 
Duration of follow-up (years) 
Variable present (n=74) 
Variable absent (n=86) 
 
 
10.7 ± 6.7 
12.5 ± 7.8 
 
0.159 
Glomerular CD68 count 
Variable present (n=41) 
Variable absent (n=51) 
 
 
9.9 ± 7.1 




























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between GG, AG and AA 




4.3.16 Discussion of genotyping results of genes involved in B-cell receptor 
signalling 
BLK (B-lymphoid tyrosine kinase), BANK1 (B-cell scaffold protein with ankyrin 
repeats) and LYN (v-yes-1 Yamaguchi sarcoma viral related oncogene homolog) are 
all involved in B lymphocyte activation following signalling through the B-cell 
receptor (BCR). BANK1 and LYN are binding partners in that the BANK1 protein 
mediates the interaction between LYN and the IP3 receptors leading to their 
phosphorylation (Yokoyama et al., 2002). Epistatic interactions have been shown 
between BANK1 and BLK polymorphisms that increase lupus susceptibility 
(Castillejo-Lopez et al., 2012). 
 
BLK polymorphisms have been shown to be associated with SLE in European and 
East Asian populations (Kozyrev et al, 2008; Han et al, 2009; Chung et al., 2011; 
Lee et al., 2012; Yang et al, 2012). BANK1 variants have been associated in SLE 
GWAS in European and Chinese populations (Kozyrev et al., 2008; Chung et al., 
2009). LYN polymorphisms have been associated with SLE with genome wide 
significance in European patients only. In a large replication study of African 
American SLE patients, BLK and BANK1 polymorphisms were found to be 
associated with the disease (Sánchez et al, 2011). A case-control study testing 90 
SNPs in LYN found associations with American SLE patients of European ancestry 
but not in patients of African American or Korean ancestry (Lu et al., 2009).  
 
In our cohort, the BLK rs2736340 polymorphism was associated with lupus nephritis 
in patients of European and East Asian ancestry but not in patients of African 
ancestry. The BANK1 rs10516487 risk allele was more commonly found in African 
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control data from the 1,000 Genomes Project than in our African lupus nephritis 
cohort. The LYN rs7829816 risk allele was not associated with lupus nephritis in any 
of the ancestral groups in our study. 
Lupus nephritis patients carrying the BANK1 rs10516487 risk allele were 
significantly more likely to have sporadic onset than familial disease. Individuals 
with the BANK1 rs10516487 variant were more frequently ANA positive than those 
without the risk allele (OD 7.46, 95% CI 0.418 to 133). 
Patients with the BLK rs2736340 risk allele were significantly less likely to be anti-
Ro antibody positive than those without the risk variant. Carriers of the risk allele 
were marginally more likely to progress to ESRD (OD 1.19 95% CI 0.401 to 3.50) 
and were more often lupus anticoagulant positive (OD 1.68, 95% CI 0.824 to 3.43). 
LYN rs7829816 risk allele carriers were more likely to have familial lupus nephritis 
(OD 2.53, 95% CI 0.824 to 7.78). ANA positivity was higher in patients with the 
risk allele as was the coexistence of Antiphospholipid syndrome, anti-cardiolipin 
antibody and lupus anticoagulant.  RNA-containing autoantibodies anti-Ro, anti-
RNP and anti-Sm were all more frequent in LYN risk allele carriers. 
No associations were observed with the CD68 glomerular count and with any of the 













4.3.17  PTPN22 (rs2476601) genotyping results 
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The difference in PTPN22 (rs2476601) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 




Table 4.41: Univariate analysis exploring clinical parameters associated with the 
PTPN22 (rs2476601) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
1.26 0.268 to 5.95 
 
First degree family history 
 
0.25 0.0145 to 4.43 
 
Juvenile onset (<18 years) 
 




































1.68 0.562 to 5.04 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=16) 
Variable absent (n=144) 
 
 
21.2 ± 6.5 
26.1 ± 11.5 
 
0.114 
Duration of follow-up (years) 
Variable present (n=16) 
Variable absent (n=144) 
 
 
14.1 ± 6.6 
11.4 ± 7.4 
 
0.092 
Glomerular CD68 count 
Variable present (n=8) 
Variable absent (n=84) 
 
 
10.1 ± 6.8 



























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AG and GG 
genotypes nor was there a difference between those who were risk allele positive 
or negative.  
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4.3.18 Discussion of PTPN22 genotyping results in lupus nephritis 
 
PTPN22 encodes the protein Lyp, a tyrosine phosphatase. Its primary function is in 
the regulation of T-cell activation by inhibiting Src and Syk family kinase signalling 
in conjunction with Csk (Stanford et al., 2012). The lupus associated PTPN22 
1858C>T polymorphism affects the bindings of Lyp to Csk, resulting in abnormal 
regulation of T-cell activation (Fiorillo et al., 2010; Vang et al., 2012). 
The PTPN22 1858C>T polymorphism is one of the most strongly associated genetic 
risk factors for autoimmunity outside of the HLA region. In addition to SLE, this 
variant is also associated with several other autoimmune diseases including 
rheumatoid arthritis, type I diabetes mellitus, Hashimoto’s thyroiditis, Graves’ 
disease and juvenile inflammatory arthritis (Lee et al., 2007). The frequency of the 
1858T risk allele varies significantly between different ancestral groups. It is most 
commonly seen in those of Northern European origin and is rarely present in African 
and Asian populations. In keeping with this, our study showed no African or East 
Asian lupus nephritis patients who were homozygous for the risk allele and only one 
African patient who was heterozygous. 
The first association of the 1858T variant with SLE was in a case-control study of 
American patients of European ancestry (Kyogoku et al., 2004). The authors did not 
find any differences in clinical manifestations such as nephritis, central nervous 
system disease, arthritis or autoantibody prolife in SLE patients who were carrying 
the risk allele compared to those who were not. The 1858T variant was later found to 
have genome wide significance of association with SLE in a cohort of European 
ancestry (Gateva et al., 2009). A further GWAS of anti-dsDNA positive SLE 
patients confirmed the association (Chung et al., 2011). 
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Previously, those who have shown associations between PTPN22 risk variants and 
SLE have not demonstrated a stronger association with the development of nephritis 
than for SLE in general (Orozco et al., 2005; Reddy et al., 2005). We did not find an 
association of the PTPN22 risk allele with lupus nephritis patients in our study 
either. 
Carriers of this risk allele in our cohort did not have a higher prevalence of 
autoantibodies or a more frequent progression to ESRD. They were more likely to 
have sporadic than familial lupus nephritis, however, and were significantly younger 
at disease onset than those without the risk variant. 
An association has been previously reported between PTPN22 risk variants and 
Antiphospholipid syndrome, anti-cardiolipin antibody and lupus anticoagulant 
(Ostenak et al., 2014). This was verified in a second study which showed a positive 
association between the 1858T variant and SLE patients who had moderate to high 
titres of IgG anti-cardiolipin antibody (Namjou et al., 2013). In our study, the 
carriers of the risk allele were also more likely to have Antiphospholipid syndrome 
(OD 1.74, 95% CI 0.515 to 5.87) and lupus anticoagulant (OD 1.68, 95% CI 0.562 to 
5.04). No association was seen with anti-cardiolipin antibodies although antibody 










4.3.19     TNFSF4 (rs2205960) genotyping results  
















AA 5.2% (n=20) 9.8% (n=6) 
 
   






0.362 to 0.832 
GG 63.1% (n=239) 44.3% (n=27) 
 









   
AA 0% 0% 
 
   






0.295 to 2.72 
GG 93.1% (n=229) 92.3% (n=48) 
 
   








   
AA 6.6% (n=13) 7.7% (n=1) 
 
   






0.293 to 1.57 
GG 53.8% (n=106) 38.5% (n=5) 
 
   
 
 
The difference in TNFSF4 (rs2205960) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test  and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 




Table 4.43: Univariate analysis exploring clinical parameters associated with the 
TNFSF4 (rs2205960) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
1.17 0.477 to 2.85 
 
First degree family history 
 
0.71 0.230 to 2.18 
 
Juvenile onset (<18 years) 
 




































1.11 0.554 to 2.23 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=65) 
Variable absent (n=95) 
 
 
24.0 ± 10.1 
26.7 ± 11.7 
 
0.188 
Duration of follow-up (years) 
Variable present (n=65) 
Variable absent (n=95) 
 
 
12.4 ± 7.4  
11.3 ± 7.3 
 
0.304 
Glomerular CD68 count 
Variable present (n=38) 
Variable absent (n=54) 
 
 
10.5 ± 7.1 





















































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AG and GG 





4.3.20 Discussion of TNFSF4 genotyping results in lupus nephritis 
 
TNFSF4 (TNF superfamily, member 4) also known as OX40 ligand (OX40L) is a 
co-stimulatory molecule present on the surface of antigen presenting cells. Binding 
of OX40L to its receptor OX40 leads to activation of CD4+T lymphocytes and 
inhibition of regulatory T-cells (Gramaglia et al., 2000; Ito et al., 2006). 
OX40/OX40L signalling is also involved in activation and differentiation of B 
lymphocytes (Stuber et al., 1995). 
Polymorphisms in TNFSF4 were initially found to be associated with SLE in 
European and East Asian GWAS (Cunninghame Graham et al., 2008; Han et al., 
2009; Yang et al., 2010). Subsequently associations were found in African American 
SLE patients (Sánchez et al, 2011; Manku et al., 2013).  
The TNFSF4 rs2205960 risk variant was strongly associated with lupus nephritis in 
European patients in our cohort. No association was seen with African or East Asian 
patients. Very few African patients in our study carried the risk allele. 
It has been previously published that the TNFSF4 rs2205960 risk allele is associated 
with the presence of the anti-Sm autoantibody in African and European SLE patients 
(Manku et al., 2013). We did not see this association in our study. In fact, we found 
that the anti-Sm antibody was significantly more frequent in lupus nephritis patients 
without the risk allele. Apart from this observation, no other significant trends were 
seen in autoantibody profile, disease onset, familial nephritis, prevalence of ESRD or 






4.3.21    NCF2 (rs10911363) genotyping results 















AA 7.9% (n=30) 13.1% (n=8) 
 
   







0.503 to 1.14 
CC 52.5% (n=199) 45.9% (n=28) 
 









   
AA 6.9% (n=17) 11.5% (n=6) 
 
   






0.545 to 1.33 
CC 44.7% (n=110) 42.3% (n=22) 
 
   








   
AA 29.9% (n=59) 53.8% (n=7) 
 
   






0.343 to 1.75 
CC 19.3% (n=38) 30.8% (n=4) 
 
   
 
 
The difference in NCF2 (rs10911363) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 




Table 4.45: Univariate analysis exploring clinical parameters associated with the 
NCF2 (rs10911363) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
0.81 0.330 to 1.97 
 
First degree family history 
 
0.81 0.278 to 2.35 
 
Juvenile onset (<18 years) 
 




































1.51 0.738 to 3.08 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=93) 
Variable absent (n=67) 
 
 
25.8 ± 10.8 
25.3 ± 11.7 
 
0.529 
Duration of follow-up (years) 
Variable present (n=93) 
Variable absent (n=67) 
 
 
12.0 ± 7.8 
11.3 ± 6.6 
 
0.803 
Glomerular CD68 count 
Variable present (n=54) 
Variable absent (n=38) 
 
 
10.4 ± 7.6 




























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). CD68 positivity was higher in AC genotype than CC (*p=0.0372) otherwise 
there was no significant difference between genotypes. There was no difference 
between those who were A allele positive or negative.  
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4.3.22 Discussion of NCF2 genotyping results in lupus nephritis 
 
NCF2 (neutrophil cytosolic factor 2) is a component of the NADPH oxidase 
complex and encodes the p67 protein. Mutations in NCF2 have previously been 
documented in Chronic Granulomatous Disease (CGD) (Noack et al., 1999; Patino et 
al., 1999). Neutrophils from NCF2 mutated CGD patients have confirmed that the 
p67 protein functions in the respiratory burst mediated by NADPH oxidase 
(Okamura et al., 1990). NCF2 may also play a role in production of free radicals 
during B-cell activation leading to increased autoantibody production (Vene et al., 
2010). Interestingly, an overlap has been reported between X-linked CGD cases and 
lupus with co-existent diagnoses of both diseases in several case reports. Female 
relatives of CGD patients have an increased rate of SLE and discoid lupus (Cale et 
al., 2007). Furthermore, neutrophils are receiving increased recognition for their role 
in lupus pathogenesis given that neutrophil extracellular traps (NETs) have been 
identified as major producers of type I interferon through pDC activation via TLR9 
(Garcia-Romo et al., 2011; Lande et al., 2011; Villaneuva et al., 2011). 
A large replication study in European patients showed an association between NCF1 
rs10911363 polymorphism and SLE. We did not find any association with this 
polymorphism in any of the ancestral groups in our study. Carriers of the NCF2 risk 
allele in our cohort were not any younger at disease onset neither did they have an 
increased frequency of ESRD. Antiphospholipid syndrome was more prevalent in 
those with the risk allele (OD 1.25, 95% CI 0.533 to 2.94). In addition, anti-
cardiolipin antibody and lupus anticoagulant were more common in patients with the 




4.3.23    ETS1 (rs6590330) genotyping results 
Table 4.46: Association of ETS1 (rs6590330) polymorphism with lupus nephritis 
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 lupus nephritis 
(n=13)  
 
   




   






0.372 0.164 to 0.841 
 




   
 
 
The difference in ETS1 (rs6590330) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test  and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 





Table 4.47: Univariate analysis exploring clinical parameters associated with the 
ETS1 (rs6590330) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
1.01 0.419 to 2.44 
 
First degree family history 
 
2.25 0.760 to 6.66 
 
Juvenile onset (<18 years) 
 




































0.44* 0.209 to 0.924 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=67) 
Variable absent (n=93) 
 
 
27.3 ± 12.4 
24.4 ± 10.4 
 
0.286 
Duration of follow-up (years) 
Variable present (n=67) 
Variable absent (n=93) 
 
 
10.1 ± 6.1 
12.9 ± 8.0 
 
0.051 
Glomerular CD68 count 
Variable present (n=40) 
Variable absent (n=52) 
 
 
9.6 ± 7.3 




























































































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AG and GG 




4.3.24 Discussion of ETS1 genotyping results in lupus nephritis 
 
ETS1 (V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1) is a member 
of the ETS family of transcription factors. The ETS family is defined by a conserved 
DNA-binding domain that recognizes the core consensus DNA sequence GGAA/T 
of target genes (Dwyer et al., 2007). Ets-1 plays an inhibitory role in Th17 and B-cell 
differentiation (Bories et al., 1995; Moisan et al., 2007). Ets-1 deficient mice develop 
autoimmunity with autoantibody production (anti-dsDNA, anti-histone, anti-
cardiolipin), immune complex deposition and inflammatory infiltrates in the kidney 
(Wang et al., 2005).  
Polymorphisms in ETS1 have been shown to be associated with SLE in East Asian 
GWAS but have not been confirmed with genome wide significance in other 
ancestral groups (Han et al, 2009; Yang et al., 2010). ELF1, another member of the 
ETS family, has also been associated with East Asian SLE but was not examined in 
our study (Yang et al., 2011). In our cohort, there was an association between the 
ETS1 rs6590330 risk allele and lupus nephritis in East Asian and African patients. 
The association with African lupus nephritis has not been previously reported to our 
knowledge.  
Patients with familial lupus nephritis were more likely to carry the ETS1 risk allele, 
(OD 2.25, 95% CI 0.76 to 6.66), although carriers did not have younger onset 
disease or increased progression to ESRD. ANA and anti-Ro positivity were more 
common in carriers of the risk allele. Anti-RNP and anti-Sm were significantly 
associated with the ETS1 risk variant (OD 3.02, 95% CI 1.51 to 6.05 and OD 2.85, 




4.3.25     RasGRP3 (rs13385731) genotyping results 
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The difference in RasGRP3 (rs13385731) allelic distribution between lupus nephritis 
patients and healthy subjects was examined by Pearson X
2 
test  and odds ratios (OR) 
with 95% confidence intervals (CIs) were calculated as an estimation of relative risk 
for lupus nephritis. A value of p<0.05 was considered to be significant. Control data 




Table 4.49: Univariate analysis exploring clinical parameters associated with the 
RasGRP3 (rs13385731) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
2.85 0.359 to 22.7 
 
First degree family history 
 
0.62 0.0759 to 5.05 
 
Juvenile onset (<18 years) 
 




































1.50 0.511 to 4.40 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=16) 
Variable absent (n=144) 
 
 
25.1 ± 11.9 
25.6 ± 11.1 
 
0.748 
Duration of follow-up (years) 
Variable present (n=16) 
Variable absent (n=144) 
 
 
13.7 ± 10.1 
11.5 ± 7.0 
 
0.560 
Glomerular CD68 count 
Variable present (n=3) 
Variable absent (n=89) 
 
 
5.8 ± 5.6 









Figure 4.26: CD68 immunostaining in RasGRP3 (rs13385731) polymorphism with 

















































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There were no patients with the GG genotype within the cohort.  CD68 
positivity was significantly lower (**p=0.0097) in the AG genotype than those with 














Table 4.50: Lupus nephritis patients carrying the RasGRP3 (rs13385731) risk 
allele 
 
Gender Ancestry Juvenile 
onset 
Familial Class of nephritis 
Female African 
 
- - Class V 
Female South Asian 
 
- - Class II 
Female East Asian 
 
- - Class V 
Female Other Ancestry 
 
- - Tissue not available 
Female European 
 
- - Tissue not available 
Female South Asian 
 
- - Class III 
Female African 
 
- - Class V 
Female European 
 
- - Tissue not available 
Female African 
 
- - Tissue not available 
Female Other Ancestry   
 
- - Class IV-G 
Female African 
 
- - Class V 
Female European 
 
- - Tissue not available 
Female European 
 
+ - Class III 
Female European 
 
+ - Class V 
Female East Asian 
 
+ - Class V 
Male East Asian 
 
+ + Tissue not available 
Female African + - 
 








4.3.26 Discussion of RasGRP3 genotyping results in lupus nephritis 
 
RasGRP3 (Ras guanyl nucleotide releasing protein 3) belongs to a family of guanine 
nucleotide-exchange factors (GEFs) that provide a link between cell surface 
receptors and Ras, resulting in activation of Ras and related GTPases such as Rap1 
(Rebhun et al., 2000). There is increasing evidence in the literature supporting the 
role of the RasGRP family in the development of autoimmunity. RasGRP1 and 
RasGRP3 work in tandem, downstream of the TCR and BCR, regulating the 
adaptive immune response.  A role for RasGRP3 in innate immunity has also been 
proposed involving Ras and Rap1 stimulation during phagocytosis by macrophages 
(Botelho et al., 2009). Aged Rasgrp1-/- mice develop autoimmunity with ANA 
production and splenomegaly while Rasgrp3-/- mice exhibit 
hypogammaglobulinemia and decreased BCR-regulated Ras-Erk signalling (Layer et 
al., 2003; Coughlin et al., 2005). A number of reports of defective RasGRP1 
expression in SLE patients have also emerged (Yasuda et al., 2007; Rapoport et al., 
2011). 
 
The RasGRP3 rs13385731 polymorphism has been associated with SLE in East 
Asian GWAS but has not been confirmed in other ethnicities (Han et al, 2009; He et 
al., 2010). No patients in our study were homozygous for the risk allele and only 13 
were heterozygous. No association between the RasGRP3 rs13385731 
polymorphism and lupus nephritis was observed in our study. There were, however, 
a number of mutations in Ras related genes identified in our cohort by WES.  These 
include RASGRF2, RASSF5 and RIN. They will be discussed in more detail in a later 
section of this thesis. 
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Our lupus nephritis patients with the RasGRP3 risk allele were more likely to 
progress to ESRD (OD 1.44, 95% CI 0.294 to 7.04). Anti-dsDNA, anti-Ro, anti-RNP 
were all more frequently seen in these patients also.  Malar rash, discoid rash, 
serositis and ANA positivity have been associated with this variant in a previous 
case-only study (He et al., 2010). In our study group Antiphospholipid syndrome and 
lupus anticoagulant were more prevalent in those carrying the risk allele compared to 
those without (OD 1.74, 95% CI 0.515 TO5.87 and OD 1.50, 95% CI 0.511 to 4.40, 
respectively). 
An interesting observation was made that patients who were heterozygous for the 
RasGRP3 mutation appeared to have significantly lower glomerular CD68 cell 
counts than those without the variant. It is difficult to draw firm conclusions from the 
data, however, as there was only renal biopsy tissue available from three patients 











4.3.27     FCGR2A (rs1801274) genotyping results 
Table 4.51:  Association of Fc gamma 2a (rs1801274) polymorphism with lupus 
nephritis 














GG 25.9% (n=98) 
 
33.3% (n=20)    
AG 48.2% (n=183) 
 
58.3% (n=35) *0.011 1.67 1.12 to 2.48 
AA 25.9% (n=98) 
 






 lupus nephritis 
(n=45) 
 
   
GG 23.2% (n=57) 
 
28.9% (n=13)    
AG 51.2% (n=126) 
 
51.1% (n=23) 0.323 1.25 0.799 to 1.97 
AA 25.6% (n=63) 
 
20% (n=9)    




 lupus nephritis 
(n=13) 
 
   
GG 7.6% (n=15) 
 
23.1% (n=3)    
AG 47.7% (n=94) 46.2% (n=6) 
 
0.121 1.87 0.839 to 4.15 
AA 44.7% (n=88) 30.7% (n=4) 
 
   
 
The difference in Fc gamma 2a (rs1801274) allelic distribution between lupus 
nephritis patients and healthy subjects was examined by Pearson X
2 
test and odds 
ratios (OR) with 95% confidence intervals (CIs) were calculated as an estimation of 
relative risk for lupus nephritis. A value of p<0.05 was considered to be significant. 




Table 4.52: Univariate analysis exploring clinical parameters associated with the 
FCGR2A (rs1801274) risk allele 
Categorical Variables 
 
Odds ratio 95% Confidence Interval 
Gender (female) 
 
0.94 0.291 to 3.01 
 
First degree family history 
 
0.68 0.173 to 2.66 
 
Juvenile onset (<18 years) 
 




































0.75 0.303 to 1.84 
 
Continuous Variables Mean, SD p-value 
 
Age at diagnosis (years) 
Variable present (n=123) 
Variable absent (n=26) 
 
 
26.2 ± 11.6 
25.3 ± 10.8 
 
0.957 
Duration of follow-up (years) 
Variable present (n=123) 
Variable absent (n=26) 
 
 
12.3 ± 7.6 
9.9 ± 7.4 
 
0.100 
Glomerular CD68 count 
Variable present (n=87) 
Variable absent (n=22) 
 
 
8.0 ± 6.8 









Figure 4.27: CD68 immunostaining in FCGR2A (rs1801274) in proliferative lupus 
nephritis. 

























































































































































Average number of CD68 positive cells per glomerular tuft (corrected per surface 
area). There was no significant difference in CD68 positivity between AA, AG and GG 
genotypes nor was there a difference between those who were A allele positive or 
negative. Classes I, II and V excluded. 
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4.3.28 Discussion of FCGR2A genotyping results in lupus nephritis 
 
Fc gamma receptors (FcγRs) are cell surface proteins that recognise the constant (Fc) 
portion of immunoglobulin. They facilitate antibody-antigen interactions with the 
immune system and play an essential role in clearance of immune complexes. There 
are 3 families of FcγR in humans, FcγRI (CD64), FcγRII (CD32) and FcγRIII 
(CD16). FcγRI is the only high affinity Fcγ receptor while the others are all low 
affinity. The FcγRs can be defined as either activatory receptors (FcγRIIa, FcγRIIIa, 
FcγRIIIb) or as an inhibitory receptor (FcγRIIb). The FcγR complex has a high 
degree of sequence homology and is subject to frequent copy number variation 
(CNV).  
Polymorphisms in FcγRs have been well documented in SLE. Polymorphisms in 
FCGR3A have been associated with SLE and progression to ESRD (Edberg et al., 
2002; Magnusson et al., 2004; Alarcon et al., 2006). Low CNV of FCGR3B is 
associated with SLE (Aitman et al., 2006; Willcocks et al., 2008). FcγR 
polymorphisms have not featured largely in SLE GWAS. This may be due to 
confounding by high sequence homology and CNV. 
We examined the FCGR2A rs1801274 polymorphism in our cohort. This 
polymorphism is caused by a histidine to arginine switch at position 131 (H131R). 
The R131 and H131 alleles differ substantially in their ability to bind human IgG2 
and IgG3. H131 is the high-binding allele while the R131 variant has a lower 
binding affinity for IgG2, resulting in impaired IgG2-mediated phagocytosis, less 
efficient immune complex clearance and an increased likelihood of immune complex 
deposition. Heterozygotes have intermediate IgG2 binding function (Bredius et al., 
1993; Shashidharamurthy et al, 2009). 
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The FCGR2A rs1801274 risk variant has been associated with lupus nephritis in 
studies of European SLE patients (Duits et al 1995; Norsworthy et al., 1999). Other 
studies have not found an association in Caucasian individuals with SLE (Botto et 
al., 1996; Manger et al., 1998). The RR genotype has been associated with anti-C1q 
positivity in lupus nephritis patients (Norsworthy et al., 1999). The R allele has been 
found to be a significant predictor of lupus nephritis in East Asian SLE populations 
(Song et al., 1998; Yun et al., 2001). Proteinuria was more severe in those with the 
R/R rather than the H/R and H/H genotypes. No difference in anti-dsDNA positivity, 
creatinine clearance or chronicity index was reported in their study (Song et al, 
1998). In European patients, the RR genotype was associated with significantly 
higher levels of proteinuria, haemolytic anaemia, anti-RNP antibodies and low 
complement levels (Manger et al., 1998). Associations have been reported with lupus 
nephritis in African American and Hispanic patients (Salmon et al 1996; Zuniga et 
al., 2001). The FCGR2A rs1801274 risk allele has also been linked to 
Antiphospholipid syndrome (Karassa et al., 2003). 
 
We found an association with the FCGR2A rs1801274 risk variant and lupus 
nephritis in patients of European ancestry. There was no association with familial 
disease, juvenile onset or increased progression to ESRD. Anti-Ro and anti-RNP 
antibodies were more common in patients carrying the minor allele (OD 1.24, 95% 
CI 0.49 to 3.12) (OD 1.13, 95% CI 0.46 to 2.79). Antiphospholipid syndrome was 






4.3  Overall Chapter Conclusion 
Using ImmunoChip as a genotyping tool and comparing with ancestral matched 
control data from the 1,000 Genomes Project, we have found associations in 
European lupus nephritis patients for both of the HLA region polymorphisms 
studied, the IRF5 rs2070197 polymorphism, three ITGAM variants, both STAT4 
polymorphisms examined, both TNFAIP3 variants and in TNFSF4. Associations 
were found in African lupus nephritis patients in ITGAM rs1143679, STAT4 
rs7574865 and ETS1. All of these polymorphisms have been associated with SLE 
with genome-wide significance, so it is not surprising that we have found 
associations with lupus nephritis, even within the confines of our small multi-
ancestral cohort. No associations were seen with IRF7, IRF8, IRAK1, PTPN22, 
NCF2, IFIH1, BANK1, BLK, LYN or RASGRP3, however lack of power in this study 
cannot rule out an association of these susceptibility genes with lupus nephritis. 
Some interesting patterns were observed when analysing clinical parameters with the 
presence of risk alleles in susceptibility genes, particularly regarding age at diagnosis 
and familial disease. HLA region and IRF5 polymorphisms are the most strongly 
associated variants with SLE in GWAS. Risk alleles from both IRF5 polymorphisms 
studied and the HLA rs3135394 variant were more likely to be present in adult onset, 
sporadic cases, predominantly of European ancestry. However the HLA rs9271366 
polymorphism was prevalent in familial, juvenile onset cases, as the risk allele was 
frequently present in African patients.  
The PTPN22 rs247660 polymorphism is one of the most strongly associated genetic 
risk factors for autoimmunity outside of the HLA region. We found this variant to be 
almost exclusively present in European lupus nephritis patients, more prevalent in 
juvenile onset cases but not associated with familial disease.  
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Genes involved in NFκB pathways were frequently mutated in familial lupus 
nephritis. The IRAK1 risk variant was prevalent in juvenile onset, familial cases, and 
those who progressed to ESRD. Both TNFAIP3 polymorphisms studied were 
prevalent in familial disease. Furthermore, a rare variant in IRAK1 was identified in 
familial lupus nephritis by WES, which will be discussed later in this thesis.  
Genes involved in B-cell receptor signalling studied in our cohort included BLK, 
BANK1 and LYN. The BLK and BANK1 variants was more prevalent in adult-onset, 
sporadic disease while the LYN polymorphism was frequently seen in familial 
disease undoubtedly due to the high frequency of the risk allele in African patients. 
For the vast majority of polymorphisms examined here, glomerular CD68 count did 
not differ significantly whether a patient was carrying a risk allele or not. There 
were, however, some notable exceptions. Individuals who were homozygous for the 
risk allele in any of the three ITGAM polymorphisms studied tended to have low 
CD68 glomerular counts. Patients with ITGAM risk variants tended to be of adult-
onset and have sporadic disease. Given the known impairment of phagocytosis and 
adhesion in those with the ITGAM rs1143679 minor allele (MacPherson et al., 2011; 
Rhodes et al., 2012), it is interesting that glomerular CD68 positive cells were less 
abundant in patients carrying this variant.  
No patients in our cohort were homozygous for the RASGRP3 risk allele. Seventeen 
patients were heterozygous for the risk variant and renal tissue was available from 
ten of these. Three RASGRP3 heterozygotes had proliferative nephritis on biopsy and 
were included in our glomerular CD68 analysis. Six RASGRP3 heterozygotes had 
class V nephritis and one patient had class II nephritis. RASGRP3 has also been 
proposed to have a functional role in phagocytosis in macrophages (Botelho et al., 
2009) and it is intriguing that patients carrying risk alleles in these genes would have 
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predominantly membranous nephritis and a low glomerular CD68 in those with 
proliferative nephritis. 
Two susceptibility genes were associated with higher glomerular CD68 counts, 
IKZF1 and those homozygous for the HLA rs9271366 risk allele. Patients with either 
of these risk variants tended to have juvenile onset nephritis.  
The factors that determine glomerular CD68 infiltration remain unclear.  Age at 
disease onset and the influence of genetic variants may certainly play a role. It may 
be interesting to examine lupus nephritis patients with extremes of glomerular CD68 
immunostaining further, by returning to ImmunoChip and testing if other 
polymorphisms are associated with either end of the CD68 immunostaining 
















Polygenic risk score of lupus susceptibility genes in lupus 
nephritis patients 
 
The purpose of this chapter is to: 
1. Introduce the concept of a polygenic risk score of susceptibility alleles. 
2. Assess if a composite genetic risk score of risk alleles is informative 












5.1  Introduction 
Given the modest effects contributed by polymorphisms in individual susceptibility 
genes to the overall heritability of SLE, an interesting approach would be to combine 
risk alleles in a composite score for clinical comparison within our lupus nephritis 
cohort. This approach may help answer some important questions regarding SLE 
aetiopathology. For example: 
 Does age of disease onset correlate with polygenic risk score, 
considering that younger onset patients have a more severe disease 
phenotype? 
  Can we expect male lupus nephritis patients who generally have 
earlier onset disease to have a higher polygenic risk score than 
females? 
 Do familial lupus nephritis cases have a higher polygenic risk score 
than in sporadic onset disease, in that they have inherited an 
accumulation of susceptibility alleles in common or alternatively do 
familial nephritis patients have a lower polygenic risk score than 
sporadic cases pointing towards an alternative monogenic aetiology 
in these individuals. 
As described previously with regard to population stratification, allelic frequency 
differs significantly between ancestral groups and hence clinical comparisons using  
polygenic risk score were carried out ancestry by ancestry. When compiling a list of 
polymorphisms to include in a polygenic risk score it is important to avoid adding 
multiple SNPs that are in linkage disequilibrium with each which would lead to 
falsely high or indeed falsely low scores. In addition, it may be preferable to select 
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SNPs that have been associated with SLE in at least 2 different ancestral groups. By 
adopting this approach certain genes were eliminated from the composite score in 
our study, for example RASGRP3 as it has only been associated with SLE in East 
Asian individuals. Overall we included 20 SNPs from 17 lupus susceptibility genes 
in our polygenic score. Genotyping results for these SNPS were obtained from 
ImmunoChip analysis as outlined in Chapter 4. 
 
5.2 Polygenic risk score computation 
Polygenic risk score was assessed by 2 methods, a simple polygenic risk score and a 
weighted polygenic risk score. The simple polygenic risk score was calculated by 
counting the number of risk allele carried by an individual (GRS, count GRS). 
 In the weighted polygenic risk score (wGRS), the risk allele is weighted by the 
logarithmic odds ratio (log OD) for that allele. The overall wGRS is the sum of the 










Table 5.1: Lupus susceptibility polymorphisms included in polygenic risk score 
Gene SNPs 
HLA region rs3135394, rs9271366 










TNFAIP3 rs6920220, rs5029939 
TNFSF4 rs2205960 













5.3.1  cGRS results 
 
Figure 5.1:  cGRS in female versus male lupus nephritis 
 














































In European lupus nephritis patients the mean cGRS in females was 11.3 ± 2.6 as 
compared to 11.9 ± 1.8 in males (p=0.542). In African patients, the female cGRS 
score was 9.2 ± 2.5 and 10.0 ± 3.2 (p=0.637). South Asian female patients had a 
mean cGRS of 9.8 ± 2.4 and males had a mean score of 11.5 ± 2.7 (p=0.132). East 





Figure 5.2: cGRS in familial versus sporadic lupus nephritis 
 



































The mean cGRS in African familial cases was 10.3 ± 2.2 in comparison to 8.9 ± 2.7 
in sporadic onset African patients (p=0.098). There were no familial patients of 
European ancestry. South Asian familial patients mean cGRS was 13.0 ± 2.0 while 
the sporadic patients mean score was 9.8 ± 3.2 (p=0.057). East Asian familial mean 









Figure 5.3: Correlation of cGRS and age at diagnosis 
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Age at diagnosis of nephritis did not correlate strongly with cGRS in European, 
African or East Asian patients (r= 0.0581, p=0.651) (r= -0.0859, p=0.566) and 
(r=0.269, p= 0.375) respectively. South Asian patients with younger onset disease 









Figure 5.4: Correlation of cGRS and CD68 
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There were weak positive correlations between cGRS and CD68 count in the 
glomerular tuft in all ancestral groups; European (r=0.179, p=0.238), African 










5.3.2  wGRS results 
Figure 5.5: wGRS in female versus male lupus nephritis 
 


















































Mean wGRS in female lupus nephritis patients of European ancestry was 0.75 ± 
0.18 as compared to 0.76 ± 0.09 in European males (p=0.931). In African 
patients mean wGRS was 0.61 ± 0.17 in females and 0.66 ± 0.22 in males 
(p=0.716). South Asian female and male mean wGRS were 0.66 ± 0.23 and 
0.75 ± 0.16 respectively (p=0.154). In East Asian patients wGRS was 0.60 ± 










Figure 5.6: wGRS in familial versus sporadic lupus nephritis 
 






































Mean wGRS in African familial cases was 0.68 ± 0.15 as compared to 0.59 ± 
0.18 in sporadic onset patients (p=0.121). South Asian familial patients has a 
mean wGRS of 0.83 ± 0.13 while sporadic onset patients of this ancestry 
scored 0.66 ± 0.22 (p=0.215). There were no European lupus nephritis 
patients with familial disease. East Asian familial cases scored 0.51 ± 0.16 in 











Figure 5.7: Correlation of wGRS with age of diagnosis 
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There was no significant correlation between age at diagnosis of lupus nephritis and 
wGRS in European and African patients, (r=0.044, p=0.745) and (r= -0.097, 
p=0.519) respectively. South Asian patients with younger onset disease had a higher 
wGRS (r= -0.383, p=0.097). A weak positive correlation was seen in East Asian 








Figure 5.8: Correlation of wGRS and CD68 
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There were weak positive correlations between wGRS and CD68 count in the 
glomerular tuft in all ancestral groups; European (r=0.0896, p=0.588), African 











Figure 5.9: Individuals with high and low wGRS 
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Overall distribution of wGRS in lupus nephritis patients within our cohort, mean 














5.4 Discussion of relevance of polygenic risk score in lupus nephritis 
Overall there was minimal difference in the outcomes of our analysis whether cGRS 
or wGRS were used, presumably due to the modest odds ratios of most lupus 
susceptibility alleles.  
European lupus nephritis patients in general had the highest cGRS and wGRS, while 
African and East Asian patients tended to have the lowest scores which validates our 
approach of analysing each ancestry separately. This phenomenon is presumably due 
to the fact that most of the SNPs included in the score have stemmed from 
associations found in GWAS of European SLE patients and to lesser degree East 
Asian patients and very few large scale studies of African SLE patients exist. 
European and East Asian males and females had similar GRS by either scoring 
system. In African and South Asian patients, there was a minor trend towards males 
having higher cGRS and wGRS but these did not reach statistical significance.  
A trend was seen towards higher cGRS and wGRS in African and South Asian 
familial cases as compared to sporadic disease but these did not reach statistical 
significance. The opposite was seen in East Asian lupus nephritis patients where 
sporadic cases had higher cGRS and wGRS than familial disease. 
No convincing correlations were seen between age at diagnosis of lupus nephritis 
and cGRS or wGRS in European, African or East Asian patients. In the South Asian 
cohort higher cGRS and wGRS were seen in younger patients. Weak positive 
correlations between polygenic risk score and CD68 count in the glomerular tuft 




A previous study of 1,317 SLE patients comprised of 43% Europeans, 27% African 
Africans, 12% Hispanic, 10% Gullah, and 2% East Asian patients using a polygenic 
risk score of 19 SNPs found a significant difference in the number of risk alleles 
carried by juvenile onset as compared to adult onset patients in Gullah and African 
American groups. There was no association between the number of risk alleles 
carried and age of onset in European or Hispanic patients (Webb et al., 2011). 
Another study of 1,919 SLE patients all of European ancestry and using a weighted 
composite score of 22 susceptibility polymorphisms attempted to subphenotype 
patients and found that age at diagnosis, anti-dsDNA antibodies and haematologic 
disorder associated with cumulative genetic risk score while nephritis and arthritis 
were most associated with single known genes in the HLA region and ITGAM 
(Taylor et al., 2011). 
It may be interesting to consider the lupus nephritis patients within our cohort who 
have a low polygenic risk score. Of 24 patients whose wGRS was in the 25th 
percentile, 14 were African, 4 were East Asian, 3 were South Asian and 3 were of 
European ancestry. These individuals were generally of adult onset with sporadic 
disease and may represent suitable candidates for exome sequencing, seeking an 












Whole exome sequencing of familial lupus nephritis 
(Mendelian approach) 
 
The purpose of this chapter is to: 
1. Introduce whole exome sequencing (WES) and its applications to Mendelian 
and complex diseases. 
2. Provide an overview of the workflow for WES and functional stratification of 
gene candidates. 
3. Describe the clinical characteristics of 8 families with clustering of lupus 
nephritis. 














One of the major areas of interest in SLE research is identifying the causal genes 
underlying the disease. Variants identified in GWAS and linkage-studies are thought 
to account for an estimated 15% of the heritability of SLE. In general, common 
variants identified by GWAS explain a limited amount of the heritability of complex 
diseases either on an individual basis or when the effects of these variants are 
combined (Manolio et al., 2009). The genetic heritability that is unknown and 
remains unexplained is known as ‘missing heritability’ and may be due at least in 
part to rare variants with large effect sizes as opposed to the common susceptibility 
variants with small effect sizes.  
WES has been successfully employed to identify both the causal genes underlying 
Mendelian disorders and to ascertain the extent to which rare variants contribute to 
the heritability of complex diseases.  WES specifically sequences the exons or 
protein-coding sections of the genome with approximately 5% of the sequencing 
required for whole genome sequencing (WGS). The first major breakthrough using 
WES to identify the cause of a Mendelian disorder was the elucidation of the genetic 
mutations underlying Miller syndrome, a severe disease with prominent facial and 
limb abnormalities (Ng et al., 2010). Since then, successful application of WES has 
led to the discovery of the causative variants underpinning multiple diseases. 
Rare highly penetrant variants with large effect sizes are of considerable interest as 
they provide valuable insights into the pathogenesis of disease. Instances of such 
variants in lupus include mutations in TREX1, DNASE1, DNASE1L3, PRKCD and in 
complement pathways (Yasutomo et al., 2001; Crow et al., 2006; Al-Mayouf et al., 
2011; Rice et al., 2013; Belot et al., 2013; Rice et al., 2014). These have been 
discussed in detail in the ‘Genetics of SLE’ section of the thesis introduction. While 
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these rare variants do not explain lupus in every single individual with the disease, 
they have taught us valuable lessons regarding the role of type-I interferon, nuclease 
defects and immune complex clearance in disease pathogenesis. Each rare variant we 
discover contributes a further piece of information to advance of understanding of 
SLE. 
Rare variants are unlikely to become significantly frequent in the general population 
as they are likely to be removed by natural selection due to their detrimental effects 
on survival. Dominant variants may arise however, as a result of de novo mutations 
and recessive variants may persist at low frequencies in the population. The majority 
of rare variants with detrimental effects on protein-coding regions of the genome are 
likely to be of recent origin and tend to be population-specific rather than trans-
ethnic (Tennessen, et al., 2012). Novel variants are up to three times more common 
in individuals of African ancestry than in European or Asian populations (Abecasis et 
al., 2012).  
 
Careful selection of cases and controls, for example selecting patients with a strong 
family history of disease will increase the probability of discovering highly penetrant 
variants with large effects. Unlike common variants with small effects identified by 
GWAS that are present in the healthy population, variants with large effects are 
much less likely to be present in unaffected individuals.  Thus selecting patients at 
either end of the phenotypic distribution in an ‘extreme phenotype’ approach or a 
‘family based approach’ may optimise the chances of discovering causal variants. 
The ‘family-based approach’ to WES involves sequencing multiple affected 
members within the same family and using family pedigree information to direct 
analysis. Family 1 in our cohort, for example, looks most likely to be an autosomal 
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recessive pattern of inheritance and hence seeking mutations that are homozygous in 
the children (probands) and heterozygous in the unaffected parents may be a sensible 
approach. The ‘extreme phenotype’ approach assumes genetic homogeneity amongst 
the affected individuals with hence analysis focusing on rare mutations that are 
common to a group of patients.  A third option for WES is sequencing parent-child 
trios seeking de novo mutations in which the child is affected but the parents are 
healthy. 
 
6.2  Methods 
6.2.1 Workflow for WES 
WES of our families with clustering of lupus nephritis was performed in 
collaboration with Professor Jean-Laurent Casanova, St Giles Laboratory of Human 
Genetics of Infectious Disease, the Rockefeller University, New York. Analysis of 
WES data was undertaken by Dr Natasha Jordan during a one-month placement in 
Professor Casanova’s lab with guidance from Dr Bertrand Boisson and Dr Yuval 
Itan. 
Genomic DNA was extracted from thawed whole blood using the GenElute™ Blood 
Genomic DNA Kit (Sigma Aldrich) as per the manufacturer’s instructions. An RNase 
treatment step was included in the protocol. 5ug of DNA was required with a 
concentration not less than 40ng/ul for WES. An agarose gel of the DNA samples 
was run to check for degradation prior to sequencing.  
Exome sequencing was carried out at the New York Genomics Centre on an Illumina 
HiSeq 2000 sequencing machine. Following sequencing, a FASTQ file was produced 
with all the sequencing reads. BWA (Burrows-Wheeler Aligner) software was then 
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used to align the sequencing reads against the human genome reference sequence (Li 
et al., 2009). Further downstream processing was carried out using GATK (genome 
analysis toolkit), SAMtools (Sequence Alignment/Map) and Picard for removal of 
duplications, realigning to the genome and variant calling (Li et al., 2009) (McKenna 
et al., 2010) (http://picard.sourceforge.net). Ultimately, the WES analysis was 
performed using an annotation software system developed in-house at the 
Rockefeller University in New York. 
6.2.2 Workflow for WES analysis 
Discrete Filtering 
The first step in WES analysis is filtering the variants found in the study patients’ 
data set against known polymorphisms in public databases such as dbSNP, Exome 
Variant Server (EVS) and the 1,000 Genomes Project (1KG). This narrows down the 
list of candidates based on the assumption that any variant found frequently in the 
public filter set cannot be causative. With this in mind and considering the 
prevalence of lupus nephritis in the general population, we choose mutations where 
the MAF (minor allele frequency) was <1% for homozygous mutations and where 
variants were absent from public data bases in the case of heterozygous mutations. 
 
Functional Stratification of Candidates                                                                   
Following reduction of the number of genes to a minimum number of potential 
candidates by discrete filtering, candidate genes can be further stratified based on the 
predicted functional impact or deleteriousness of the mutation in question. 
Stratification by functional class can be a useful method of prioritising candidates.  A 
stop codon or frameshift mutation, for example, is more likely to have a significant 




Candidate stratification may be guided by prior knowledge of gene function or its 
predicted role in a biologic pathway. The candidate gene may be a functional partner 
of a gene known to be involved in the disease in question. The expression pattern of 
the gene may provide useful information or a mouse model may yield valuable clues. 
 
Qualitative estimates may provide further evidence of the candidate mutation having 
a potential functional effect. PolyPhen (Polymorphism Phenotyping) and SIFT 
(Sorting Intolerant From Tolerant) predict the likelihood of the mutation being 
damaging based on the predicted change in the protein by amino acid substitutions. 
PolyPhen is a structure-sequence-based amino acid substitution prediction method 
and utilizes data available on UniProKB/UniRef100. Its predictions are based on 
conservation, protein folding and crystal structure (Adzhubei et al., 2010). SIFT 
predictions are mainly based on sequence homology (Kumar et al., 2009). Neither 
method is entirely fool-proof with an estimated sensitivity of 68% for PolyPhen and 
69% for SIFT. Both methods are superior at predicting loss-of-function mutations 




















The analysis of our cohort of familial lupus nephritis is outlined as follows: 
 
 Description of the approach to WES analysis for each individual family using 
pedigree information. 
 Due to the large number of variants identified a brief description is provided 
of a short-list of notable candidates for each family. These candidates include 
variants of significant functional classes such as stop codons/frameshift 
mutations, variants predicted to be highly deleterious by PolyPhen/SIFT, and 
mutations in genes that could be feasibly thought to be involved in the 
pathogenesis of SLE (Appendices 6-20). The full list of mutations found in 
each family is available on http://brahma.rockefeller.edu/polyweb 
 A more in-depth discussion of candidates being considered for future 
functional investigation including genes identified with mutations in more 
than one family of affected patients and genes with functions considered to 
be highly relevant to lupus pathogenesis. These are described under the 
following headings: 
o Related groups of genes with candidates in multiple families 
o Individual genes with mutations in multiple families 
o Candidates of interest identified in individual families 
 Analysis considering ‘genetic homogeneity’ seeking rare mutation common 




























6.3  Results 
6.3.1 Clinical vignette of Family 1(Siblings of South Asian ancestry) 
 





The first family with clustering of lupus nephritis identified in our cohort was of two 
brothers with severe juvenile-onset disease. The parents (II-4 and II-5) are originally 
from Mauritius of South Asian (India) ancestry and moved to the UK. The probands 
were born in the UK. No other known relatives had clinical evidence of SLE or 
autoimmune disease. The father of the family is adopted and hence no clinical 
information is available on his extended family.  
The first brother (III-4) who is currently 29 years old was diagnosed with SLE at 11 
years of age with positive ANA, anti-dsDNA antibodies and low complement levels 
and was initially treated with plasma exchange, methylprednisolone and 
cyclophosphamide. Repeated renal biopsies showed evidence of diffuse 
membranoproliferative lupus glomerulonephritis requiring therapy with 
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mycophenolate mofetil and subsequently with rituximab.  In addition, he had 
evidence of renal thrombotic microangiopathy, positive anti-cardiolipin antibodies 
and lupus anticoagulant thus fulfilling the classification criteria for APS. Concurrent 
diagnoses included steroid-induced osteoporosis and hypothyroidism. Despite a 
severe post renal biopsy haemorrhage leading to nephrectomy and recurrent 
septicaemia, his renal function  remains well preserved with an estimated glomerular 
filtration rate of 74 (70 - 130 mL/min). 
The second brother (III-5) who is currently 26 years old was diagnosed with SLE at 
age 14 with diffuse proliferative lupus glomerulonephritis on renal biopsy, low 
complement levels and positive ANA and anti-dsDNA antibodies. Regardless of 
aggressive immunosuppression including corticosteroids, azathioprine, 
cyclophosphamide, mycophenolate mofetil and rituximab he developed recurrent 
episodes of nephritis progressing to end-stage renal failure by age 20. He received a 
living-related donor renal transplantation from his father at age 21 and despite a 
number of episodes of acute cellular rejection he remains clinically stable on an 
immunosuppressive regimen of tacrolimus and sirolimus. WES candidates of interest 































Homozygous mutations in both probands 
Heterozygous in parents 
dbSNP/EVS/1KG: MAF<1% 
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(mother potential carrier) 
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Heterozygous mutations in both probands 
Not present in parents 









Heterozygous mutations in both probands 
Present in one parent 





















6.3.2: Clinical vignette of Family 2 (Siblings of African ancestry) 
 




Family 2 consists of a brother: sister sibling pair with severe lupus nephritis of 
juvenile onset. Generation II are originally from Nigeria now living in the UK. 
Generations III and IV were born in the UK. DNA was also available for exome 
sequencing from an unaffected brother currently aged 33 (III-9). Their other four 
siblings are unaffected by SLE or other autoimmune diseases. No clinical 
information was available regarding generation I. Generation II are thought to be 
unaffected and generation IV are all paediatric and asymptomatic to date. 
The sister (III-4) who is currently aged 39 was diagnosed with SLE at age 11 with 
musculoskeletal involvement and diffuse mesangioproliferative nephritis. She is 
positive for multiple lupus autoantibodies including ANA, anti-dsDNA, anti-C1q, 
anti-Sm, anti-RNP and anti-Ro. At the age of 12 she developed neutropenic sepsis 
which was thought to of iatrogenic origin. During her disease course she has required 
intensive immunosuppression with cyclophosphamide, azathioprine, methotrexate, 
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mycophenolate mofetil and corticosteroids for recurrent nephritis. Her most recent 
renal biopsy in 2009 showed ISN/RPS class IV-S nephritis. At age 32 she had an 
episode of cryptococcal meningitis. She has also had a suspected episode of septic 
arthritis of the knee. Currently she remains clinically stable on baseline 
immunosuppression of azathioprine and low dose corticosteroid. Her renal function 
is severely impaired with an estimated glomerular filtration rate of 25 mL/min. The 
brother (III-11) who is currently aged 29 developed SLE with nephritis at disease 
onset at age 17. He is positive for ANA and anti-Ro autoantibodies. Repeated renal 
biopsies showed proliferative lupus nephritis and he responded poorly to 
immunosuppression progressing rapidly to end-stage renal disease. By age 22 he 
required haemodialysis and underwent renal transplantation by age 25. His lupus 
activity has remained quiescent since transplantation. WES candidates of interest for 
Family 2 are summarized in Appendix 8. 
 


















2 heterozygous mutations in same gene 
















Heterozygous mutations in probands 
Not present in unaffected brother 








6.3.3 Clinical vignette of Family 3 (Father and daughter of African ancestry) 
 




Family 3 consists of a father: daughter with SLE. Both parents (II-8 and II-9) were 
born in Nigeria and their children (III-1, III-2 and III-3) were born in the UK. The 
affected daughter (III-2) who is currently 19 years old was diagnosed with SLE at 
age 9 with widespread joint involvement and haematologic abnormalities. She 
developed ISN/RPS class III lupus nephritis at age 10. She is ANA, anti-dsDNA, 
anti-Ro, anti-RNP and anti-Sm antibody positive. Her disease has proven difficult to 
control requiring a course of rituximab infusions on two separate occasions. Neither 
of her siblings, aged 22 and 12 respectively, has developed SLE to date. 
 
Her father (II-9) who is currently ages 59 was initially diagnosed with discoid lupus 
in his thirties and subsequently developed ISN/RPS class V lupus nephritis. 
Unfortunately he has been lost to clinical follow-up and DNA was not available for 
exome sequencing. WES candidates of interest for Family 3 are summarized in 
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6.3.4 Clinical vignette of Family 4 (Siblings of African ancestry) 
 
Figure 6.5: Family 4 pedigree 
 
 
Family 4 is comprised of two sisters with adult onset lupus nephritis. The family is 
originally from Sierra Leone and now living in the UK. The first sister (III-1) is 
currently 64 years old and was diagnosed with SLE at age 34 and was found to have 
WHO class IV nephritis on renal biopsy. She is ANA, anti-dsDNA and anti-Ro 
antibody positive. The second sister (III-7) is currently 52 years old and was 
diagnosed with SLE at age 40 also with WHO class IV nephritis on biopsy. She is 
ANA, anti-dsDNA, lupus anticoagulant and anti -cardiolipin positive. Both sisters 
have had a relatively benign disease course, responding well to immunosuppression 
and maintaining their renal function. WES candidates of interest for Family 4 are 

































2 heterozygous mutations in same gene 
















Heterozygous mutations in probands 
Not present in unaffected sister 





















6.3.5 Clinical vignette of Family 5 (Mother and son of South Asian ancestry)  
 




The parents (I-1 and I-2) of family 5 are originally from Kashmir and are now living 
in the UK. Generations II and III were born in the UK. The affected son (II-2) is the 
patient with the youngest onset of SLE in our cohort with diagnosis at age 2. He 
developed recurrent membranous nephritis throughout his childhood and then WHO 
class IV nephritis in his teens. He is ANA, anti-dsDNA and lupus anticoagulant 
positive. He progressed to end-stage renal failure and underwent renal 
transplantation 4 years ago at age 23. His mother (I-1) developed proliferative lupus 
nephritis in her early 30’s when her affected son was 10 years old. Three younger 
brothers remain unaffected to date. WES candidates of interest for Family 5 are 
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6.3.6 Clinical vignette of Family 6 (Siblings of East Asian ancestry)  
 
Figure 6.7: Family 6 pedigree 
 
 
Family 6 consists of 2 brothers with juvenile onset lupus nephritis. The family are 
originally from Vietnam of Han Chinese ancestry. The parents (II-7 and II-8) were 
born in Vietnam and moved to the UK. The probands (III-4 and III-6) were born in 
the UK. They have 3 adult sisters (III-1, III-2 and III-5) who are unaffected. 
The first brother (III-4) who is now 29 years old was diagnosed with SLE at age 17 
with WHO class III lupus nephritis on renal biopsy. 8 years later he had a recurrence 
of disease and a repeat renal biopsy showed ISN/RPS class III + V nephritis. The 
second brother (III-6) is currently 27 years old and was diagnosed with SLE at age 
14 with WHO class IV nephritis on renal biopsy. A relapse of disease at age 21 
necessitated a repeat renal biopsy which showed ISN/RPS class IV-G nephritis. 
Despite recurrent disease both brothers have maintained their renal function and 
remain clinically stable on low level maintenance immunosuppression. WES 
candidates of interest for Family 6 are summarized in Appendices 16 and 17. 
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6.3.7 Clinical vignette of Family 7 (Siblings of African ancestry)  
 




Family 7 consists of two sisters with lupus nephritis. The family is originally from 
Nigeria; both probands were born in the UK. III-1 and III-5 died in childhood due to 
Sickle-cell disease. III-2 carries the Sickle-cell trait and III-4 has Sickle-cell disease 
in addition to SLE.  
III-2 who is currently 45 years old was diagnosed at age 31 with class II lupus 
nephritis. She is ANA, anti-dsDNA, anti-Ro, anti-RNP and lupus anticoagulant 
positive. III-4 who is currently 43 years old was diagnosed at 28 years of age with 
class V nephritis. She is ANA, anti-dsDNA, anti-RNP and anti-Sm antibody positive. 
Both sisters remain clinically stable on low dose maintenance immunosuppression 
and have maintained their renal function. WES candidates of interest for Family 7 





























2 heterozygous mutations in same gene 
















Heterozygous mutations in both probands 






















6.3.8 Clinical vignette of Family 8 (Siblings of South Asian ancestry)   
 
Figure 6.9: Family 8 pedigree 
 
 
Family 8 is comprised of 3 siblings (two brothers and a sister) and a female first 
cousin with SLE. The family is based in Lahore, Pakistan and were identified as part 
of an ongoing collaboration with the Rheumatology Department there. This is a 
consanguineous family as the parents (II-9 and II-12) are first cousins. The mother 
(II-9) has died of breast carcinoma and the father (II-12) is unaffected.  
III-3 is currently 33 years old and was diagnosed with lupus nephritis at age 28 
years. III-5 has class III lupus nephritis. III-6 is currently 28 years old and was 
diagnosed with SLE mainly musculoskeletal involvement at age 20. In addition the 
probands have a first cousin with SLE living in the United States; however the 
clinical details are not available to us at this time. WES candidates of interest for 
Family 8 are summarized in Appendices 19 and 20. 
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6.4 Discussion of Candidates of Interest from WES for Potential 
Functional Testing 
 
 Related Groups of Genes with Candidates in Multiple Families 
 
6.4.1 Genes involved in activation of Ras pathways  
A number of mutations in genes involved in Ras functioning were discovered in our 
cohort of patients including mutations in RASGRF2, RASSF5 and RIN1. Ras proteins 
are small GTPases that are ubiquitously expressed and play important roles in the 
modulation of cellular signal transduction.  When Ras proteins become activated, 
they in turn activate other proteins such as those involved in cell growth, 
differentiation and survival.  HRAS, KRAS, and NRAS, the most common Ras genes 
in humans, are the most frequently mutated oncogenes in human malignancies. 
Recently, RASopathies, which include rare neurodevelopmental disorders such as 
Noonan syndrome and Noonan-related syndromes, have been proposed as novel 
monogenic conditions predisposing to the development of SLE (Bader-Meunier et 
al., 2013). A number of genes have been implicated in these syndromes including; 
PTPN11, SOS1, KRAS, NRAS, RAF, BRAF and SHOC2. The authors described the 
case of a 13 year old boy with Noonan syndrome who subsequently developed SLE. 
Following a literature review they identified 7 further cases of co-existent 
RASopathy and SLE. These patients tended to have a clinical phenotype including 
polyarthritis, autoimmune cytopenias and pericarditis but skin involvement and 
lupus nephritis were not prominent features. 
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In our study, a heterozygous missense mutation (arginine to cysteine at protein 
position 640) in RASGRF2 (Ras protein-specific guanine nucleotide-releasing factor 
2) predicted to be highly deleterious by both PolyPhen and SIFT was found in both 
probands and their unaffected brother in Family 2. RASGRF2 functions as a calcium-
regulated nucleotide exchange factor that activates Ras and RAC1 by exchanging 
bound GDP for GTP and is involved in the coordination of MAPK pathway 
signalling (Fan et al., 1998). Interestingly, a predicted functional partner of 
RASGRF2, RASGRP3 (Ras guanyl-releasing protein 3) is a known lupus 
susceptibility gene from an East Asian GWAS. A functional role for RASGRP3 has 
been proposed in the activation of Ras and Rap1 during phagocytosis in 
macrophages (Botelho et al., 2009). 
A heterozygous missense mutation (glutamic acid to glutamine at protein position 
200) in RASSF5 (Ras Association (RalGDS/AF-6) domain family member 5) 
predicted to be damaging by PolyPhen, was found in the proband of Family 5. 
Synonyms for this gene include NORE1 and RAPL. RASSF5 is a member of the Ras 
association domain family and its encoded protein associates with the GTP-activated 
forms of Ras and Rap1. It has been shown to be an effector molecule in integrin-
mediated adhesion and migration of lymphocytes and dendritic cells involving LFA-
1 and ICAM-1 (Katagiri et al., 2003, 2004). RASSF5 may be also be involved in 
regulation of Ras induced apoptosis (Vos et al., 2003). 
A heterozygous missense mutation (arginine to tryptophan at protein position 257) in 
RIN1 (Ras and Rab interactor 1), predicted to be deleterious by both PolyPhen and 
SIFT was found in both probands and absent in an unaffected sister in Family 4. 
RIN1 is a Ras effector protein that influences Ras signalling on a number of levels. 
RIN1 interacts with the GTP-bound form of Ras proteins and competes with RAF1 
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for binding to activated Ras (Han et al., 1997; Wang et al., 2002). RIN1 interacts 
with the ABL tyrosine kinase enhancing its activity and regulating epithelial cell 
adhesion and migration (Afar et al., 1997; Hu et al., 2005). In addition, RIN1 
activates RAB5A, by exchanging bound GDP for free GTP and facilitates Ras-
activated receptor endocytosis (Tall et al., 2001).  
6.4.2 Genes involved in the antioxidant system 
A recent paper by Ramos et al examined the association of polymorphisms in 
reactive intermediate genes in SLE patients of different African ancestries. They 
studied both African American patients who may have some degree of European 
admixture and a population of Gullah SLE patients. Individuals of a Gullah 
background are from a genetically homogeneous African group with minimal 
European admixture.  The most significantly associated polymorphism identified in 
their study was in GSR (glutathione reductase) in African American SLE patients. 
SNPs in NDUFS4 (NADH dehydrogenase) and NOS1 (nitric oxide synthase) were 
most strongly associated with the Gullah patients. When both population groups 
were combined, the GSR polymorphism remained the most significant association 
overall (Ramos et al., 2013).  
In our cohort, rare mutations have been identified in GSR, NOS1 and NDUFA13. In 
Family 5, there was a homozygous mutation in GSR for a stop codon at position 32, 
predicted to be highly deleterious and have significant functional consequences. A 
further heterozygous mutation in NDUFA13 (NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex 13) was seen in Family 5, resulting from an arginine to glutamine 
substitution at protein position 81, that was also predicted to be highly damaging by 
PolyPhen and SIFT. A mutation in NOS1 was discovered in both probands of Family 
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4, that resulted from a glycine to valine substitution at protein position 50 and was 
predicted to be highly damaging by both PolyPhen and SIFT.  
Overproduction of nitric oxide and reactive oxygen species and an altered redox state 
are well recognised in SLE patients and has been shown to correlate with disease 
activity, complement levels, proteinuria, renal damage and lack of response to 
therapy (Kurien et al., 2003; Oates et al., 2008; Wang et al., 2010). GSR is a central 
enzyme of cellular antioxidant defence. Its primary role is in the reduction of 
oxidized glutathione disulfide to glutathione (GSH). There is increasing evidence 
that depletion of intracellular GSH may play a role in dysregulation of apoptosis 
(Franco et al., 2009). An early event in the cascade of apoptosis is a decrease in 
cellular GSH. GSH is essential for cell survival as demonstrated in mouse models 
with abnormal GSH undergo massive apoptotic cell death (Valverde et al., 2006).  
Rare mutations in GSR have been reported to result in favism, hyperbilirubinaemia, 
and cataracts. GSR deficiency in erythrocytes was previously reported in an SLE 
patient that was correctable in vivo with riboflavin. The same deficiency was found 
in the patient’s mother and other relatives who were asymptomatic (Fajnholc et al., 
1971). A previous report of a consanguineous family of three children with almost 
complete absence of GSR activity in erythrocytes resulted in favism in one child and 
cataracts in the other two. GSR activity in leucocytes was also reduced in this family 
but no history of recurrent infections or autoimmunity was reported (Loos et al., 
1976). 
GSR potentiates host defence by sustaining phagocytic oxidative burst and 
enhancing production of NETs (Yan et al., 2012). This may be of relevance in SLE 
given the increasing evidence of the role of NETs in lupus pathogenesis (Lande et 
al., 2011; Garcia-Romo et al., 2011; Villanueva et al., 2011). GSH levels are 
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decreased in peripheral T-lymphocytes from SLE patients (Gergely et al., 2002; 
Shah et al., 2010, 2011). (NZB NZW) F1 lupus prone mice treated with N-acetyl 
cysteine, a precursor of GSH have less autoantibody production, less severe nephritis 
and increased survival (Suwannaroj et al., 2001). 
 
6.4.3 Synaptotagmin-like proteins (SLPs) 
A number of mutations in genes encoding synaptotagmin-like proteins were 
identified in our cohort. A non-frameshift mutation in SYTL5 was found in both male 
probands in Family 6. A heterozygous missense mutation (aspartic acid to histidine 
at protein position 25) in SYTL3, predicted to be highly deleterious by both PolyPhen 
and SIFT, was found in both male probands in Family 1. A heterozygous intronic 
mutation in SYTL2 was found in Family 5. 
 In addition, two compound heterozygous mutations in MLPH (glutamic acid to 
lysine at protein position 323) and (glutamic acid to valine at protein position 363), 
both of which were predicted to be highly deleterious were identified in Family 3. 
MLPH encodes the protein for melanophilin and is predicted to be a functional 
partner of the SYTL genes. 
SLP protein family members contain a unique homology domain at the N-terminus, 
known as the Slp homology domain (SHD). The SHD has been shown to specifically 
bind to the Ras-related GTPase Rab-27A which has a proposed regulatory role in the 
function of lysosome-related organelles, including melanosome motility in 
melanocytes (Strom et al, 2002; Kuroda, 2004).  
MLPH encodes a member of the exophilin subfamily of Rab effector proteins. The 
protein forms a complex with Rab27A and myosin Va (Bahadoran et al., 2003). 
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Mutations in MLPH and RAB27A lead to impairment of melanosome transport and 
result in haemophagocytic syndrome and abnormal hair pigment distribution in 
Griscelli syndrome (Bahadoran et al, 2003). 
 
6.4.4 Mutations in genes encoding the epsilon DNA polymerase complex 
The central component of the epsilon DNA polymerase complex consists of four 
subunits: POLE, POLE2, POLE3 and POLE4. Mutations in POLE and POLE3 were 
found in our cohort of patients. POLE (polymerase (DNA directed), epsilon, 
catalytic subunit) encodes the catalytic subunit of DNA polymerase epsilon, an 
enzyme involved in DNA repair. Mutations in POLE have been associated with 
colorectal cancer and FILS syndrome (facial dysmorphism, immunodeficiency, 
livedo, and short stature) (Pachlopnik Schmid et al., 2012; Palles et al., 2013). 
POLE3 (polymerase (DNA directed), epsilon 3, accessory subunit) is also known as  
CHRAC17 (chromatin accessibility complex, 17-KD subunit) and encodes a histone-
fold protein.    
A heterozygous missense mutation (isoleucine to phenylalanine at protein position 
238) in POLE predicted to be highly deleterious by PolyPhen and SIFT, was 
identified in both male probands and two of three unaffected sisters in Family 6. A 
heterozygous missense mutation (valine to leucine at protein position 69) in POLE3 
predicted to be highly deleterious by PolyPhen and SIFT, was identified in all 3 





6.4.5 Chromodomain helicase DNA binding proteins 
Chromodomain helicase DNA binding (CHD) family are ATP-dependent chromatin 
remodellers. The CHD family are divided into 3 subgroups of genes; Chd1-Chd2 
subfamily, Chd3-Chd4 subfamily, and Chd5-Chd9 subfamily. CHD family members 
have been shown to have roles in transcriptional activation, repression and 
elongation (Woodage et al., 1997; Kelley et al., 1999). They interact with H3K4me 
and may have HDAC activity (Flanagan et al., 2005; Pray-Grant et al., 2005). A 
number of human diseases have been associated with CHD3 and CDH4 including 
Hodgkin’s lymphoma and neuroblastoma (Law et al., 2005; White et al., 2005). In 
addition, CHD3 and CHD4 have been identified as autoantigens in the autoimmune 
condition dermatomyositis (Seelig et al., 1995). CHARGE syndrome, a rare disease 
with ocular abnormalities, cardiac defects, renal and genital anomalies, growth 
retardation and deafness has been associated with CHD7 (Vissers et al., 2004).  
 In our cohort, mutations were identified in two CHD family members, CDH8 and 
CHD9. In Family 3, compound heterozygous mutations (glutamic acid to lycine at 
protein position 88) and (alanine to serine at protein position 1132) were identified in 
CHD8 in the proband. Only one of these mutations was present in the unaffected 
mother. Neither of these mutations were predicted to be deleterious by PolyPhen or 
SIFT, however. 
In Family 8, in which there was a history of consanguinity, all three probands were 
homozygous for a missense mutation (proline to arginine at protein position 2114) in 
CHD9 which was predicted to be highly damaging by both PolyPhen and SIFT. 




6.4.6 Genes involved in ubiquitination pathways 
Ubiquitination is a process by which proteins undergo post-translational 
modification by the addition of ubiquitin molecules, initiating a chain of events 
resulting in the degradation of the protein by the proteasome. Polymorphisms in 
genes involved in ubiquitination have been associated with SLE such as TNFAIP3, 
TNIP1 and UBE2L3. Mutations in 2 genes involved in ubiquitination were found in 
our patient cohort; USP36 and UBR4. 
Missense mutations in USP36 (ubiquitin specific peptidase 36) were identified in 2 
families within our cohort. In Family 3, a heterozygous missense mutation (valine to 
leucine at protein position 409) in USP36 was present in the affected daughter but 
absent in the unaffected mother and was predicted to be highly deleterious by both 
PolyPhen and SIFT. In the proband of Family 5, a further USP36 heterozygous 
mutation (glycine to valine at protein position 468) was identified and predicted to 
be moderately deleterious by PolyPhen and highly deleterious by SIFT.   
Compound heterozygous mutations (cysteine to phenylalanine at protein position 
933) (leucine to valine at protein position 4129) in UBR4 (ubiquitin protein ligase E3 
component n-recognin 4) were found in the proband of Family 5. The former was 
predicted to be highly deleterious while the later was not.  
USP36 is part of a family of cysteine proteases that function as deubiquitination 
enzymes (Quesada et al., 2004). UBR4 encodes a protein present in the cytoskeletal 
component of the cytoplasm and the chromatin scaffold in the nucleus. In 
combination with clathrin, it creates meshwork structures such as those involved in 
cytoskeletal organization. UBR4 may also play a role in regulation of integrin-
mediated signalling (Nakatani et al., 2005). 
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6.4.7 Serine/threonine protein kinases 
A number of mutations in serine/threonine protein kinases were identified in our 
lupus families including MAPK3, MAP3K6 and STK33.  
The 3 probands of Family 8 were all discovered to have a homozygous MAPK3 
mutation (glycine to aspartic acid at protein position 9). This was not predicted to be 
damaging by either qualitative score, however. The unaffected father was 
heterozygous for this mutation and the unaffected sibling did not have the mutation. 
A frameshift deletion in MAP3K6 (mitogen-activated protein kinase kinase kinase 6) 
was seen in the proband of Family 5.  
MAPK1/ERK2 and MAPK3/ERK1 act in a signalling cascade regulating vital 
cellular processes. Following activation by upstream kinases, they, in turn, become 
activated, resulting in translocation to the nucleus where nuclear targets are 
phosphorylated. Defective activity of MAPK1 and MAPK3 has been seen in 
peripheral blood T-lymphocytes of SLE patients and may be linked to altered 
coupling of Ras guanine nucleotide exchange factor hSos (human Son of Sevenless) 
to the adapter protein Grb2 (Cedeno et al, 2003).  
Mutations in STK33 (serine/threonine-protein kinase 33) were present in 2 individual 
families in our cohort. In Family 2, a heterozygous missense mutation (lysine to 
asparagine at protein position 512) was present in both probands and their unaffected 
brother and predicted to be highly deleterious. In Family 5, a further heterozygous 
mutation (isoleucine to threonine at protein position 306) was identified in STK33 in 
the proband and was predicted to be moderately deleterious by PolyPhen and highly 
deleterious by SIFT. 
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STK33 is a member of the CAMK group (Ca2+/calmodulin-dependent kinase) of 
serine/threonine kinases. STK33 was found to be critical for abnormal cell growth in 
human cell lines expressing mutations in the oncogene KRAS. A knock down of 
STK33 using siRNA induced apoptosis in KRAS-dependent Acute Myeloid 
Leukaemia cell lines (Scholl et al., 2009).  When small-molecule inhibitors of STK33 
were used to target KRAS-dependent cells, however, they were found to be 
ineffective (Luo et al., 2012). Interestingly, polymorphisms in STK17A were 
associated with SLE in a recent Brazilian study (da Silva Fonseca et al., 2013). 
6.4.8 Mutations in TLR and interferon signalling pathways 
Mutations in IRF9 (interferon regulatory factor 9) were found in 2 families in our 
study. In Family 1, a heterozygous missense mutation (arginine to histidine at protein 
position 102) in IRF9 was present in the both probands but was not predicted to be  
deleterious by either PolyPhen or SIFT. In Family 3, compound heterozygous 
mutations in IRF9 were present in the proband (valine to phenylalanine at protein 
position 222) and (alanine to glutamic acid at protein position 258). Neither of these 
mutations was predicted to be damaging however. A heterozygous mutation in TLR9 
was present in both probands of Family 1 (alanine to serine at protein position 1185) 
and was predicted to be deleterious by SIFT but not by PolyPhen. Given the known 
role of endosomal TLRs and type I interferon pathways in lupus pathogenesis as 








Individual Genes with Mutations in Multiple Families 
6.4.9 MACF1
 
Mutations in MACF1 (microtubule-actin crosslinking factor 1) were discovered in 
three families in our cohort. MACF1, also known as ACF7 (actin cross-linking family 
protein 7) is a member of a family of proteins whose primary role is the formation of 
bridges between different cytoskeletal elements (Kodama et al., 2003). MACF1 also 
acts as a positive regulator of Wnt signalling pathways (Chen et al., 2006).  
In Family 8, compound heterozygous MACF1 mutations were found in all 3 
probands (threonine to asparagine at protein position 166) (cysteine to phenylalanine 
at protein position 3484). The first predicted to be moderately deleterious by 
PolyPhen and highly deleterious by SIFT but the second was not predicted to be 
damaging. 
 In Family 3, compound heterozygous mutations (arginine to glutamine at protein 
position 389) (valine to isoleucine at protein position 1692) in MACF1 were seen in 
the proband. The former was predicted to be deleterious while the later was not. One 
of these mutations was present in the unaffected mother in this family.  
In Family 5, compound heterozygous MACF1 mutations (glutamine to histidine at 
protein position 2980) (arginine to glutamine at protein position 1070) were found in 
the proband. The first was predicted to be deleterious by both PolyPhen and SIFT 
while the second was not. 
6.4.10 DDR1 
Mutations in DDR1 (discoidin domain receptor tyrosine kinase 1) were identified in 
2 separate families in our cohort. In
 
Family 5, a homozygous missense mutation 
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(arginine to glutamine at protein position 119) was present in the proband and was 
predicted to be moderately deleterious by PolyPhen but not by SIFT. In Family 3, a 
heterozygous mutation (glutamine to glutamic acid at protein position 38) was 
present in both the proband and the unaffected mother but was not predicted to be 
deleterious. 
DDR1 is a cell surface tyrosine kinase receptor. Once activated by binding to fibrillar 
collagen, it regulates cell differentiation, proliferation and migration (Vogel et al., 
1997; Hou et al., 2002). DDR1 has been proposed to play a role in renal injury. 
There is increased expression of DDR1 in the glomeruli of mice and in podocytes 
and cellular crescents of humans with crescentic glomerulonephritis (2 lupus 
nephritis cases and 3 Goodpasture's syndrome cases) (Kerroch et al., 2012). 
Inhibition of DDR1 activity by deletion of the gene or injection of antisense 
oligodeoxynucleotides protects against crescentic glomerulonephritis and loss of 
kidney function in mice (Kerroch et al., 2012). 
 
6.4.11 COL6A5 
Mutations in COL6A5 (collagen, type VI, alpha 5) were found in 2 separate families 
in our cohort. Compound heterozygous mutations (stop codon at protein position 
1563) (threonine to proline at protein position 299) were found in both probands and 
their unaffected brother in Family 2. A heterozygous missense mutation 
(phenylalanine to valine at protein position 680) was identified in the proband of 
Family 5 and predicted to be highly deleterious by PolyPhen but not by SIFT. 
COL6A5 belongs to the family of collagens containing von Willebrand factor type A 
domains, which are involved in organisation of tissue architecture and cell adhesion.  
COL6A5 is highly expressed in the skin and to a lesser degree in the lung, small 
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intestine and colon (Soderhall et al., 2007). Variants in COL6A5 were previously 
reported to be associated with atopic dermatitis. Subsequent studies, however, have 
failed to show an association (Soderhall et al., 2007; Naumann et al., 2011). 
6.4.12 BOC 
Mutations in BOC (BOC cell adhesion associated, oncogene regulated) were present 
in Family 4 and Family 6, although neither was predicted to be damaging. BOC is a 
member of the immunoglobulin/fibronectin type III repeat family. It is a component 
of a cell-surface receptor complex with CDON (cell adhesion associated, oncogene 
regulated) that mediates cell-cell interactions and promotes myogenic differentiation 
(Kang et al., 2002). 
Candidates of Interest for Potential Functional Testing Identified in Individual 
Families 
6.4.13 TRAP1/DNASE1 
In Family 5, compound heterozygous mutations were found in the exon of TRAP1 
overlapping with the intron of DNASE1. The first mutation was an arginine to 
glutamine substitution at position 650 and was not predicted to be deleterious. The 
second mutation was a threonine to lysine substitution at position 65 and was also 
not predicted to be deleterious. 
Dnase-1 deficient mice develop clinical features strongly reminiscent of human 
lupus with autoantibody production and glomerulonephritis (Napirei et al., 2000). A 
functional heterozygous missense mutation in DNASE1 was previously identified in 
2 unrelated Japanese SLE patients (Yasutomo et al., 2001). An autosomal recessive 
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mutation in DNASE1L3 has been described in familial juvenile onset SLE patients in 
Saudi Arabia (Al-Mayouf et al., 2011).  
TRAP1 (tumour necrosis factor receptor associated protein 1) is a member of the heat 
shock protein 90 family (HSP90). TRAP1 is a mitochondrial chaperone protein 
whereas most other HSP90 proteins are mainly located in the cytosol and 
endoplasmic reticulum (Chen et al., 2005). Annotated transcripts from TRAP1 are 
known to overlap with transcripts from the DNASE1 gene suggesting that 
transcription of one of these genes will strongly influence the other (Fismen et al., 
2013). 
 
In the NZBxNZW lupus mouse model, progression from mild to end-stage renal 
disease corresponds with significant reduction in DNaseI expression. This down 
regulation of DNaseI leads to decreased chromatin fragmentation and subsequent 
deposition of these chromatin fragments in the glomerular basement membrane 
where they form immune complexes with immunoglobulin (Fenton et al., 2009) 
(Thiyagarajan et al., 2012; Fismen et al., 2013). Trap1 is progressively upregulated 
during this process as demonstrated by qPCR and Western blot analyses (Fismen et 
al., 2013). In human lupus nephritis, immunohistochemistry of renal sections shows 
normal DNASE1 staining in control kidneys and in mesangial lupus nephritis but 
significantly reduction of staining in ISN/RPS class IV. TRAP1 immunostaining is 
similar between controls and lupus nephritis biopsies (Fismen et al., 2013). 
 
6.4.14 ADCY7 
In Family 8, all 3 probands had a homozygous ADCY7 mutation (alanine to valine at 
protein position 480). This mutation was predicted to be moderately deleterious by 
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PolyPhen and highly damaging by SIFT. Their unaffected father was heterozygous 
for this mutation while their unaffected sibling did not have the mutation. 
Adenylyl Cyclases (ACs) are a group of enzymes that catalyse the formation of 
cyclic AMP from ATP (Ludwig et al., 2002). ADCY7 has been implicated in the 
neuronal regulation of mood and may be involved in the pathophysiology of 
depression (Joeyen-Waldorf et al., 2012). Polymorphisms in ADCY7 have been 
associated with alcohol dependence (Desrivières et al., 2011). ADCY7 expression is 




Compound heterozygous mutations in DEFB119 (defensin, beta 119) were found in 
both probands of Family 6 and only one of these mutations was found in each of 
their three unaffected sisters. The first mutation was an alanine to valine substitution 
at protein position 33 which was not predicted to be damaging. The second mutation 
was a threonine to asparagine substitution at protein position 70 which was predicted 
to be moderately deleterious by PolyPhen and highly damaging by SIFT.  
There are a growing number of reports in the literature supporting the role for 
defensins in lupus pathogenesis. Defensins are natural antimicrobials and an 
important component of innate immunity. Interestingly, they are known to contribute 
to the formation of NETs. α-defensin is a granulopoiesis-related marker and is 
upregulated alongside the interferon-α signature in SLE patients (Bennett et al., 
2003; Ishii et al., 2005; Sthoeger et al., 2009). β-defensin and human neutrophil 
peptides are elevated in SLE patients and these correlate with disease activity 
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(Vordenbaumen et al., 2010). Polymorphisms in DEFB1 have been associated with 
SLE in Brazilian patients (Sandrin-Garcia et al., 2012). CNV of DEFA1A3 has been 
described in East Asian SLE patients (Cheng et al., 2013). 
 
6.4.16 PTBP3 
A homozygous mutation in PTBP3 (polypyrimidine tract binding protein 3) that 
resulted from a proline to leucine substitution at position 7 was found in both 
probands in Family 1. This mutation was predicted to be highly deleterious by both 
PolyPhen and SIFT. Both parents were heterozygous for this mutation. 
PTBP3, also known as ROD1 (regulator of differentiation 1) is an RNA binding 
protein that regulates differentiation (Yamamoto et al., 1999). ROD1 may play a role 
in cell survival during hypoxia (Fasanaro et al, 2012). Knock down of ROD1 by 
siRNA inhibits motility of lung cancer cells in vitro (Tano et al., 2010). There has 




A non-frameshift deletion in TRAK1 (trafficking protein, kinesin binding 1) was 
found in the probands of Family 1. TRAK1 has been shown to regulate endocytic 
trafficking of GABA receptors in the central nervous system and mutations in mice 
result in hypertonia (Gilbert et al., 2006). TRAK1 also modulates axonal 
mitochondria trafficking (van Spronsen et al., 2013; Ogawa et al., 2014). TRAK1 
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expression is elevated in colorectal cancer patients but the significance of this is 
unclear (Zhang et al., 2009; An et al., 2011). 
 
6.4.18 HCFC1 
Both of the male probands in Family 1 were found to be hemizygous for a HCFC1 
mutation (alanine to glutamic acid at protein position140). HCFC1 (host cell factor 
C1) is located on the X chromosome and this mutation was predicted to be highly 
damaging by both PolyPhen and SIFT. 
HCFC1, also known as VP-16 accessory protein, is involved in cell cycle control 
and regulation of transcription. Rare mutations in HCFC1, previously identified by 
WES, have been shown to cause transcriptional dysregulation leading to disruption 
of cobalamin metabolism. HCFC1 does not encode an enzyme directly in the 
cobalamin pathway but is a transcriptional regulator of the enzymes involved. These 
mutations resulted in a severe neurological phenotype of intractable epilepsy and 












6.5 Genetic homogeneity 
 
An alternative to the ‘family-based approach’ is to analyse the WES data focusing on 
rare mutations common to a number of patients within the familial lupus nephritis 
cohort. Mutations with a MAF <1% in public databases (dbSNP, EVS and 1KG) 
were selected and their frequency within the lupus nephritis patients was compared 
with in-house WES cohorts at the Rockefeller University, namely Mendelian 
Susceptibility to Mycobacterial Disease (MSMD) patients (n=170) and a congenital 
asplenia cohort (n=52). A threshold p-value was chosen of 0.05/20,000 (number of 
genes = 2.50E-06). A selection of genes identified are shown in Table 6.9 however 
only mutations in IGLV3-22 (immunoglobulin lambda variable 3-22) and IFI44L 
(interferon-induced protein 44-like) were exclusively present in the lupus nephritis 
cohort and not seen in the MSMD and congenital asplenia groups.  
 
One missense mutation, (proline to histidine at protein position 62) in IGLV3-22 was 
found in 9 lupus nephritis patients in our cohort and also in 6 unaffected family 
members. This mutation was predicted to be deleterious by both PolyPhen and SIFT. 
Three mutations in IFI44L, a type I interferon response gene were found in 5 lupus 
nephritis patients and in 1 unaffected family member in our study group. The first of 
these mutations was a heterozygous missense mutation (glycine to glutamic acid at 
protein position 209) (rs75931592) present in both probands of Family 7. Their 
unaffected mother did not have this mutation. This family was of African ancestry 
and the MAF in this population is 0.012. This variant was predicted to be highly 
damaging by both PolyPhen and SIFT. The second heterozygous missense mutation 
(serine to proline at protein position 193) (rs149221815) was present in both 
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probands of Family 2 and absent in their unaffected brother. This family was also of 
African ancestry and the MAF in this population is 0.001. The mutation was 
predicted to be highly deleterious by both PolyPhen and SIFT. The third IFI44L 
mutation (valine to alanine at protein position 62) was present in 1 proband and 1 
unaffected sister in Family 6 but was not predicted to be damaging.  
 
 























1 9 0 0 0 0 
EHHADH 
4 7 0 0 3 3 
IFI44L 
3 5 0 0 0 0 
PUS7 
3 6 0 0 2 2 
C3orf67 
5 6 1 1 2 2 
MOCS2 
3 6 0 0 5 5 
CCR3 
2 5 0 0 2 2 
 
 
A comparison of rare variants (MAF<1%) present in the familial lupus nephritis 
cohort as compared to MSMD and congenital asplenia WES cohorts. EHHADH; 
enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase, PUS7; pseudouridylate 
synthase 7 homolog (S. cerevisiae), C3orf67; chromosome 3 open reading frame 67, 









The purpose of this chapter is to: 
1. Summarize the main findings of this research. 
2. Discuss the limitations of this research 

















7.1  Introduction 
In this thesis, a multi-ancestral cohort of biopsy proven lupus nephritis patients have 
undergone genotype-phenotype correlations for common susceptibility 
polymorphisms in genes identified in SLE GWAS and, in select cases, for rare 
variants identified by WES.  
Throughout this thesis, we progressed systematically from the initial clinical 
characterisation of the patient cohort to the generation of a list of novel genes for 
functional validation.  We performed a number of demographic comparisons 
including between ancestries, gender, familial versus sporadic nephritis and juvenile 
versus adult onset disease. We explored autoantibody positivity, histology findings 
and renal outcomes in each of these categories and identified subgroups of patients 
with a severe clinical phenotype. We then correlated this clinical data with 
ImmunoChip findings in susceptibility polymorphisms involved in the HLA region, 
immune complex uptake, type I interferon signalling pathways, B and T cell 
signalling, and NFκB pathways. Finally, we used WES as a tool to identify rare but 
potentially causative mutations in cases of familial lupus nephritis. 
7.2  Discussion of results 
 
7.2.1 Discussion of clinical characterisation of lupus nephritis 
The clinical characterisation of our lupus nephritis cohort has been extensively 
discussed in Chapter 2 and I will summarize some of the key findings here.  
To recap, the ancestral background of our patient cohort was as follows: 41% 
European, 33% African, 13% South Asian, and 9% East Asian. East Asian patients 
had the earliest onset disease at 20.9 ±9.1 years, followed by South Asians at 23.9 
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±12.0 years and Africans at 26.8 ±10.7 years. Patients of European ancestry had the 
latest onset of disease at 27.1 ±11.9 years. 6% of patients of European ancestry have 
progressed to ESRD, while 12% of non-European patients have advanced renal 
impairment. This is consistent with reports in the literature of outcomes in patients 
with lupus nephritis in different ancestral groups (Dooley et al., 1997; Alarcon et al., 
2001; Thumboo et al., 2001; Bastian et al., 2002; Johnson et al., 2006; Korbet et al., 
2007). 
Sixteen patients in our cohort had a first-degree family history of lupus nephritis 
including five sibling pairs. 69% of familial cases were African, 19% were South 
Asian and 13% were East Asian. No European patients in our study had a first degree 
relative with lupus nephritis. Familial cases were younger at diagnosis of nephritis, 
with 50% of juvenile onset as opposed to 22% in the sporadic onset group. Juvenile 
onset patients with a first degree family history of lupus nephritis in our study 
population were significantly more likely to develop advanced renal impairment than 
sporadic onset juvenile cases (25% versus 7%). In general, the literature supports this 
association of a more severe clinical phenotype with familial lupus nephritis 
(Freedman et al., 1997; Apenteng et al., 2006; Al-Mayouf et al., 2006). A large study 
of multiplex SLE families of European ancestry, however, did not demonstrate 
worse clinical outcomes compared to sporadic cases (Michel et al., 2001). 
27% of patients in our cohort were diagnosed with nephritis before 18 years of age, 
19% before the age of 16 years and 2% under the age of 10 years. This is consistent 
with the literature (Jimenez et al., 2003; Mina et al., 2010; Watson et al., 2012). In 
our study, juvenile onset patients were more likely to progress to ESRD than those 
with adult onset disease (16% versus 7%).  It is well established that juvenile onset 
lupus nephritis patients tend to have a more aggressive disease course when 
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compared to those with adult onset disease (Font et al., 1998; Brunner et al., 2008; 
Sato et al., 2012). 57% of juvenile onset patients who progressed to ESRD in our 
study population were of African ancestry, 29% were of South Asian descent and 
14% were European. This finding is consistent with a previous study that clustered 
juvenile onset SLE into mild, moderate and severe disease and demonstrated that 
20% of European patients were in the severe cluster as compared to 51% of Asian 
and 41% of African patients (Levy et al., 2013).  
In our cohort, males were diagnosed with lupus nephritis at a significantly younger 
age (21.3 ± 14.8 years) than their female counterparts (26.6 ± 10.2 years). We did not 
demonstrate a significant difference in progression to advanced renal impairment 
between genders with 9% of females and 12% of males reaching KDOQI stages 4 
and 5. Some authors have observed an increased rate of progression to ESRD in 
male lupus nephritis (Specker et al., 1994; Carbone et al., 2002) while others have 
not demonstrated a difference in disease severity (Miller et al., 1983; Renau et al., 
2012). 
In our study, juvenile onset, familial cases of non-European ancestry had a 
particularly severe clinical phenotype.  Several probands within these families have 
progressed to ESRD and are currently on dialysis or have already undergone renal 
transplantation. These patients and their unaffected relatives, where available, in 
addition to genotyping by ImmunoChip, have undergone WES to search for rare but 
highly penetrant variants that may have contributed to the development of their 






7.2.2 Discussion of histopathological findings in lupus nephritis 
The histologic variables examined in this research were CD68, as a general 
monocyte/macrophage marker, and the ISN/RPS classification of lupus nephritis. 
ISN/RPS classes I, II and V nephritis were found to have minimal glomerular CD68 
infiltration and were, henceforth, excluded from our clinical analysis. We focused 
instead on the proliferative classes III, IV-G and IV-S. Class III nephritis had 
significantly less CD68 enrichment than classes IV-G and IV-S. We did not find a 
significant difference in glomerular CD68 cell count between class IV-G and IV-S. 
This is contrary to previous work by Hill et al, who showed that class IV-G nephritis 
had more glomerular monocytes/macrophages than class IV-S nephritis (Hill et al., 
2005). A number of retrospective studies have shown significant clinical and 
morphological differences between classes IV-G and class IV-S. There is a lack of 
consensus, however, as to which class has a worse clinical outcome. In our study, of 
the patients who progressed to ESRD, 56% had class IV-G, 33% had class IV-S, and 
11% had class III nephritis.  
Glomerular CD68 count correlated with age at diagnosis of nephritis (r=-0.314, 
**p=0.0096). A subgroup of patient with disease onset before age 10 years had 
particularly high CD68 counts. We found a strong positive correlation between 
CD68 with AI (r= 0.525, ****p<0.0001) and a negative correlation between CD68 
and CI (r= -0.3128, *p=0.021) indicating a role for CD68 cells in active 
inflammation. CD68 count was higher in familial nephritis (13.3 ± 8.0) than in 
sporadic cases (8.9 ± 6.8) but this did not reach statistical significance (p=0.07).  As 
a continuation of this work, immunostaining of renal biopsies with CD16 is ongoing 
and will help decipher the functional heterogeneity of the mononuclear phagocytic 
system in lupus nephritis. Other markers are also being considered for 
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immunostaining including CX3CR1. In situ hybridization in renal tissue is being 
considered as it offers the prospect of examining a number of markers 
simultaneously at transcript level. 
Correlation of glomerular CD68 count and ImmunoChip polymorphisms revealed 
some interesting observations. Patients who were homozygous for the risk allele in 
any of the three ITGAM polymorphisms studied tended to have low CD68 
glomerular counts. The ITGAM rs1143679 minor allele is known to cause functional 
impairment of phagocytosis and adhesion (MacPherson et al., 2011; Rhodes et al., 
2012). Low CD68 glomerular infiltration was also evident in carriers of the 
RASGRP3 risk allele. RASGRP3 has also been proposed to have a functional role in 
phagocytosis in macrophages (Botelho et al., 2009). This gene was originally 
associated with SLE in an East Asian GWAS and has not to date been replicated in 
European or African SLE patients (Han et al., 2009). No one in our cohort was 
homozygous for the RASGRP3 risk allele. Patients who were heterozygous for the 
risk variant had predominantly membranous nephritis and, in those with proliferative 
nephritis, low glomerular CD68 immunostaining was seen. Two gene candidates 
from GWAS were associated with higher glomerular CD68 counts, IKZF1 and those 
homozygous for the HLA rs9271366 risk allele. Patients with either of these risk 
variants tended to have juvenile onset nephritis.  
The factors that determine glomerular CD68 infiltration remain unclear.  From our 
research, age at diagnosis of nephritis and the influence of genetic polymorphisms 
may play a role. It is our intention to return to ImmunoChip and test if other 
polymorphisms, in addition to the SLE GWAS polymorphisms already tested in our 




7.2.3 Discussion of ImmunoChip results 
We used the ImmunoChip to perform genotyping of known susceptibility 
polymorphisms associated with SLE in GWAS. A major drawback of this approach 
is that the ImmunoChip is designed for use in populations of European ancestry and 
is therefore less informative in other ancestral groups. Advantages of the 
ImmunoChip are that it is relatively inexpensive as compared to GWAS chips and 
that its use may allow clinical comparisons and collaborations with other research 
groups who have used the same tool. 
GWAS have identified common variants but, due to their small effect sizes, these 
have only contributed a limited amount to the overall understanding of the 
heritability of SLE. Their discovery has, thus far, had little clinically meaningful 
impact on the ability to predict who will develop SLE, who will develop nephritis, 
who will have intractable disease and progress to ESRD and whether or not patients 
will be likely to respond to different treatment modalities. 
In this thesis, susceptibility polymorphisms have been examined both individually 
and in aggregate where the effects of common variants were combined in a 
polygenic risk score. A discussion of each individual polymorphism has been 
provided in Chapter 4. In our cohort, we have found associations in European lupus 
nephritis patients with both of the HLA region polymorphisms studied, the IRF5 
rs2070197 polymorphism, three ITGAM variants, both STAT4 polymorphisms 
examined, both TNFAIP3 variants and with TNFSF4. Associations were found in 
African lupus nephritis patients with ITGAM rs1143679, STAT4 rs7574865 and 
ETS1. No associations were seen in any ancestral group with IRF7, IRF8, IRAK1, 
PTPN22, NCF2, IFIH1, BANK1, BLK, LYN or RASGRP3, however lack of power in 
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this study cannot rule out an association of these susceptibility genes with lupus 
nephritis. 
With regard to our polygenic risk score, European lupus nephritis patients tended to 
have the highest scores while African and East Asian patients tended to have lower 
scores. Two previous studies have found a higher polygenic risk score in juvenile 
onset SLE patients (Taylor et al., 2011; Webb et al., 2011). Our study did not reveal 
any convincing correlation between age at diagnosis of lupus nephritis and cGRS or 
wGRS in European, African or East Asian patients. South Asian juvenile onset 
patients in our cohort had a higher cGRS and wGRS than those of the same ancestry 
with adult onset disease.  
In our polygenic risk score, we combined polymorphisms in genes functioning in a 
variety of different biologic pathways. An interesting alternative approach may be to 
devise risk scores for specific functional pathways. An interferon-related polygenic 
risk score, for example, could be devised by combining 
IRF5/IRF7/IRF8/STAT4/IFIH1 risk alleles. An NFκB pathway polygenic score could 
be comprised of IRAK1 and TNFAIP3 risk alleles. A B-cell risk score could be 
compiled by combining BLK, BANK1 and LYN polymorphisms. This approach may 
determine which biologic pathways are most affected in patient subgroups, 
potentially identifying pathways to target therapeutically. 
It may be worthwhile to focus, in the future, on the patients in our cohort who have a 
low polygenic risk score. These individuals may represent interesting candidates in 
which WES could be used in order to seek an alternative genetic aetiology of their 




The associations between known susceptibility polymorphisms and lupus nephritis 
seen in our study were mainly in patients of European ancestry. As already 
mentioned above, polygenic risk scores were also highest in Europeans. The 
majority of variants tested in this research were identified in GWAS of European 
SLE patients and to a lesser extent in East Asian populations. Many of these variants 
have not been associated with African SLE. The paucity of GWAS data on patients 
of African ancestry is a significant limitation in lupus research in general as these 
individuals have more frequent and more severe disease. There is little known, 
therefore, about the genetic aetiology of lupus in patients of African ancestry and 
there is the possibility that, as yet, unidentified common variants may be present in 
these individuals. Rare variants almost certainly contribute, as de novo mutations are 
known to be up to three times more common in individuals of African ancestry than 
in European or Asian populations (Abecasis et al., 2012).  
 
Further exploration of the Immunochip data in our cohort may include examining the 
frequency of polymorphisms on ImmunoChip in lupus nephritis patients as 
compared to ancestry matched healthy control data. To date we have focused on 










7.2.4 Discussion of WES results 
The first step in our WES analysis was to filter the variants found in our study 
patients’ data set against known polymorphisms in public databases such as dbSNP, 
EVS and the 1,000 Genomes Project. This narrowed down the list of candidates 
based on the assumption that any variant found frequently in the public filter set 
cannot be causative. With this in mind and considering the prevalence of lupus 
nephritis in the general population, we chose mutations where the MAF was <1% for 
homozygous mutations and where variants were absent from public data bases in the 
case of heterozygous mutations. WES of the lupus nephritis families in our cohort 
identified a large number of potential candidates. A promising short list from these 
candidates was then identified using pedigree information focusing on variants 
predicted to be damaging and by incorporating prior knowledge of the biologic 
pathways implicated in lupus.  
 
Further key family members integral to analysis are being recruited for WES 
including the affected mother and unaffected father and brothers in Family 5.  In 
Family 8, with a consanguineous background living in Pakistan, a cousin has been 
identified living in the United States who is reported to have a diagnosis of SLE. We 
are in the process of contacting this individual, obtaining further clinical details and 
DNA for WES if possible.  
 
Mutations in genes involved in activation of Ras pathways (RASGRF2, RASSF5, 
RIN1) are potentially very interesting candidates for functional investigation. Recent 
literature suggesting that RASopathies may be associated with SLE and the previous 
identification of RASGRP3 in East Asian GWAS adds credence to the candidates 
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identified in our study. In addition, all of these candidates were predicted to be 
highly deleterious. 
Variants found in reactive intermediate genes (GSR, NOS1, NDUFA13) are also of 
considerable interest. These mutations are all predicted to be damaging and the 
literature supports their role in lupus pathogenesis. Mutations in two of these genes 
(GSR, NDUFA13) were found in one patient in our cohort who is of South Asian 
ancestry. The mutation in NOS1 was found in two sisters with lupus nephritis of 
African descent which is of interest as polymorphisms in NOS1 have been associated 
with SLE patients of African ancestry (Ramos et al., 2013).  
Mutations in genes encoding the epsilon DNA polymerase complex (POLE, POLE3) 
are certainly potential candidates for functional testing given their role in DNA 
repair and histone folding. Both mutations were predicted to be deleterious however 
two unaffected sisters in Family 7 had the POLE variant which would argue against 
direct causation by this gene if apparently healthy individuals carry the mutation. 
One complexity which could arise and must be taken into consideration is the 
possibility of incomplete penetrance where a given genetic mutation is not 
phenotypically expressed in all those who carry it. 
Mutations in genes involved in ubiquitination (USP36 and UBR4) are worthy of 
consideration for functional validation. The mutations identified were likely to be 
damaging and the evidence from the literature supports the importance of 
ubiquitination in lupus pathogenesis.  
The compound heterozygous mutations in DEFB119 found in Family 6 are also 
worthy of consideration for functional testing. The role of defensins in innate 
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immunity, NET formation and as a granulopoiesis-related marker makes this gene an 
attractive candidate for validation studies (Bennett et al., 2003; Ishii et al., 2005; 
Sthoeger et al., 2009; Vordenbaumen et al., 2010).  
Mutations in genes encoding synaptotagmin-like proteins and chromodomain 
helicase DNA binding proteins were identified in multiple families within our 
cohort. A number of factors render these genes less attractive candidates for 
functional investigation. It is not immediately apparent how these genes would 
feature in lupus pathogenesis; however, this would not eliminate these candidates 
from the list for functional testing. It was noted that not all of these mutations are 
predicted to be deleterious by PolyPhen and SIFT. A number of diseases have 
already been associated with these genes which may argue against their role as 
causative genes in SLE. 
Mutations in serine/threonine protein kinases (MAPK3, MAP3K6, STK33) were seen 
in a number of families in our study. Disappointingly the mutation in MAPK3, 
present in all three probands in Family 8 was not predicted to be damaging. A 
potentially deleterious mutation in STK33 was seen in Family 2 in both probands but 
was also present in their unaffected brother. A further mutation in STK33 in Family 5 
was predicted to be damaging. Recently polymorphisms in STK17A were associated 
with SLE in a Brazilian study (da Silva Fonseca et al., 2013). 
Mutations in MACF1, COL6A5, DDR1 and BOC were present in more than one 
family with SLE but these mutations were not consistently predicted to be 
deleterious. In the case of DDR1, a role has been proposed for this gene in renal 
damage and inhibition of DDR1 activity has also been shown to be protective against 
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renal damage in crescentic glomerulonephritis, a somewhat contradictory finding if 
one assumes we have identified a loss-of-function mutation (Kerroch et al., 2012). 
One of the most interesting WES findings in our cohort was the discovery of 
compound heterozygous mutations in TRAP1/DNASE1 in Family 5. Our current 
knowledge of lupus aetiology supports the functionality of these mutations with 
evidence both from murine models and monogenic lupus, with previous DNASE1 
and DNASE1L3 mutations identified in SLE patients in Japan and Saudi Arabia 
(Yasutomo et al., 2001; Al-Mayouf et al., 2011). Disappointingly neither of the 
mutations identified in our study were predicted to be deleterious.  
Candidate mutations in IRF9 and TLR9 are also of interest given the well-established 
role of endosomal TLRs and type I interferon pathways in the pathogenesis of SLE. 
The mutations were for the most part not predicted to be deleterious however. 
Family 1 provided the most complete set of familial WES data as DNA was available 
for both affected sons and for their unaffected parents. This allowed for a more 
streamlined analysis. In this family, an autosomal recessive or an X-linked recessive 
model of inheritance looked most likely. With this in mind, mutations in PTBP3 and 
HCFC1 seem to be two interesting candidates for functional testing. Both affected 
sons were homozygous for the PTBP3 mutation (which was predicted to be 
damaging) while the parents were both heterozygotes. The mutation in HCFC1 
which is located on the X chromosome could make sense in the context of Family 1 
if the mother were an unaffected carrier.  
The proband in Family 5 merits special mention given the constellation of 
deleterious mutations discovered in this individual by WES. This patient was the 
youngest and, phenotypically, the most severe in our cohort with his disease onset at 
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the age of 2 years and early progression to ESRD requiring renal transplantation. His 
mother also had lupus nephritis but with an older age of disease onset and a less 
severe clinical phenotype. The proband had mutations in two reactive intermediate 
genes; GSR and NDUFA13, two variants in ubiquitination genes; UBR4 and USP36, 
and mutations in STK33 and RASSF5. This same individual had the IGLV3-22 
mutation, in common with other patients in our cohort, as identified by the genetic 
homogeneity approach. Mutations in other potentially interesting genes such as the 
autophagy gene, ATG13, and in ACIN1 (apoptotic chromatin condensation inducer) 
were also found in this patient, both of which were predicted to be damaging. He 
also had the functionally interesting though not predicted to be damaging mutation in 
TRAP1/DNASE1. A high composite genetic risk score analysed from GWAS 
polymorphisms in ImmunoChip was present in this patient. As mentioned 
previously, his parents and unaffected brothers are being recruited for WES. This 
should help elucidate which of these interesting mutations are contributing to the 
disease phenotype in this fascinating case. Recent data has suggested that every 
human genome harbours significant numbers of loss-of–function variants including 
stop codons, frameshift mutations and large deletions and that the load of potentially 
damaging rare variants carried by and tolerated by apparently healthy individuals is 
significantly larger than was anticipated (MacArthur et al., 2012). It is important to 
consider the possibility of epistasis in which the effect of one gene or genetic 
mutation depends on the presence of one or more modifier genes.  
IGLV3-22 and IFI44L were identified using the genetic homogeneity approach. Both 
of these genes are potentially interesting candidates in the context of SLE 
pathogenesis. IFI44L expression is increased in the synovium of SLE patients and a 
genome-wide methylation study of CD4+ T cells from lupus patients showed 
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significant hypomethylation of IFI44L amongst other interferon-regulated genes 
(Nzeusseu Toukap et al., 2007; Coit et al., 2013). There is no specific literature on 
IGLV3-22 in the context of SLE although a gene involved in VDJ recombination 
may certainly be of interest in SLE given the important role of autoantibodies in the 
disease. The IGLV3-22 and IFI44L mutations were also seen in unaffected family 
members, however, weakening the claims for these mutations to be causative in 
lupus pathogenesis.  
 
A useful tool under development that may allow us to narrow down the list of 
candidate genes of interest is the GDI (Gene Damage Index). The GDI is a genome-
wide estimation of mutational damage per base pair per individual for all protein-
coding genes in humans with respect to all other human genes. The GDI can be 
applied to the analysis of NGS data, as less damaged genes are more likely to 
underlie rare monogenic diseases (as yet unpublished, courtesy of Dr Yuval Itan, 












Functional validation of the top candidates is being planned to determine how a 
variant may have a meaningful impact in the disease processes underpinning SLE.   
 
7.2.5 Outline of plan for functional validation of gene candidates: 
 Initial verification of candidate mutations by Sanger sequencing 
 Validate at the transcript level 
 Validate at the protein level (Western blot/mass spectrometry) 
 Modelling to predict changes in protein structure 
 Consider animal model, for some candidates models are already in 
existence, if not consider a knock-in model for the mutation of 
interest. 
 Consider RNA-Seq (RNA sequencing) or eQTL (expression 
quantitative trait loci) to complement WES data. 
 Devise functional assay for candidate gene mutations, for example 
serum DNase activity in the patient with DNASE1/TRAP1 mutation. 
 PBMCs, serum and further renal biopsy tissue are available for the 
majority of patients. There is also ethical approval to return to the 
patients/unaffected relatives for repeat sampling. 
 Opportunity to collaborate with other research groups who are using 
WES in juvenile and familial SLE cases who may have found 






7.3 Limitations of this research 
One of the main limitations of this research is the number of lupus nephritis patients 
studied, in particular with regard to common variants with low effect sizes. This was 
further limited by the need for population stratification given the difference in allelic 
frequencies in different ancestral groups and the need to avoid bias.  The East and 
South Asian lupus nephritis patients comprised a particularly small group. It was not 
our intention, however, to replicate a GWAS but, rather, to examine known 
susceptibility polymorphisms in patients with lupus nephritis who are seen in every 
day clinical practice. Despite this, we did still find associations in several GWAS hits 
such as polymorphisms in the HLA region, ITGAM, TNFAIP3 and STAT4. Other 
candidate gene polymorphisms identified in GWAS were not associated with lupus 
nephritis in our cohort, although, given the lack of power in the study we cannot 
state that these are not associated with disease. In addition, there are polymorphisms 
in candidate genes that have been associated with SLE but that have not been 
covered by this research including ATG5, UBE2L3, IL10, TYK2, ELF1, TNIP1 and 
WDFY4. 
Another limitation of this research is that autoantibody results and renal biopsies 
material were not available for all patients recruited. Autoantibody availability was 
as follows; ANA 99% (n=162), anti-dsDNA 98% (n=160), anti-Ro 93% (n=152) and 
92% (n=151) for anti-RNP and anti-Sm. Paraffin-embedded renal biopsy tissue was 
available from 77% (n=126) of the patients recruited to the study. When 
immunostaining was analysed, slides with < 7 glomeruli present were excluded, 
leaving 117 biopsies for CD68 analysis and 114 biopsies for ISN/RPS classification. 
Urinary protein-creatinine ratio, AI and CI results were not available for all study 
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participants. We have reported if a patient ever tested anti-dsDNA antibody positive 
but did not collect information regarding antibody titres. Anti-C1q antibody 
information was not collected.  
To minimise the effects of immunosuppressive medication on renal biopsy findings, 
biopsies were traced back to the time of the patients’ original diagnosis of lupus 
nephritis (n=107) or, where this was not possible biopsies taken at the onset of a new 
nephritis flare before induction immunosuppression was commenced were obtained 
(n=19).  Many patients were likely to be taking some degree of immunosuppression 
at the time of biopsy but this has not been adjusted for and is a potential cause of 
bias. Collecting the data regarding details of immunosuppression at time of biopsy 
proved to be difficult due to the retrospective nature of this research and the fact that 
patients were attending a number of different hospitals.   
With regard to the WES results, key family members have not yet been sequenced, 
for example in Family 3, Family 5 and Family 8. This constitutes a considerable 
limitation to the data so far in that the list of potential candidates for functional 
testing cannot be narrowed down to a reasonable number without these individuals. 
This issue is now being addressed and recruitment of additional family members is 
ongoing.  
We reported the clinical outcomes in our lupus nephritis patients using the NKF 
KDOQI scoring system as a measure of the degree of chronic kidney disease. We did 
not use any of the validated lupus activity or damage scores such as the BILAG, 
SELENA-SLEDAI or SLICC which may be considered a limitation. The 
retrospective nature of the study prohibited collection of this data which was further 
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compounded by the fact that the patients were recruited from a number of different 




















7.4 Concluding remarks and future perspectives 
SLE susceptibility genes identified in GWAS have certainly contributed to our 
understanding of the aetiopathogenesis of the disease. The ‘missing heritability’ of 
SLE remains somewhat of a mystery, however. Interestingly, GWAS hits may 
represent markers for the true underlying causative variants.  IFIH1, for example, 
was initially associated with SLE in a large replication study of European SLE 
patients and recently mutations in IFIH1 have been identified as causing 
interferonopathy (Cunninghame-Graham et al., 2011; Rice et al., 2014).  
In our study, a number of mutations in genes involved in activation of Ras pathways 
were discovered.  This is interesting as RASGRP3, a functional partner of these 
genes, was associated with SLE in a GWAS of East Asian patients (Han et al., 2009) 
and RASopathies were recently proposed as novel monogenic conditions 
predisposing to the development of SLE (Bader-Meunier et al., 2013). 
Polymorphisms in reactive intermediate genes were previously associated with SLE 
in African patients. In our cohort, rare mutations were identified in GSR, NOS1 and 
NDUFA13. The most striking of these was a homozygous mutation in GSR that 
encodes for a stop codon early in the protein that was predicted to be highly 
deleterious and to have significant functional consequences. 
When using WES to discover novel variants in SLE, we focused on patients with an 
extreme clinical phenotype, in particular those with familial disease and who had 
juvenile onset of disease. With increasing accessibility to WES and reducing costs, 
research groups are using this technology to sequence large groups of unrelated 
patients to search for residual unidentified common variants of disease. Furthermore, 
WGS is becoming increasingly available and will provide information on mutations 
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throughout the entire genome rather than focusing exclusively on the exome. This 
approach will reveal much larger candidate mutation lists and the challenge will be 
to identify the true causative variants.  
Several other parameters need to be taken into consideration in the context of the 
genetics of SLE which we have not explored or discussed in our study. Gene-gene 
and gene-environment interactions undoubtedly play a role in SLE pathogenesis.   
Epigenetic alterations such as DNA methylation and histone modifications are also 
likely to contribute to the development of disease and may explain some of the 
‘missing heritability’ of SLE. 
We look forward to the functional validation of the candidates identified in this 
research and sincerely hope that these will deepen our understanding of the disease 
processes underlying SLE. Five further families with clustering of two or more 
individuals with SLE and eight juvenile sporadic onset male lupus nephritis patients 
are currently undergoing WES (Appendices 21-23). It will be interesting to see what 
new variants emerge and if mutations in the candidate genes uncovered in this data 
set will also be identified in these families.  
 
For too long, SLE therapy has relied on general immunosuppressive agents with 
non-specific effects to which many patients remain refractory. It is essential that 
more targeted therapies, focusing on the root causes of the disease, are developed in 
order to improve outcomes for patients. Studies of patients with monogenic causes of 
SLE may be particularly instructive.  The phenotype of the Trex1 knock out mouse, 
for example, has been salvaged using reverse transcription inhibitors and trials in 
AGS patients are soon to begin (Beck-Engeser et al., 2011). While monogenic 
causes of SLE are rare, they provide extremely useful insights into our understanding 
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of the disease pathways underlying SLE. The monogenic causes of SLE identified to 
date have helped fill in the gaps in our knowledge of lupus pathogenesis and helped 
to elucidate the roles of complement pathways, apoptosis and aberrant TLR and type 






























Class I 2% (n=1) 
 
3% (n=1) 0% 0% 
Class II 
 
7% (n=3) 0% 13% (n=2) 0% 
Class III 
 
20% (n=9) 36% (n=13) 31% (n=5) 27% (n=3) 
Class IV-G 
 
29% (n=13) 22% (n=8) 25% (n=4) 9% (n=1) 
Class IV-S 
 
33% (n=15) 17% (n=6) 31% (n=5) 27% (n=3) 
Class V 
 










Appendix 2: ISN/RPS classes of lupus nephritis in familial and sporadic disease 
 
















0% 2% (n=2) - - - 
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0% 2% (n=2) - - - 
Class II 
 
0% 6% (n=5) - - - 
Class III 
 
30% (n=9) 26% (n=22) 0.787 1.13 
 




23% (n=7) 25% (n=21) 0.764 0.86 0.324 to 2.29 
Class IV-S 
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Mutation PolyPhen SIFT Function 
Homozygous Mutations     
PTBP3 










trafficking protein, kinesin binding 1 
 
E/- 630, 
non frameshift deletion 
Chromosome 3 
 
- - Regulation of endosome-to-
lysosome trafficking 
 







Moderate High Duchenne and Becker muscular 
dystrophies 
GNL3 




non frameshift deletion 
 
- - Role in stem cell proliferation 
 
HCFC1 




High High Chromatin modulation 




The full list of mutations found in Family 1 is available at http://brahma.rockefeller.edu/polyweb 
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Mutation PolyPhen SIFT Function 
XIRP2 





- - Role in actin binding 
 
CENPF 
(centromere protein F) 
 
Stop codon 
 Q/* 2580 
Chromosome 1 
 
- - Component of nuclear matrix 




(secretoglobin, family 2A) 
 
Frameshift deletion 
 DSI/- 86 
Chromosome 11 
 
- - Androgen binding 
 
CX3CR1 




Moderate High Fractalkine receptor 
VSIG2 




High High SNPs associated with SLE 
(Kariuki et al., 2010) 
TLR9 




Low High Endosomal TLR 
IRF9 










High High Role in vesicle trafficking 
 
The full list of mutations found in Family 1 is available at http://brahma.rockefeller.edu/polyweb 
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Mutation PolyPhen SIFT Function 
Homozygous Mutations 
 
    
GMNC 










    
COL6A5 




Low Low Roles in organisation of 
tissue architecture and cell 
adhesion 
 





- -  
Heterozygous Mutations 
 
    
STK33 




High High Serine/threonine protein 
kinase 
RASGRF2 
Ras protein-specific guanine  
nucleotide-releasing factor 2  
R640C 
Chromosome 5 
High High Nucleotide exchange factor, 
activating RAS/RAC1 
 
The full list of mutations found in Family 2 is available at http://brahma.rockefeller.edu/polyweb 
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Appendix 9: WES Compound Heterozygous Mutations of Interest in Family 3 
Gene 
 
Mutation PolyPhen SIFT Function 
IRF9 

























High High  
MACF1 

















The full list of mutations found in Family 3 is available at http://brahma.rockefeller.edu/polywe 
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Mutation PolyPhen SIFT Function 
ATP8B4 






- - Role in phospholipid 
transport in the cell 
C4A 












Moderate High Intracellular 
adhesion molecule 
USP36 




High High Transcriptional 
repressor   
ATP6AP1 (ATPase, H+ transporting, 
lysosomal accessory protein) 
 
V1361 High High Transporter activity 
RALGAPB 




High High GTPase activator  
DDR1 










The full list of mutations found in Family 3 is available at http://brahma.rockefeller.edu/polyweb 
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Mutation PolyPhen SIFT Function 
Homozygous Mutations 
 
    
BOC 








Low Low Mediates cell-cell 
interactions between 
muscle precursor cells 
TRPC7 
transient receptor potential cation 




Low Low Nil of note 
Compound Heterozygous Mutations 
 
    
HSPG2 








- - Perlecan protein, 
ITGA2 






Moderate Low Integrin, associated with 
bleeding disorder, platelet-
type 9 
 Variant in UTR 
 
- -  
 








Mutation PolyPhen SIFT Function 
NOS1 
nitric oxide synthase 1 
G50V 
Chromosome 12 

















High High ATP-dependent 
RNA helicase 
PRRC2B 




























- - Reduces glutathione 
disulfide (GSSGG) to the 
sulfhydryl form GSHH 
 
DDR1 
(discoidin domain receptor tyrosine kinase) 
 





Moderate Low Regulates β1 integrin 








Low Low IRAK1 SNPs associated 
























Mutation PolyPhen SIFT Function 
TRAP1  
(overlap with DNASE1) 
TNF receptor-associated protein 1 
R650Q 
Chromosome 16 
Low High  
DNASE1 monogenic  
 T65K 
Chromosome 16 
Low Low  
UBR4 
ubiquitin protein ligase E3 component 
 n-recognin 4 
C933F 
Chromosome 1 
High High Part of the chromatin 
scaffold in the nucleus. 
 L4122V 
Chromosome 1 
















Moderate High  
MACF1 














High Low  
 
The full list of mutations found in Family 5 is available at http://brahma.rockefeller.edu/polyweb 
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Mutation PolyPhen SIFT Function 
HIRA 






- High Transcriptional regulator 
MAP3K6 





- - Serine/threonine protein kinase 
STK33 




Moderate High Serine/threonine protein kinase 
ATG13 
autophagy related 13 
M359I Low Low Required for autophagosome 






intronic - - Regulatory role in functioning 




ubiquitin specific peptidase 36 
 
G468V Moderate High Transcriptional repressor 
RASSF5 
Ras association (RalGDS/AF-6) domain family 
member 5 
 
E200Q High Low Regulation of integrin 







collagen, type VI, alpha 5 
 
*Mutation in COL6A5 in Family 2 
 
 
F680V High Low Roles in organisation of tissue 
architecture and cell adhesion 
ACIN1 
apoptotic chromatin condensation inducer  
 
R146H Moderate High Induces apoptotic chromatin 




NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 13 
 
R81Q High High Subunit of the mitochondrial 




























    
DEFB119 




Low Low Immune defence 




Moderate High  
FAT3 





Low Low Nil known 
 T70N 
Chromosome 11 
High High  
X-linked Mutations 
 


















Low Low Association with epilepsy 
 
The full list of mutations found in Family 6 is available at http://brahma.rockefeller.edu/polyweb 
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Mutation PolyPhen SIFT Function 
POLE 




I238F High High Involved in DNA repair 
BOC 




D79V Low Low Mediates cell-cell 
interactions between 
muscle precursor cells 
IL12RB1 
interleukin 12 receptor, beta 1 
 





















Mutation PolyPhen SIFT Function 
SESTD1 






Low Low Primary docking protein 
directing membrane 
turnover and assembly of 









Low Low Role in transducing signals 
















transcription factor AP-2 alpha 







High High Transcription factor 
 
TULP4 












The full list of mutations found in Family 7 is available at http://brahma.rockefeller.edu/polyweb 
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Mutation PolyPhen SIFT Function 
MAPK3 















Low Low Nil known 
ADCY7 







Moderate High Catalyses the formation 
of cyclic AMP from ATP 
 
CHD9 
Chromodomain helicase DNA  






High High Role in chromatin 
remodelling 
FAM129C 
family with sequence similarity 129, 




High Low Associated with CLL 
 








Mutation PolyPhen SIFT Function 
Compound Heterozygous Mutations 
 
    
MACF1 












High Low  
HEATR1 





Moderate High Involved in nucleolar 





Low Low  
Heterozygous Mutations 
 
    
POLE3 





High High Histone-fold protein  
 
 





Appendix 21: Multiplex families currently undergoing WES 
 
















Appendix 22: Multiplex families currently undergoing WES 
Subject  
Identifier 
Age at  
diagnosis 
Gender Clinical Features 
F9-A  Proband (III-5) 27 F Class IV-G 
F9-B  Proband (III-6) 24 M End-stage renal failure 
secondary to lupus nephritis 
F9-C Proband (III-1) 20 F Cutaneous involvement only 
F9-D Unaffected (III-2) - F No SLE features 
F9-E Unaffected (?) (II-7) - F Primary biliary cirrhosis, 
inflammatory arthritis 
F10-A Proband (III-5) 16 F Class IV-S lupus nephritis 
F10-B Proband (III-6) 19 F Antiphospholipid syndrome, 
non-renal lupus 
F10-C Unaffected (II-6) - M No SLE features 
F10-D Unaffected (II-5) - F No SLE features 
F11-A Proband (III-1) 20’s F Cutaneous/musculoskeletal SLE 
F11-B Proband (III-2) 20’s F Cutaneous/musculoskeletal SLE 
F12-A Proband (III-2) 25 F Class V nephritis 
F12-B Proband (II-1) 
 
40’s F Discoid lupus 
musculoskeletal involvement 
F12-C Unaffected (III-1) - F No SLE features 
F12-D Unaffected (II-2) - M No SLE features 
F13-A Proband (IV-5) 
 
18 F Class IV nephritis 
severe skin involvement 
F13-B Proband (III-2) 57 F Cutaneous/musculoskeletal 
Antiphospholipid syndrome 













SLE 18 South Asian 10 Class IV-S ANA, anti-dsDNA, anti-Ro 
SLE 29 European 17 Class IV-G ANA, anti-dsDNA 
SLE 31 European 7 Class IV-G ANA, anti-dsDNA 
SLE 54 African 11 Class III ANA, anti-dsDNA, anti-Ro, 
anti-Sm, anti-RNP 
SLE 85 African 15 Class IV-G ANA, anti-dsDNA, anti-Ro 
SLE 106 European 11 Class IV-S ANA, anti-dsDNA, anti-Ro 
SLE 122 South Asian 14 Class IV-G ANA, anti-dsDNA, anti-Ro 
SLE 158 African 16 Class V ANA, anti-dsDNA 
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